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Abstract 
 Resistance to artemisinin combination therapies (ACTs) has emerged in southeast Asia 
threatening the most widely used treatment against antimalarial-resistant Plasmodium falciparum 
worldwide. Artemisinin resistance has been associated with a reduced rate of parasite clearance 
following treatment with an ACT and is attributed to increased survival of ring-stage parasites. 
Single nucleotide polymorphisms (SNPs) in kelch gene (K13) has been associated with delayed 
in vivo clearance half-life of artemisinin-resistant P. falciparum and is the only known molecular 
marker of resistance. The absence of reliable in vitro phenotypes for artemisinin resistance has 
limited our understanding of the resistance mechanism(s) and fitness costs, therefore we have 
culture adapted and cloned patient isolates from Thailand and Cambodia that had clinical 
resistant phenotypes. Stable reduced susceptibility to artemisinin derivatives and mefloquine was 
observed using a modified [
3
H]hypoxanthine drug susceptibility assay. In addition we devised an 
in vitro phenotype assay of artemisinin resistance, known as the delayed clearance assay (DCA), 
that was positively correlated with the in vivo delayed clearance and presence of K13 SNPs of 
artemisinin resistance. Remarkably we discovered for the first time altered patterns of 
intraerythrocytic development in artemisinin-resistant P. falciparum. In the absence of drug 
pressure most artemisinin-resistant clones have a prolonged ring phenotype with temporally 
compressed trophozoite stage, yet with the normal overall asexual life cycle period. Parasites 
remain in ring-stage up to 14 hours longer than wild-type, whereas time spent in trophozoite-
stage is dramatically reduced. One parasite, PL08-09 (5C), exhibited an accelerated 36-hour life 
x 
cycle in the absence of drug pressure and progressed through asexual development in equal time 
spent at each intraerythrocytic stage. These data support our hypothesis that parasite resistance to 
artemisinin results from reduced exposure to drug at the most susceptible stage of development 
(trophozoite). Interestingly, the most prevalent K13 mutation C580Y is associated with both cell 
cycle phenotypes. Another cell cycle phenotype, ring-stage dormancy, has been associated with 
artemisinin resistance in vitro reducing the dormant period of artemisinin-resistant parasites 
following dihydroartemisinin exposure allowing resistant parasite cultures recrudesce before 
wild-type. However, sensitive parasites have the ability to enter ring-stage dormancy causing 
recrudescence in vitro. It is possible that multiple cell cycle phenotypes enhance the survival and 
fitness of the resistant parasite population as a whole in the face of antimalarial exposure. We 
have demonstrated that there is a fitness cost associated with artemisinin resistance and remains 
an important component in the spread of genetic mutations associated with artemisinin 
resistance. Resistant parasites outcompeted sensitive in vitro only when exposed to 
dihydroartemisinin. Two mutations associated with artemisinin resistance, including a mutation 
in K13, were lost in artemisinin resistant parasite by the end of the study. Conversely, parasite 
cultures maintained artemisinin resistance phenotypes in vitro only if exposed to artemisinin 
drug pressure every 21-42 days. The mechanism of artemisinin resistance remains elusive and 
how the parasites alter their intraerythrocytic development is unknown. Therefore. we 
transfected green fluorescent protein (GFP) or luciferase into artemisinin-resistant P. falciparum 
clones from Thailand and Cambodia to aid the study the cell cycle phenotypes associated with 
artemisinin resistance. Artemisinin resistance phenotypes were maintained in stably transfected 
clones. Increased growth of artemisinin-resistant clones was observed following exposure to 
ACT partner drug. Low concentrations of antimalarials synchronized the luciferase expression of 
xi 
artemisinin-resistant parasites having different cell cycle phenotypes in the absence of drug 
pressure. Ring-stage dormancy was observed with many antimalarial drugs and contributes to 
recrudescence observed by antimalarials other than artemisinin. Our results show evidence that 
current ACT treatments are selecting multidrug resistant parasites in the field that are better able 
to tolerate all antimalarials through regulatory cell cycle mechanisms. These cell cycle 
phenotypes associated with artemisinin resistance contribute to reducing the fitness cost 
associated with genetic mutations causing artemisinin resistance. This leads to the survival of the 
most fit population of parasites that survive combination drug treatments, thus demonstrating the 
importance of discovering novel drugs to target ACT-resistant P. falciparum. 
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Chapter 1 
Introduction 
Malaria: Global Health Impact 
 Plasmodium falciparum. An estimated 200 million episodes of malaria and 1 
million deaths are caused by the malaria parasite with most fatalities occurring in Africa . 
The most deadly malaria parasite, Plasmodium falciparum, is endemic in much of the 
world including northern parts of South America, much of South-East Asia, and most of 
Africa. The complex life cycle of Plasmodium falciparum includes 3 distinct 
developmental stages: sexual, asexual exerythrocytic, and asexual erythrocytic stages. 
The sexual phase of the life cycle is completed in a female Anopheles mosquito. When a 
female takes a blood meal on a human she will inject sporozoites that will travel to the 
liver to complete the exerythrocytic portion of the life cycle. The parasite will undergo 
asexual development in a hepatocyte to become a schizont containing multiple 
merozoites that will burst out of the cell and enter the erythrocytic phase of the life cycle. 
After invading an uninfected red blood cell a merozoite will develop into a ring, 
trophozoite, and eventually a blood stage schizont. A schizont contains multiple 
merozoites that will reinvade new unifected red blood cells and continue asexual 
erythrocytic development. A portion of parasites will be predetermined to develop into 
gametocytes, the sexual stage, that will be taken up by a female Anopheles mosquito 
during a blood meal to complete sexual development in the mosquito.  
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Disease burden is associated with the erythrocyctic portion of the life cycle 
causing fever and nonspecific symptoms, such as vomiting and diarrhea (Greenwood, 
2008). Ring stages and gametocytes can be found in circulating blood while mature 
trophozoite and schizont stages adhere to endothelial lining of vasculature leading to 
severe disease. Intermittent episodes of fevers and chills are associated with the rupture 
of schizont-infected red blood cells and the subsequent immune response initiated. 
Historically, antimalarial treatment has included killing intraerythrocytic stages 
associated with the disease burden of malaria.  
Antimalarial Drugs and Generation of Resistance 
Quinine  
Quinine, a natural component of bark from the cinchona tree, was the first 
antimalarial drug used in recorded history. Dating back to the early 1600’s cinchona bark 
was used in South America to treat fevers associated with malaria. By the late 1600’s the 
discovery had spread throughout Europe and was widely available in a ground powder 
form to be mixed into liquid and drunk [1]. Pure quinine, an aryl amino alcohol, was 
successfully isolated and used to treat patients in the early 1920’s while synthesis was not 
achieved until 1944 [2]. Quinine synthesis remains complicated and not cost effective. 
 World War II led to an increasing interest in the discovery of new synthetic 
antimalarials and a drastic cut off of the world supply of quinine. By the mid 1940’s 
chloroquine had been discovered and proved to be cost effective to distribute to the 
masses. Quinine remains one of the most effective antimalarials at treating uncomplicated 
malaria when ACTs are not available and severe malaria in regions where artesunate and 
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artemether are not available [3]. Quinine, along with other quinolones (4-
aminoquinolones and 8-aminoquinolones), act by interfering with hemozoin formation at 
the schizont-stage of the intraerythrocytic cycle and resistance to quinine develops slowly 
[4]. Low-grade resistance to quinine has been reported in parts of Asia and South 
America as decreased sensitivity to drug but has not led to increase in treatment failure 
[5]. 
Methylene Blue 
 In the 1800’s with the advent of the industrial revolution synthetic dyes were 
becoming increasingly studied and widely available at reduced prices. The synthetic dye 
industry fueled medical research because newly made dyes were being used to visualize 
infectious pathogens under the microscope for the first time. Paul Ehrlich was the first to 
use a synthetic drug, methylene blue, to cure patients of malaria in 1891. Methylene blue 
interferes with heme degradation, like other quinolones, and leads to increase in oxidative 
stress [6]. While methylene blue was not widely effective against Plasmodium falciparum 
infections it remained important to research because of it did not have cross resistance 
with other quinolones suggesting alternative mechanisms of resistance and methylene 
blue became the core quinolone structure that 8-aminoquinolones were developed from 
leading to the first compounds discovered to prevent relapse of Plasmodium vivax. 
4-Aminoquinolones 
With the supply of quinine dramatically reduced during World War II the 
American military along with other countries such as Britian and Australia gained an 
interest in developing synthetic antimalarials to replace quinine, mainly 4-
 4 
aminoquinolones. Maintaining the quinolone core and modifying methyl side groups as 
learned from methylene blue became important strategies in developing new synthetic 
drugs [7]. One of the sixteen-thousand newly synthesized compounds, resochin, was a 
strong candidate but overlooked because of toxicity in humans [2]. After several rounds 
of chemical alterations made by many countries involved in the war; including the United 
States, Germany and France chloroquine became the most promising antimalarial of the 
time. 
Chloroquine 
 The first 4-aminoquinolone derived from resochin, chloroquine, took until the 
end of World War II (1945) to develop as the front line treatment for malaria.  
Chloroquine has been the most effective drug at treating malaria because of its safety 
against multiple forms of Plasmodium and its affordability to produce in large quantities. 
Chloroquine is the most common prophylaxis used and is currently the first line treatment 
for P. vivax in countries where chloroquine-resistance has not emerged. Chloroquine-
resistant P. vivax has only been reported in Indonesia and Papau New Guinea [3]. 
Chloroquine remains the safest recommendation for prophylaxis treatment of pregnant 
women and continues to be a safe alternative for relapsing P. vivax when primaquine 
cannot be used (discussed below).    
Chloroquine Resistance  
Chloroquine accumulates in the digestive vacuole and acts by interfering with 
hemoglobin metabolism. It was not until chloroquine was introduced into table salt in 
parts of South America, Africa, and Asia in the 1950’s and early 1960’s that resistance 
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began to emerge [2]. Chloroquine resistance was first documented on the Thailand-
Cambodia border 2 years after being implemented through the WHO malaria eradication 
program and emerged separately in South America after another 2 years [8]. Resistance 
emerged in Africa 17 years following the first case in Asia. Through molecular 
epidemiology of the chloroquine resistance transporter gene (pfcrt) researchers found the 
African strain originated from the Southeast Asian strain [9]. A putative transporter 
PfCRT was identified through a genetic cross of chloroquine resistant and sensitive 
parasites that contains 10 transmembrane domains located on the digestive vacuole 
membrane [10]. Several point mutations in pfcrt are attributed to chloroquine resistance. 
One crucial mutation, K76T, is present in all chloroquine resistant strains and has been 
correlated with the resistant phenotype [11, 12]. Mutated PfCRT transports chloroquine 
out of the digestive vacuole where it would normally accumulate and become toxic to the 
parasite by inhibiting hemoglobin metabolism [13]. Once chloroquine treatment had 
ceased in Southeast Asia the prevelance of K76T had diminished and parasites became 
increasingly sensitive to chloroquine, suggesting a fitness disadvantage for maintaining 
the resistant mutation [14]. 
Amodiaquine 
In order to overcome chloroquine resistance the lipophilicity of the single side 
chain was enhanced by incorporation of an aromatic ring structure, becoming 
amodiaquine. Amodiaquine has been effective against low-level chloroquine resistance 
but not high-level chloroquine resistance [15]. Unfortunately severe hepatotoxicity is an 
adverse effect associated with long-term prophylaxis over 3 weeks, thus amodiaquine is 
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only used in combination to treat African countries where low-level chloroquine 
resistance has been observed [7]. 
Pyronaridine 
Like amodiaquine, pyronaridine is a modified structure of chloroquine. 
Amodiquine consists of two mannich base side chains while pyronaridine has one. This 
addition was thought to help overcome the severe hepatotoxicity associated with 
nucleophilic attack by amodiaquine [16]. Pyronaridine was effective and well tolerated 
when given to Thai patients having multidrug-resistant P. falciparum malaria [17, 18]. 
However, pyronaridine has been shown to be toxic to neutrophils [19]. High activity was 
observed against chloroquine-resistant African isolates and chloroquine-resistant mixed 
infections from Indonesia suggesting some cross-susceptibility of pyronaridine to 
chloroquine [20, 21]. More recently, artesunate-pyronaridine was the most effective ACT 
against artemisinin-resistant P. berghei suggesting its use as a partner drug against 
artemisinin-resistant P. falciparum [22].  
Piperaquine 
 An alternative strategy to overcome chloroquine-resistance was to connect two 4-
aminoquinolone structures by various linkers preventing the compound from fitting the 
biniding site of PfCRT [7]. The best dimeric 4-aminoquinolone produced was 
piperaquine because it was well tolerated and appeared to be effective against 
chloroquine-resistant African field isolates. Piperaquine became one of the first line 
recommended partner drugs for ACTs because of its slow elimination from the body and 
safety. While ACT-resistance including reduced susceptibility to the partner drug, 
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piperaquine, has been reported in areas of Asia it is currently the recommended partner 
drug for use with dihydroartemisinin to treat P. falciparum malaria. In low-transmission 
settings, especially parts of Asia, ACTs such as dihydroartemisinin-piperaquine are 
partnered with low-dose primaquine, a gametocytocidal drug, to reduce further 
transmission and possibly eliminate transmission in those areas [3].  
Antifolates: Sulfadoxine and Pyrimethamine (DHFR, DHPS) 
 With the advent of chloroquine resistance sulphadoxine-pyrimethamine (SP) 
became the recommended treatment. High levels of pyrimethamine resistance were 
observed in the same regions of South America and Asia as chloroquine and had spread 
to Africa less than a decade later [8]. Pyrimethamine and Sulfadoxine act by inhibiting 
folate biosynthesis and recycling that leads to blockage of DNA synthesis [23]. 
Sulfadoxine inhibits the enzyme dihydropteroate synthase (DHPS) and pyrimethamine 
inhibits the enzyme dihydrofolate reductase (DHFR). Several mutations within the genes 
dhfr and dhps have been associated with resistance to SP. The most essential amino acid 
change on the dhfr gene, S108N, for pyrimethamine has been directly linked to the in 
vitro phenotype, while an amino acid change at position 437 of the dhps gene (A437G) 
confers sulfadoxine resistance [24, 25]. Levels of resistance increase as mutation number 
increases [26]. 
Mefloquine 
In addition to modifying the quinolone core to generate synthetic 4-
aminoquinolones and 8-aminoquinolones researchers were interested in testing the 
efficacy of quinolone methanols as a newly synthetic antimalarial. Mefloquine was the 
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first quinolone methanol derivative selected for antimalarial treatment because it 
displayed high activity against chloroquine-resistant isolates tested [27]. Rapid clearance 
of parasites and reduced relapse was observed in mefloquine treated patients. Resistance 
to mefloquine was known to generate quickly and it was suggested for use in 
combination therapy with artemisinin derivatives. Due to it’s fast action and long half-life 
(remaining in blood for over 3 weeks) mefloquine was an ideal artemisinin combination 
therapy partner drug [28].  
Mefloquine and multi-drug resistance (pfmdr1) 
With the spread of chloroquine and pyrimethamine resistance there was an urgent 
need for new antimalarials that would not cross-react with these antimalarials. 
Mefloquine became the next line of defense because it was the most effective at curing 
chloroquine and pyrimethamine resistant infections [29]. However, mefloquine 
accumulates in the digestive vacuole just as chloroquine does [30]. Mefloquine resistance 
is associated with overexpression of the multi-drug resistance gene, pfmdr1, and it’s 
protein product, Pgh1, which acts as an energy dependent drug efflux pump across the 
digestive vacuole [31-33]. Increased copy number of pfmdr1 is the most useful 
determinant of mefloquine resistance and is more associated with mefloquine resistance 
in vivo than SNPs in pfmdr1 [34]. Pfmdr1 amplification has also been associated with 
resistance to quinine and halofantrine [35]. More recently, increased copy number of 
pfmdr1 has been associated with artemisinin resistance in vitro [36, 37]. 
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Artemisinin Combination Therapies (ACTs). 
Currently, artemisinin combination therapies (ACTs) are the recommended first 
line chemotherapy treatment for malaria. An ACT includes an artemisinin derivative with 
a short half-life, approximately 1-3 hours, paired with a slowly eliminated partner drug. 
Artemisinin, qinghaosu, was isolated from a chinese sweet wormwood plant, Artemisia 
annua, in the mid-1970s but has been used to treat malaria since 340 C.E. [29]. 
Dihydroartemisinin was synthesized shortly after proving to be more potent because it is 
the active metabolite produced in the body from artemisinin. Other artemisinin 
derivatives include artemether, arteether, artelinic acid, artesunate, and others all 
containing an endoperoxide bridge through which the drug acts [38]. Partner long lasting 
antimalarials, including sulfadoxine-pyrimethamine, piperaquine, lumefantrine, and 
mefloquine, have significantly longer half-lives remaining in the body for several weeks. 
Artemisinin (Endoperoxides) 
Artemisinin has been vital to current malaria control programs. The rapidity of 
action has been associated with the ability of artemisinin to act on the early ring-stage but 
appears to act on all stages of intraerythrocyctic development of Plasmodium relieving 
symptoms associated with malaria rapidly [39]. In addition, artemisinin has the ability to 
block transmission by acting on late-stage gametocytes [40]. A partner drug is vital to 
treatment and eliminating the emergence of artemisinin resistance. A partner drug, having 
a longer half-life than artemisinin, is responsible for killing remaining parasites after 
artemisinin has been eliminated from the body. This is thought to contribute to a decrease 
in the development and spread of artemisinin resistance. 
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Artemisinin Mechanism of Action 
The mechanism of action of artemisinin is not well understood and remains 
controversial. Artemisinin is a sesquiterpene lactone with an endoperoxide bridge that is 
essential for antimalarial activity. Iron-mediated cleavage of the endoperoxide bridge 
triggers the rapid release of carbon centered free radicals [7]. Artemisinin-derived free 
radicals have been shown to interfere with heme detoxification following hemoglobin 
degradation by the parasite, destabilize parasite membranes by oxidative damage, and 
inactivate parasite proteins somewhat nonspecifically [41-43].  
Artemisinin accumulates in neutral lipids of parasite membranes and digestive 
vacuole and induces oxidative damage on parasite membranes [43, 44]. Artemisinin has 
been shown to specifically inhibit an ATP-dependent Ca
2+ 
pump located on the 
endoplasmic reticulum, PfATP6, a homolog of mammalian sarcoplasmic/endoplasmic 
reticulum Ca
2+
 ATPase (SERCA) and a translationally controlled tumor protein (TCTP) 
found in the digestive vacuole and cytoplasm [45]. TCTP reduces cellular stress by 
binding calcium, aids in microtubule stabilization during cell cycle, and induces 
apoptosis in cancer [46]. In addition, artemisinins have been shown to bind several heme-
mediated proteins such as catalase, cytochrome c, and hemoglobin. Protease inhibition 
has also been associated with mechanism of action of artemisinin. General alkylation of 
cysteine residues interferes with protein function in the parasite and alkylation of 
falcipains, cysteine proteases, blocks hemoglobin degradation in the digestive vacuole 
[46]. Further studies are needed to understand the complex mechanism of action of 
artemisinin and determine interactions that are most responsible for parasite killing. 
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Artemisinin Resistance 
Since artemisinin is thought to interact with many different protein targets 
development of resistance is thought to be low; however, the rapid action of artemisinin 
increases the chances that residual parasite populations will survive treatment and select 
for parasites that tolerant artemisinin [39]. Therefore, artemisinin combination therapies 
are essential for the prevention of developing artemisinin resistance in the field. A partner 
drug remains in circulation killing parasites that have survived artemisinin exposure. 
Pairing artemisinin derivatives with partner drugs that parasites have not developed 
resistance to is essential for effective antimalarial treatment and reducing the risk of ACT 
resistance. 
Resistance to ACTs 
Clinical resistance to ACTs has emerged independently in two regions of South-
East Asia, in western Cambodia near Pailin and along the Thailand-Myanmar border 
[47]. Recent reports suggest resistance has spread as far as the western border of 
Myanmar shared with India [48]. Defined by delayed parasite clearance following 3-day 
treatment with an ACT [49]. Recently, increase in treatment failure rates following a 3-
day ACT regiment has been observed in areas where artemisinin resistance is emerging 
[50]. Increased treatment failure following combination therapy suggests resistance to 
artemisinin might involve a multidrug resistance and/or tolerance mechanism in order to 
survive multiple classes of antimalarials. 
Artemisinin resistance has proven to be complex. A molecular marker, a single 
nucleotide polymorphisms on chromosome 13 in the kelch gene (PF3D7_1343700), has 
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been established that is strongly associated with increased clearance half-life observed 
following ACT treatment in vivo [51]. Many mutations have been identified in the kelch 
(K13) gene to associate with resistance in vivo, most occurring within the propeller 
domain. One mutation, C580Y, appears to be the most prevalent but does not always 
associate with an increase in clearance half-life in vivo. In fact, many parasites 
maintaining a kelch mutation have a wild-type clearance phenotype in vivo and increased 
parasite clearance half-lives are observed in patients with parasites maintaining wild-type 
kelch. This suggests kelch mutations serve as a good molecular marker for field 
surveillance of artemisinin resistance but additional factors are thought to contribute to 
the mechanism of artemisinin resistance.  
Interestingly, insertion of K13 mutaitons into wild-type parasites confer resistance 
in vitro but with varying phenotypic responses among different laboratory strains [52]. 
An in vitro phenotype of artemisinin resistance, ring survival assay (RSA), was used to 
associate K13 mutations with clinical resistance [53]. Cambodian isolates had an 
increased phenotypic response compared to other reference strains tested suggesting the 
genetic background of the parasite contributes to K13-mediated resistance. 
Nonsynonomous mutations in ferredoxin, apicoplast ribosomal protein S10, multidrug 
resistance protein 2, and chloroquine resistance transporter are markers of a genetic 
background on which K13 mutations are thought to arise from [54].  
Mechanism of Artemisinin Resistance 
Kelch has been associated with a variety of protein-protein interactions in cellular 
function. Plasmodium kelch protein has similar homology to human KAEP1 (kelch-like 
ECH-associated protein 1) consisting of a BTB/POZ domain and a C-terminal 6-blade 
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propeller domain [51]. N-terminal BTB/POZ domain (Broad-Complex, Tramtrack and 
Bric a brac; or Poxvirus and Zinc-finger domain) is thought to be involved in multiple 
cellular roles, including recruitment to E3 ubiquitin ligase complexes [55]. C-terminal 
propeller domain is involved more specifically in organization of the cytoskeleton by 
binding actin and intermediate filaments.  
In mammalian cells, kelch (KAEP1) interacts with Nrf2 (nuclear factor-erythroid 
2-related factor 2), a transcription factor part of the signaling pathways that regulates 
detoxifaction of xenobiotics and reactive oxygen species. KAEP1 is a negative regulator 
of antioxidant response element (ARE) activation. In response to oxidative stress, Nrf2 
dissociates from KAEP1 and is translocated to the nucleus where it binds ARE of genes 
involved in antioxidant defense. Proteins produced are involved in feedback mechanisms 
that regulate antioxidant signaling pathways, including thioredoxin and interactions are 
highly conserved among many different cell types [56]. Mutations in KAEP1 have been 
associated with the dysregulation of KAEP1/Nrf2 signaling pathways in cancer and Nrf2 
constitituve expression has been associated with chemoresistance in cancer [57]. 
Regulation of Nrf2 expression is vital for cell homeostatis in antioxidant and xenobiotic 
defense. Many interacting partners contribute to the transcriptional regulation in addition 
to KAEP1. Protein kinases (PKC, PI3K/Akt, JNK) are involved in the regulation of Nrf2 
signaling pathway and interactions with epigenetic regulators are know to contribute to 
ARE-mediated cell homeostatis [58]. Interacting partners with K13 in Plasmodium are 
not well understood and the contribution of K13 in antioxidant and xenobiotic defense 
systems require more attention in order to understand its contribution to the generation of 
artemisinin resistance in Plasmodium. 
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Protein kinases, additional transcription factors, and upstream regulators are 
associated with the coordinate regulation of Plasmodium cell cycle [59, 60]. Adaptive 
regulation of the cell cycle through epigenetic modification of gene expression has been 
thought to contribute to the evolution of the malaria parasite to survive human infection 
[61-63]. Transcriptional profiling of artemisinin resistant field isolates revealed altered 
expression of genes involved in cell cycle regulation, transcriptional regulation, 
chromatin remodeling, and intracellular signaling through intraerythrocytic development 
[64]. Three types of transcriptional profiling were observed defined by developmental 
stage and did not associate with geographical origin. Two groups consisted 
predominately of young ring-stages, one having a high gametocyte density, and a 
predominately late ring-stage group. The upregulation of transcripts involved in unfolded 
protein response (UPR) pathway, claimed to be associated with artemisinin resistance, 
was significant correlated with young ring-stage groups only. Interestingly, clinical 
presentation, usually following synchronous schizont rupture leading to high fever was 
significantly different between the two ring-stage groups, with late ring-stage group 
significantly less likely to present to clinic in evening hours. This group also had a 
significantly higher parasite clearance half-life following ACT treatment. The adaptive 
evolution of artemisinin-resistant Plasmodium falciparum to heterogeneously regulate its 
cell cycle requires further investigation.  
In Vitro Phenotypes of Artemisinin Resistance 
In vitro models to study artemisinin resistance were generated by increased 
exposure of laboratory lines to artemisinin derivatives identifying several mutations, 
including SNPs in kelch, involved in cellular homeostasis [65, 66]. In addition to 
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molecular markers identified, phenotypes contributing to the artemisinin mode of action 
began to emerge. Change in susceptibility at the ring-stage has been associated with 
artemisinin resistance in vitro [53, 67, 68]. While traditional tritium-labeled hypoxanthine 
incorporation assays to determine inhibitory concentration of antimalarials did not show 
increased susceptibility in artemisinin-resistant isolates, adding tritium-labeled 
hypoxanthine at the start of the assay when ring-stages are exposed to artemisinin allows 
one to see the changes in susceptibility of ring-stage parasites [67]. A quiescence 
mechanism has been associated with increased tolerance of the ring-stage parasite 
following exposure to dihydroartemisinin [53, 67, 69]. However, the quiescent parasites 
observed by Witkowski et al., were morphologically similar to ring-stage parasites 
suggesting an increase in the number of ring-stage parasites surviving exposure to 
dihydroartemisinin was observed. The quiescent ring-stage parasites observed by the 
Kyle lab and others have a distinctly different morphology than ring-stage parasites. 
These parasites transcriptionally arrest at the ring-stage following exposure to 
dihydroartemisinin and enter a state of dormancy observed by condensation of the 
cytoplasm [65]. Once drug is removed dormant parasites resume growth at the ring-stage 
and proceed through the intraerythrocytic cycle. Interestingly wild-type and resistant 
parasites lead to recrudescence from DHA-induced dormancy. The ability of ring-stage 
parasites to become dormant and awake following drug exposure appears to impact 
artemisinin resistance in vitro [69, 70] and the fitness advantages potentially associated 
with dormancy may contribute to the spread of artemisinin resistance in the field. Further 
understanding of the heterogeneous fates of an isogenic parasite in response to 
artemisinin pressure may offer some insight into the heterogeneity of transcriptional 
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expression and cell cycle progression found among artemisinin-resistant groups emerging 
in the field. 
Dormancy and Antimalarial Drug Tolerance.  
Recrudescence 
Treatment failure following WHO antimalarial treatment guidelines is alarming 
for malaria elimination efforts since it has long been associated with the development of 
antimalarial drug resistance. Parasites that survive treatment are not necessarily less 
susceptible to treatment but are the parasites that have been selected by drug pressure to 
propagate and infect other hosts. It can take several selective pressures before 
antimalarial resistance is observed, as demonstrated in vitro [67], suggesting there are 
innate mechanisms to resist drug treatment that preclude increased drug tolerance. This is 
especially evident in endemic regions where transmission is low and recrudescence 
occurs in non-immune individuals 28 days following treatment [71]. 
 Treatment failure occurs when parasite density falls below the level of detection 
following antimalarial treatment and surviving parasites propagate leading to a 
recrudescent infection [72]. Recrudescence has consistently been associated with the 
development of antimalarial drug resistance since first observed with pyrimethamine in 
1962. Increased treatment failure was associated with pyrimethamine resistance in Ghana 
following inadequate self-medication and recrudescent parasites were less susceptible to 
pyrimethamine treatment [73].  This trend has been observed with chloroquine and 
mefloquine resistance [74, 75]. Interestingly, increasing the concentration of antimalarial 
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or dosing frequency does not improve recrudescence rates [76], thus changing how we 
study antimalarial drug efficacy. 
 Dormancy has been suggested to explain the ability of Plasmodium falciparum to 
recrudesce following antimalarial treatment. After encountering stress, such as exposure 
to an antimalarial drug, the ring-stage parasite enters a morphologically distinct quiescent 
state in which the parasite maintains reduced metabolism and resumes intraerythrocytic 
development at the ring-stage once pressure is removed [67, 69].  
 A mathematical model was developed with a fast acting antimalarial, artesunate, 
postulating the impact of dormancy on treatment failure outcomes [77]. This model 
attempted to explain why increasing dosing frequency does not improve treatment failure 
outcomes. Hoshen suggests factors such as concentration of antimalarial drug and dosing 
frequency impact the amount of time a parasite remains dormant before recrudescing. 
Plasmodium falciparum recrudescence has been demonstrated in vitro with 
pyrimethamine, mefloquine, atovaquone, proguanil, and artemisinin [67, 69, 78-81]. 
Drug resistance also appears to impact how long a parasite remains dormant and has been 
demonstrated with artemisinin resistance in vitro.  
Role of Dormancy in Artemisinin-Resistant P. falciparum Recrudescence 
Recrudescence following exposure to an artemisinin derivative is dose dependent 
but independent of geographical background [69]. Artemisinin resistant parasites exit 
dormancy and recrudesce earlier than sensitive parasites in vitro [67, 69]. Dormant 
parasites giving rise to recrudescent infections have been observed following artesunate 
treatment in the rodent malaria model, P. vinckei [82]; and in non-immune Aotus 
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monkeys infected with Plasmodium falciparum following treatment with artemisone 
combination therapies [83]. Dormancy contributes to artemisinin resistance most likely 
by aiding in the selection of parasites surviving drug exposure and enhancing fitness 
costs associated with resistance mutations. 
Role of Dormancy and Persistence in the Spread of Drug Resistance in Biological 
Systems 
In other biological systems dormancy is thought of as a type of persistence that 
enables resistance to emerge following exposure to drug. Persistence, as a drug tolerance 
response, leads to a lack of development in a physiological state that is beneficial to the 
organism in the face of drug pressure often including a population of dormant cells that 
have built up toxic levels of intracellular protein in response to drug pressure leading to 
an orchestrated variable phenotypic response that enhances the survival of the population 
rather than each individual acting alone [84]. This “bet-hedge” strategy is often 
associated with the development of multidrug resistance in other biological systems and 
has been well characterized in bacterial infectious disease and cancer.  
 Isogenic drug-resistant bacteria can regulate phenotypic variability of persistent 
and dormant states through a “bet-hedge” strategy. An isogenic population can contain 
wild-type, persistent, and dormant phenotypic bacteria. A toxin threshold regulates the 
phenotypic response and the amount by which the threshold has been exceeded 
determines the length of the dormant state. In antibiotic tolerant E. coli, the buildup of 
HipA toxin in the hipBA toxin-antitoxin module regulated the phenotypic variability of 
the bacteria [85]. Once the threshold of toxin concentration has been reached a persister 
cell will enter a dormant state and the duration is dependent on the concentration of toxin 
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exceeding threshold. Thus, all bacteria in the population contribute to detoxification of 
toxins regulating the dormant state in E. coli. This strategy has been suggested to enhance 
the survival of the isogenic population as a whole, thus an organism’s ability to regulate 
the dormant state in response to drug exposure would contribute to the enhanced survival 
of drug-resistant bacteria by enhancing fitness of subpopulations of isogenic drug-
resistant bacteria [86].  
 Persistent bacteria that do not enter a dormant-state but have significant growth 
arrest are known to contribute to the protective strategy of the population as well. It is 
hypothesized that persistence is a social trait with cross-talk among kin leading to 
persistence in subsequent generations [87-89]. Increasing phenotypic variability in 
subsequent generations serves as an epigenetic inherited based mechanism aiding in the 
survival of drug resistant bacteria. Little work has been done on the regulatory 
mechanisms of a variable phenotypic response due to the difficulty in isolating sizable 
numbers of individual populations. Some advances are being made in the fields of 
bacteria and cancer to target these drug resistant populations. 
Global regulators of persistence were identified in antibiotic tolerant E. coli 
through which stochastic overexpression of redundant persister genes by these regulators 
led to dormancy and increased bacterial tolerance [90]. Genes affected included dnaJ and 
dnaK (chaperones), apaH (diadenosine tetraphosphatase), surA (peptidyl-prolyl cis-trans 
isomerase), fis and hns (global regulators), hnr (response regulator of RpoS), dkasA 
(transcriptional regulator of rRNA transcription), ygfa (5-formly-tetrahydrofolate cyclo-
ligase) and yigB (flavin mononucleotide [FMN] phosphatase). Identifying genes involved 
in global regulation of persistence and dormancy in Plasmodium falciparum would be 
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essential for malaria elimination if dormant parasites are responsible for the 
recrudescence and spread of antimalarial drug resistant populations. 
Combating Multidrug Resistance by Inhibiting Persistence 
Targeting persister cells specifically or enhancing their susceptibility to killing by 
existing antimicrobials are new strategies used to combat multidrug resistant organisms 
that are able thrive as persisters [91]. Death is promoted in nongrowing M. tuberculosis 
by inhibition of the proteasome or ATP synthase specifically [92]. Inhibition of the SOS 
response pathway through constitutive expression of the LexA repressor improved 
survival of genetically drug resistant E. coli mutants in a murine model [93]. 
Spread of Drug Resistant P. falciparum and the Importance of Fitness 
We understand that resistance to antimalarials emerges de-novo, generally during 
asexual reproduction, through spontaneous mutations and gene duplication events 
independent of drug pressure but are selected for through subsequent drug exposure [94]. 
Mutations allow the parasite to tolerate drug and a higher concentration of drug is needed 
to achieve parasite clearance [71]. Once de-novo selection has occurred subsequent 
spread is determined by selective advantages in the competitive environments of the 
mosquito and human hosts. The most fit parasites under drug selective pressure will 
survive at a higher rate and have a larger pool of genes available for genetic 
recombination in the mosquito to produce progeny with beneficial mutations. 
Tracking the spread of drug resistance in the field with genetic markers has 
enhanced our understanding of the evolution of drug-resistant parasites and what we need 
to do prevent further spread of ACT resistant malaria. Historically it has been shown, by 
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using molecular markers of drug resistance, antimalarial drug resistance has spread from 
Southeast Asia to Africa consistently. 
Several host and environmental factors play a pivotal role in the spread of drug-
resistant malaria. The most fit parasite will propagate and pass on its genetic mutations to 
subsequent generations at a much higher rate than a lesser fit parasite [95-97]. Many 
studies have been done to try and determine the most selective forces that drive the 
spread of drug resistance and all involve four processes: mosquito transmission, human 
host immunity, coinfection (competitive growth environments), and drug tolerance [63]. 
Low Transmission vs. High Transmission Setting 
 Drug resistance first emerges in areas of low transmission. Symptomatic carriers 
are more prevalent because transmission intensity is too low for people to acquire partial 
immunity [94]. Therefore asymptomatic carriers are rare in these settings and drug 
exposure drives the spread of antimalarial drug resistance. Parasites able to tolerate 
higher doses of antimalarials lead to prolonged parasite clearance and increased treatment 
failure [71]. Thus leading to the spread of parasites with genetic changes responsible for 
increased drug tolerance. 
 In areas of high transmission, where immunity is high, asymptomatic patients 
harbor the majority of transmissible parasites and drug pressure is less frequent. Parasites 
are exposed to drug less frequently reducing the selection of drug resistant parasites [94]. 
These factors may explain why drug resistance has historically emerged in areas of low 
transmission. 
 
 22 
Gametocyte Carriage 
 Gametocytes are responsible for the genetic mixing and evolution of the malaria 
genome. Artemisinin kills young gametocytes thus reducing gametocyte carriage and 
transmission by 6-fold [28, 98]. Theoretically, this contributes to reduced transmission 
and spread of artemisinin resistant parasites. However, gametocyte carriage is increased 
in patients infected with drug resistant parasites compared to infected with sensitive 
parasites increasing transmission of drug resistant parasites [99]. While increased 
gametocyte carriage has been associated with resistance to artesunate-mefloquine 
treatment along the Thai-Myanmar border [100], it remains unclear how gametocyte 
carriage contributes to the current spread of artemisinin resistance observed in the field. 
Human Host Immunity (Innate Mechanisms of Drug Resistance) 
Malaria has been the most influential infectious disease on the evolution of human 
genetics. It was hypothesized that genetic-based hemoglobinopathies decrease the 
invasion of Plasmodium parasites into red blood cells and protect the human host from 
severe disease. This theory, known as the “malaria hypothesis”, was confirmed by A.C. 
Allison who showed African sickle-cell trait carriers are more resistant to malaria [101]. 
The fitness advantage of having a genetic disease in malaria endemic countries, such as 
sickle-cell trait, has been naturally selected for evolutionarily over time. The 
geographical distribution of heterozygous carriers of sickle hemoglobin (HbS) and 
malaria endemicity is strongly associated globally [102]. This study also compared 
distribution of HbS and malaria endemicity globally over time, before and after control 
measures were introduced. An increase in the frequency of HbS carriers was observed in 
more malaria endemic regions of Africa over time. While it is understood that fitness is 
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the evolutionary driving force for the spread of genetic-based immunity against malaria 
the cellular mechanisms is not completely understood. 
Sickle-Cell Disease 
Sickle-cell disease is a genetically inherited disorder that alters the characteristics 
of  adult hemoglobin and leads to anemia. Adult hemoglobin consists of 2 α and 2 β 
globular subunits to make a stable tetramer protein. Sickle hemoglobin results from a 
single point mutation (GLU6VAL) on the β-globin gene [103]. Homozygous sickle 
hemoglobin (HbSS) has two mutated copies of the hemoglobin gene inherited from the 
mother and father. Deoxygenation of red blood cells leads to polymerization of mutated 
hemoglobin and distortion of the red blood cell shape into a “sickle” or banana shape, 
thus limiting the malaria parasite from infecting the red blood cell.  
Globin polymerization and disease manifestations are reduced in heterozygous 
sickle hemoglobin (HbAS), sickle hemoglobin trait, however protection against the 
malaria parasite remains evident. Intraerythrocyctic conditions altered by sickled 
hemoglobin lead to reduced parasite invasion, reduced parasite growth, reduced rosetting 
formation, and reduced cytoadherence [104]. Biochemical changes of the red blood cell 
that provide protection include: oxidative stress, low potassium levels, high 
concentrations of hemoglobin, and osmotic shrinkage. HbSS and HbAS red blood cells 
have reduced expression of P. falciparum erythrocytic membrane protein 1 (PfEMP1) 
which is associated with protection from severe disease [105]. Decreased, weak 
PfEMP1/knob interactions impair cytoadherance and decrease sequesterization of 
infected red blood cells [106, 107]. Immune protection provided by HbAS is thought to 
be due to both innate and acquired mechanisms [108]. Evidence for acquired immunity 
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was based on age-specific increase in protection provided by HbAS in African children 
2-10 years old. Innate mechanisms of protection involve increased expression of heme 
oxygenase-1 (HO-1) that aids in detoxifying the higher amount of free heme associated 
with HbSS [109]. Molecular processes responsible for the protection sickle cell trait 
provides continue to be studied due to their implications in vaccine development.  
Thalassemia 
Thalassemia is a genetically inherited blood disorder similar to sickle cell and is 
prevalent in malaria endemic countries of Sub-Saharan Africa. Decreased hemoglobin 
formation is caused by abnormal α-globin (α-thalassemia) or β-globin (β-thalassemia) 
production [110]. Disease severity is reduced in the heterozygous state. Genetically based 
protection against P. falciparum by red cells acquired with thalassemia is similar to that 
of sickle cell trait [111]. 
Ovalocytosis 
Southeast Asian Ovalocytosis (SAO) results from a 27-bp band 3 deletion 
(SLC4AΔ27) and is lethal in the homozygous state. Heterozygous carriers are prevalent 
in malaria endemic regions of Papua New Guinea (PNG) and there is some evidence to 
suggest that it is associated with protection against cerebral malaria caused by P. 
falciparum [112]. It remains unclear whether SAO provides protection against P. vivax 
malaria in PNG. One study suggests an association between SAO and protection against 
P. vivax independent of Duffy-antigen (discussed below) yet further studies are needed to 
confirm this hypothesis [113].  
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Glucose-6-Phoshate Dehydrogenase Deficiency (G6PD) 
Glucose-6-phosphate dehydrogenase is a key enzyme in the pentose phosphate 
pathway that reduces oxidative damage and regulates oxidant levels in the red blood cell. 
G6PD deficiency leads to oxidative damage of the red blood cell resulting in anemia. 
Hemizygous males and heterozygous females are protected against severe P. falciparum 
malaria [114]. Two variants, Southeast Asian G6PD-Mahidol and G6PD-Mediterranean, 
have been associated with specific ethnic groups in malaria endemic regions providing 
evidence that the fitness impairment associated with G6PD deficiency evolutionary is 
selected in malaria endemic settings due to the beneficial protection provided against 
severe malaria [115, 116]. Further, these two studies are the first to examine the 
protection red blood cell disorders provide against P. vivax malaria infection. 
Oxidative Stress 
Increased oxidative stress to the red blood cell is associated with the protective 
immunity provided by all genetic-based hemoglobinopathies (sickle cell, thalassemia, 
and ovalcytosis) and G6PD deficiency. Oxidative damage has been associated with 
alterations in surface protein expression (i.e. decreased IgG), which enhance infected 
erythrocyte recognition by macrophages and increase rates of phagocytosis [117]. In 
addition, malaria parasites initiate antioxidant defense mechanisms of the human host 
erythrocyte in response to the oxidative stress generated by the parasite through 
mitochondrial electron transport, metabolism, and hemoglobin digestion in the food 
vacuole. The host cell generates glutathione reductase to reduce oxidized glutathione 
disulfide (GSSG) intermediates to glutathione (GSH) that have been transported from the 
parasite to the host red blood cell. GSSG is pumped out of the parasite through multi-
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resistant pumps (MRP) or GSSG pumps in order to maintain a high ratio of GSH/GSSG 
for redox homeostasis. This is beneficial to the host cell because an infected red blood 
cell no longer can synthesize GSH de novo. Catalase and glutathione peroxidase are 
present in the host cell to oxidize GSH, thus reducing levels of oxidative stress in the host 
cell [118]. Redox homeostasis of the parasite and host erythrocyte is complex and vital 
for both to survive. The host has adapted to exploit mechanisms of innate resistance to 
the parasite as described, but the parasite has also adapted mechanisms to resist 
antimalarials that target redox homeostasis. 
Duffy Blood-Group Negative 
The most classic example of genetic-based human host immunity is resistance to 
P. vivax by the majority of West and Central Africans who lack the expression of Duffy 
antigen. Host erythrocytes lacking a Duffy antigen surface receptor, due to a SNP in 
promoter region of the FY gene, resist invasion by P. vivax [119]. Two co-dominant 
alleles exist, FY*A and FY*B, caused by G44D and a T-to-C mutation in the GATA box 
of the FY promoter, respectively, with the FY*A allele that arose in southeast Asia 
capable of conferring partial resistance to clinical vivax malaria [120]. The FY*A allele is 
dominant in Africa and the FY*B allele has almost reached fixation in sub-Saharan 
Africa [121]. The geographical distribution and frequency of the Duffy negative alleles 
overlaps with areas of high historical malaria transmission suggesting a protective 
advantage of the Duffy blood-group negative is being naturally selected for in endemic 
regions. However, a recent study has shown P. vivax can invade Duffy-negative 
individuals from Madagascar where Duffy-negative and positive groups coexist and P. 
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vivax prevalence is high [122]. The mechanisms P. vivax have evolved to invade 
erythrocytes in this setting is further being investigated. 
Importance of Fitness in the Emergence and Spread of ACT-Resistant Plasmodium 
Generally drug resistance emerges at a fitness cost to the parasite and overcoming 
this fitness cost is imperative for the survival and propagation of drug-resistant P. 
falciparum [63, 97]. Parasites able to tolerate combination therapies are being selected for 
as resistance to ACTs emerges and parasites surviving will be the most resistant [123]. 
Drug resistance spreads when a resistant parasite population is able to adapt and 
propagate through all host environments better than wild-type. Therefore it is important 
to understand the factors contributing to fitness advantages driving the spread of 
artemisinin resistance and partner drug resistance in order to prevent the spread of 
resistance to ACTs any further.  
Scope of Study 
 There remains a dire need for a robust, reliable in vitro phenotype assay to study 
the emergence and spread of artemisinin resistance. Artemisinin resistance appears to be 
emerging through multidrug resistance mechanisms due to the increased survival 
following combination therapy. New strategies are needed to find therapies that eliminate 
drug resistant malaria and prevent the spread of artemisinin resistance. In this study we 
have uncovered multiple phenotypes of artemisinin resistance by cloning Plasmodium 
falciparum field isolates from Cambodia and Thailand where artemisinin resistance is 
emerging. All involve adaptions to the intraerythrocytic cell cycle. We have developed a 
reliable in vitro phenotype assay that significantly correlates with delayed parasite 
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clearance half-life observed in the field and molecular markers of artemisinin resistance.  
Secondly, we determined the fitness cost associated with artemisinin resistance in vitro to 
determine how resistance might spread using sensitive and laboratory adapted 
artemisinin-resistant progeny.  
 In order to understand the emergence and spread of artemisinin resistance it 
became clear that we must also understand how these parasites tolerate artemisinin 
combination therapies (ACTs). Reports of increased treatment failures following ACT 
regimens have underscored the importance of understanding how Plasmodium is able to 
tolerate ACTs. Dormancy, a mechanism of Plasmodium parasite tolerance to drug 
exposure (or stress) at the intraerythrocytic stage of development has been associated 
with artemisinin resistance in vitro. Therefore, we wanted to understand the contributions 
of dormant parasites to the generation and spread of resistance to multiple antimalarials. 
Using piggyBac transposon mutagenesis techniques we were able to transfect GFP and 
luciferase into the genome of highly characterized artemisinin-resistant field isolate 
clones to study the phenotypes we have discovered to be associated with ACT drug 
resistance. These technologies, along with the development of new detection technologies 
will allow us to study phenotypes associated with the development of ACT resistance in 
real-time. We aim to develop new in vitro screening strategies with these technologies to 
find novel therapies that target all forms of drug-resistant malaria. This proves to be 
essential for the control and elimination of drug resistant populations that are being 
selected for in the field by current antimalarial treatment strategies. 
 
  
 29 
 
 
 
 
Chapter 2 
Artemisinin-Resistant Plasmodium falciparum Exhibit Altered Patterns of 
Development in Infected Erythrocytes 
Abstract 
 Artemisinin is used in combination with other antimalarial drugs for treatment of 
multidrug resistant malaria worldwide.  Clinical resistance to artemisinin recently 
emerged in Southeast Asia, yet in vitro phenotypes for discerning mechanism(s) of 
resistance remain elusive.  Herein we describe novel phenotypic resistance traits 
expressed by artemisinin-resistant Plasmodium falciparum.  The resistant parasites 
exhibit altered patterns of development that result in reduced exposure to drug at the most 
susceptible stage of development in erythrocytes (trophozoites) and increased exposure in 
the most resistant stage (rings). In addition a novel in vitro delayed clearance assay 
(DCA) that assesses drug effects on asexual stages was found to correlate with parasite 
clearance half-life in vivo as well as with mutations in the kelch domain gene associated 
with resistance (Pf3D7_1343700). Importantly all of the resistance phenotypes were 
stable in cloned parasites for more than 2 years without drug pressure.  The results 
demonstrate artemisinin-resistant P. falciparum have evolved a novel mechanism of 
phenotypic resistance to artemisinin drugs linked to abnormal cell cycle regulation; these 
results offer insights into a novel mechanism of drug resistance in P. falciparum and new 
tools for monitoring the spread of artemisinin resistance.  
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Introduction 
Artemisinin combination therapy (ACT) is the recommended treatment for 
multidrug resistant malaria by the World Health Organization. These combinations rely 
on the fast acting properties of the artemisinin derivative to rapidly clear parasites with 
the longer acting partner drug clearing residual parasites, thus reducing the frequent 
observation of recrudescent infections when artemisinin drugs are used alone. 
Unfortunately resistance to artemisinin derivatives has emerged in Southeast Asia and 
now threatens the utility of the most important treatment options for Plasmodium 
falciparum malaria resistant to all other antimalarial drugs. Clinical resistance to 
artemisinin is expressed as a reduced rate of parasite clearance from peripheral blood 
resulting in a parasite clearance half-life > 5 hr [124]. Resistance to artemisinin is a 
heritable trait, linked to mutations in the kelch propeller domains of Pf3D7_1343700, and 
appears to be spreading in Southeast Asia [47, 51, 124]. Clearly a public health disaster is 
looming if artemisinin resistance spreads globally like the selective sweeps previously 
observed for chloroquine and pyrimethamine resistance [9, 125, 126]. 
Despite the well-characterized clinical resistance phenotype to artemisinin, 
resistance phenotypes in classical in vitro drug susceptibility assays, used successfully for 
other antimalarial drugs, have not been useful for detecting artemisinin resistance [49]. 
Two modified in vitro assays have been used to assess resistance with some success [53, 
65] with both assessing reduced susceptibility in the ring-stage of development in 
erythrocytes; however, stable in vitro phenotypes in culture-adapted parasites remain 
elusive. Given the apparent complexities of artemisinin resistance, we hypothesized that 
artemisinin-resistant parasites have evolved novel mechanisms of resistance that are not 
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evident with previously reported phenotypes and that possible fitness defects result in 
loss of resistance phenotypes and genotypes in vitro. In this study we culture adapted and 
promptly cloned artemisinin-resistant P. falciparum. The clones were then used to 
demonstrate novel, stable resistance phenotypes that can be used to elucidate mechanisms 
of resistance to the most important class of antimalarial drugs. Remarkably the 
artemisinin resistance phenotypes include dramatic alterations in intraerythrocytic 
development in the absence or presence of artemisinin drugs. 
Materials and Methods 
Adapting Patient Samples to In Vitro Culture   
Cryopreserved infected erythrocytes were received on dry ice and immediately 
stored in liquid nitrogen. Modified thawing and culturing methods were used [127]. 
Initially patient samples were cultured with 15% heat-inactivated human AB+ plasma at 
3% hematocrit. Once reaching 2% parasitemia samples were immediately frozen in 
glycerolyte.  In addition, isolates were cloned by limiting dilution to preserve the 
heterogeneity of the parasite population within a patient sample [128]. Clones were 
immediately cryopreserved and drug susceptibility was determined for clones and isolates 
from culture-adapted patient samples. Parasitized red blood cells of parental strains and 
clones were frozen for genomic DNA extraction and filter spots made for further 
analysis. Clones maintained in culture after initial freeze/thaw were cryopreserved and 
genomic DNA was extracted over the course of two years of the study. Additional details 
about patient samples adapted to in vitro culture can be found in Table 2.1. 
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Phenotype Assays 
Time-zero [
3
H]hypoxanthine drug susceptibility assay.  Susceptibility of isolates 
and cloned progeny to artemisinin derivatives (artemisinin, dihydroartemisinin, artelinic 
acid, and artesunate) were analyzed by a modified [
3
H]hypoxanthine incorporation assay 
[129]. Artemisinin and artelinic acid (AL) were included in the artemisinin panel of drugs 
in addition to clinically relevant dihydroartemisinin (DHA) and artesunate because of the 
large increase in susceptibility observed with in vitro-selected artemisinin-resistant 
parasites [65]. [
3
H]hypoxanthine and drugs were added to culture at the start of the assay, 
allowed to incubate for 48 hours, and radiolabeled cells were harvested. The fifty percent 
inhibitory concentration (IC50) of mefloquine was determined for all parasites by adding 
[
3
H]hypoxanthine 24 hours after drug exposure (standard [
3
H]hypoxanthine incorporation 
assay) (12).  
Parasite clearance and recrudescence in vitro. Late stage parasites were 
synchronized using a MACS magnet column (Miltenyi Biotec). Once entering ring-stage, 
synchronized parasites were exposed to 700 nM dihydroartemisinin (DHA) for 6 hours at 
1.5% parasitemia. DHA exposure was repeated 24 and 48 hours after initial exposure. 
After 6-hour drug exposure parasites were washed with RPMI medium three times. 
Giemsa smears were used to quantify parasitemia at hour 0, 6, 12, 18, 24, 36, and 48. 
These data were used to generate parasite clearance curves and parasite reduction ratios 
(PRRs). In a separate study parasites were exposed to a 30 nM of DHA for 6 hr, the drug 
washed out, and parasite development followed by microscopy. Parasite maturation 
following drug exposure was measured by categorizing 100 parasites per sample at each 
of the above mentioned time points. Parasites were categorized based on early or late 
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stage normal morphology (ring or trophozoite/schizont). Parasites with dormant ring or 
pyknotic, dead forms were considered as one category; therefore; parasite clearance rates 
and PRRs were based upon prevalence of parasites with normal ring, trophozoite, or 
schizont morphology. Beginning at day 3 smears were made and stained with Giemsa 
every 24 hours to observe recrudescence. Cultures were maintained under standard 
culturing conditions until parasitemia reached >1.5%. Three clones were randomly 
selected from each isolate and clearance/recrudescence assays were run in duplicate. 
Clearance and recrudescence rates were compared to W2, an artemisinin susceptible 
laboratory clone.  
Parasite Growth in Absence of Drug Pressure   
Two methods were used to monitor parasite growth: flow cytometry and 
microscopy of Giemsa-stained blood smears. A modified flow-cytometry method was 
used to observe parasite growth under standard culturing conditions in the absence of 
drug pressure [130]. Late-stage parasites were synchronized using a MACS magnetic 
column (Miltenyi Biotec, Auburn, CA). A 10ml culture at 1.5% parasitemia was initiated 
at the start of the assay once parasites matured to ring-stage. Every 2 hours for 
approximately 60 hours a blood smear was made and 50μl of culture, in triplicate, was 
fixed in 0.05% glutaraldehyde in a 96-well round-bottom plate for flow cytometry 
analysis. Flow cytometry samples were stained with ethidium bromide and analyzed as 
described by Balu et al. [130]. Percent of ring and schizont for 3 samples was averaged 
and plotted over time (SD≤0.025). Cell cycle progression of patient clones was compared 
to W2 laboratory clone under standard culture conditions.  
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Stage-Specific Parasite Viability Following DHA Exposure 
Late stage parasites were synchronized using a MACS magnet column (Miltenyi 
Biotec). Once reaching ring-stage, parasites were exposed to 700 nM DHA for 3 hours 
and the number of visible parasites was determined using a serial dilution method as 
described previously [131]. Exposure was repeated with a new aliquot of parasite culture 
every 3 hours for one complete life cycle (up to 48 hrs). The log of viable parasites was 
compared between resistant and sensitive parasites 14 days after exposure for each time 
point along the parasite life cycle. 
Genetic Determinants of Resistance 
Genomic DNA was extracted using a phenol:chloroform method. Parasitized red 
blood cells were frozen at -80°C for at least 24 hours and treated with 0.5% saponin to 
remove red blood cells from extract. Parasite pellet was frozen 12-24 hours in Tris EDTA 
buffer. Thawed pellet was treated with 4% SDS and 20 mg/ml RNase (Life Technologies, 
Grand Island, NY).  Equal volumes of phenol:chloroform:isoamylalcohol (25:24:1) were 
added and spun at 14,000 rpm for 5 minutes at room temperature. The upper aqueous 
phase was transferred to a new tube. This separation step was repeated with 
chloroform:isoamylalcohol (24:1) and chloroform respectively. The final aqueous 
transfer was treated with 3 M potassium acetate and 100% ethanol. Pellet was washed 
with 100% ethanol and suspended in Tris EDTA buffer. Genomic DNA was quantified 
using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA). 
SNPs associated with artemisinin resistance. Pyrosequencing was used to 
quantify allele frequency of known SNPs associated with artemisinin resistance. PCR and 
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sequencing primers were designed using Biotage Pyrosequencing Assay Design software 
(Charlottesville, VA) to amplify SNP-containing genes. Primers used in this study are 
listed in Table S2.  A 5’ biotin label was added to the PCR primer binding to the opposite 
strand of the sequencing primer. Each 50μl PCR reaction mixture contained 31.5 μl 
sterile water, 10 μl 5X HF buffer, 1 μl 10 mM dNTPs, 2 μl each of forward and reverse 
primer, 0.5 μl Phusion Hot Start II DNA polymerase (Fisher Scientific, Pittsburg, PA), 
and 2 μl template DNA. Thermal cycling conditions were 98°C for 30 seconds (initial 
denaturation), followed by 40 cycles of denaturation at 98°C for 10 seconds, annealing at 
temperature indicated in Table S2 for 30 seconds, and extension at 72°C for 50 seconds, 
followed by a final extension at 72°C for 7 minutes. PCR products (10μl) were visualized 
using QiAxcel (Qiagen, Valencia, California). Sequencing primer (0.6 μM) diluted in 
annealing buffer (Biotage, Charlottesville, VA) and 40 μl of mixture was aliquoted in a 
96-well pyrosequencing plate (PSQ). Binding reaction mixture consisted of 4 μl of 
Streptavidin coated Sepharose beads (GE Healthcare) and 51 μl of binding buffer. In each 
well of a 96-well plate 55 μl of binding mixture was added to 25 μl of PCR product and 
mixed at 14,000 rpm for 10 minutes. Using the Vacuum Prep Workstation (Biotage, 
Charlottesville, VA) the Sepharose-bound PCR products were captured with the Vacuum 
Prep Tool immediately after being mixed and washed as follows: 70% ethanol for 10 
seconds, denaturing buffer (0.2M NaOH) for 10 seconds, and washing buffer (10mM 
Tris-acetate, pH 7.6) for 15 seconds. The vacuum was released and the Sepharose-bound 
PCR products were released into the PSQ plate containing sequencing primer. The plate 
was incubated at 80°C for 2 minutes and allowed to cool at room temperature. Plates 
were read on PyroMark ID (Biotage, Charlottesville, VA).  
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Results 
Cloning Artemisinin-Resistant Isolates 
P. falciparum parasites isolated from patients often have multiple populations and 
during growth in vitro, clones with fitness defects can be overgrown by more fit clones 
[97]. Drug resistance may incur fitness costs and recent evidence suggests that 
artemisinin-resistant phenotypes were lost during prolonged in vitro culture [132]. 
Therefore we aimed to increase recovery of stably resistant parasites by cloning 
immediately upon establishment of growth in vitro.  Cryopreserved isolates from clinical 
studies of artemisinin resistance in Cambodia and Thailand [49, 133, 134] were thawed, 
grown under standard culture conditions and processed for cloning as soon as growth was 
established in vitro.  Randomly selected clones (n=3 per isolate) were then characterized 
for resistance phenotypes and genotypes. 
Reduced Sensitivity to Artemisinin Derivatives In Vitro 
Ring-stage parasites of P. falciparum arrest development within the first 24 hours 
following exposure to artemisinin drugs [65, 69]. This is likely why standard in vitro 
assays have not been useful for confirmation of artemisinin resistance phenotypes.  
Therefore, we used a modified drug susceptibility assay to assess the susceptibility of 
isolates and clones to artemisinin derivatives in vitro [65].  For these assays, the growth 
indicator (
3
H-hypoxanthine) was added along with drug at the beginning of the assay 
(T=0 hr).  By using this T0 assay, we observed significant shifts in dose response curves 
thus indicating reduced susceptibility of Cambodian P. falciparum isolates and clones to 
artemisinin, artesunate, dihydroartemisinin (DHA), and artelinic acid (AL) (Figure 2.1A).  
Parasites displayed resistance to each artemisinin derivative tested with the most 
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pronounced changes occurring with artemisinin and AL. The level of resistance observed 
to each artemisinin derivative was similar to the artemisinin clones selected in the 
laboratory lines D6 and W2 [65]. Interestingly, multiple clones from the same patient 
isolate displayed differing levels of resistance to multiple drugs (Figure 2.1B). In some 
cases, drug sensitive parasites were cloned from isolates with delayed clearance in vivo; 
however, cloning isolates very early during culture adaptation prevented loss of resistant 
phenotypes in long term culture as reported by others [132]. 
The clinical phenotype for artemisinin resistance is a heritable trait [133-135], yet 
a common assumption has been the resistance phenotypes are not stable in vitro or after 
cryopreservation.  We cultivated P. falciparum clones continuously for more than two 
years and observed stability of the artemisinin resistance phenotype in the T0 assay in 
vitro (Figure 2.1C).  Cryopreservation of resistant clones did not affect the resistance 
observed in subsequent T0 assays. In addition, parasites with decreased susceptibility to 
artemisinin derivatives exhibited decreased susceptibility to other antimalarial drugs. Our 
results demonstrate the T0 assay is a stable, reliable method for assessing reduced 
sensitivity to artemisinin derivatives in artemisinin-resistant parasites selected in vitro or 
from patient isolates and clones thereof [65].  It is interesting to note that AL has never 
been used clinically, yet decreased susceptibility to this derivative was observed, 
suggesting a common mechanism of resistance that may affect many endoperoxide 
containing antimalarial drugs.   
Delayed Clearance Assay (DCA) In Vitro   
Clinical artemisinin resistance is defined as a reduced parasite clearance rate 
following treatment with artesunate alone or in combination with other antimalarial drugs 
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[49, 124].  We hypothesized that a similar phenotype could be expressed in vitro in 
resistant parasites exposed to clinically relevant concentrations of drug.  We used highly 
synchronous ring-stage clones exposed to 700 nM DHA for six hours every 24 hr for 
three days to approximate a three day dosing regimen in vivo.  At the end of each six-
hour drug exposure, drug was washed out with media (3X) and parasites placed back into 
culture.  Parasite clearance in the DCA assay was determined by quantifying the 
proportion of asexual stage parasites remaining over time following exposure to DHA. 
For all artemisinin-resistant clones from Cambodia we observed slower clearance of 
morphologically normal rings, trophozoites, and schizonts when compared to the control 
parasite clone W2 (Figure 2.2).  In the control clone (W2) only dormant ring-stage 
parasites were detected by 18 hr, whereas clones from artemisinin-resistant isolates 
remained positive for morphologically normal asexual blood stage parasites for up to 48 
hr (Figure 2.2).  Even though normal rings, trophozoites, and schizonts were cleared by 
48 hr, there were a large proportion of parasites with the previously characterized 
dormant morphology of ring-stage arrested growth following the second and third 
exposure to artemisinin drugs (Figures 2.3 and 2.9) [65].   
We estimated in vitro parasite clearance by calculating the parasite reduction ratio 
(PRR) from the first 12 or 24 hr of the DCA and compared this phenotype to parasite 
clearance half-lives from the clinical data (Figure 2.4A). Interestingly, in vivo clearance 
half-life significantly correlated with in vitro PRR12 hr or PRR24 hr (24 hr data not shown) 
following exposure to DHA (Figure 2.4A). For example positive associations between in 
vitro and in vivo parasite clearance were observed with isolate ARC08-88 and clones 
thereof.  ARC 08-88 clones 5A and 8A were more resistant to artemisinin derivatives 
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than ARC 08-88 clone 11G and took longer to clear 50% of the parasite in vitro (Figures 
2.2 and 2.9).  
Differential Parasite Maturation During Drug Exposure 
Next we evaluated the maturation of intraerythrocytic, asexual stage parasites 
following exposure to artemisinin drugs in vitro and observed that artemisinin-sensitive 
and artemisinin-resistant parasite clones had different responses to drug exposure 
(Figures 2.3 and 2.9).  In assays with three, six-hour pulse exposures to 700 nM DHA, 
only ring-stage parasites were observed in the control clone W2 and all morphologically 
normal rings were cleared by 18 hr (Figure 2.3A). Conversely with artemisinin-resistant 
clones the rate of ring-stage clearance was significantly reduced (Figures 2.3B-D and 
2.9).  For example clone 5A of ARC08-88 exhibited a prolonged rate of ring-stage 
parasite clearance with morphologically normal rings present for up to 48 hr despite two 
six-hour exposures to DHA.  Interestingly, a small proportion of mature erythrocytic 
stage parasites (trophozoites and schizonts) were observed up to 36 hr following DHA 
exposure only in artemisinin-resistant clones (Figure 2.9).  Despite the increased 
resistance exhibited by delayed clearance of both rings and trophozoites, all artemisinin-
resistant clones eventually arrested as dormant ring-stage parasites following the second 
pulse exposures to 700 nM DHA (Figures 2.3 and 2.9). The induction of ring-stage 
dormancy by DHA is consistent with our previous studies with both drug susceptible and 
laboratory induced artemisinin-resistant parasites [65, 69].   
Altered Patterns of Intraerythrocytic Development   
Morphological observations of artemisinin-resistant isolates and clones during 
continuous culture demonstrated an unusually high proportion of ring-stage parasites as 
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compared to artemisinin susceptible parasites.  Therefore, we assessed the 
intraerythrocytic development of synchronous parasites over one to two asexual life 
cycles in vitro in the absence of drug pressure.  By using highly synchronous ring-stage 
cultures, we observed a prolonged phase of ring-stage development in the artemisinin-
resistant clones (Figure 2.5) in comparison with the control clone (W2).  For example in 
the artemisinin-resistant clone 4G the ring-stage parasites were smaller and were 
morphologically consistent with ring-stage parasites that persisted up to 30 hr; in 
comparison W2 completed ring-stage development in ~16 hours (Figure 2.5). Following 
the prolonged ring phase, the trophozoite-stage of resistant clones was temporally 
compressed into a remarkably fast period of approximately eight hours followed by 
normal schizont development (Figures 2.5 and 2.6).  The prolonged ring phase of 
development in artemisinin-resistant clones was stable during long-term culture and 
importantly this phenotype was observed in multiple artemisinin-resistant clones in the 
absence of any drug pressure.   
The remarkably reduced phase of trophozoite development was further examined 
in multiple artemisinin-resistant parasites by assessing the proportion of trophozoites in 
the population during one intraerythrocytic asexual life cycle (Figure 2.6).  For 
comparison between different clones we estimated the area under the curve (AUC) for 
trophozoite development (hr) and observed that resistant clones had a much reduced 
AUC(troph hr) as compared to artemisinin susceptible parasites (Figure 2.6).  Although most 
artemisinin-resistant clones exhibited the prolonged ring phase of development followed 
by accelerated development through trophozoite-stage, the 5C clone from PL08-09 was 
found to have highly accelerated asexual development of all stages and completed its 
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intraerythrocytic life cycle within 36 hours.  In comparison with other artemisinin-
resistant clones, the 5C clone also exhibited a significantly shorter period of development 
in trophozoite-stage as compared to artemisinin susceptible parasites (Figure 2.6). 
The unusual alterations of the cell cycle in artemisinin-resistant clones of P. 
falciparum prompted additional evaluation of parasite development following drug 
exposure. In the 700 nM DHA pulse experiments there were a small proportion of clones 
that progressed to trophozoites earlier than would be expected from the development 
patterns observed in the absence of drug (Figure 2.3 and 2.9). Therefore we repeated the 
pulse experiments but used a single, six-hour pulse of 30 nM DHA followed by media 
washes and evaluation of parasite development by microscopy. This concentration was 
chosen because it was 10X the W2 IC50 for DHA. The control clone W2 progressed from 
rings into trophozoites and schizonts, yet after 30 hr only ring-stage dormant parasites 
were observed (Figure 2.3). In contrast the artemisinin-resistant clones 4G and 5C 
progressed from rings to trophozoites to schizonts following the pulse exposure to 30 nM 
DHA (Figure 2.3). Interestingly the ring-to-trophozoite progression was accelerated in 
the 4G resistant clone. In fact both artemisinin-resistant clones completed the asexual 
cycle in ~36 hr following a low dose pulse of 30 nM DHA (Figure 2.3). These results 
suggest the low dose pulse of drug actually stimulated accelerated asexual development 
in the 4G resistant clone to a rate similar to 5C in the absence of drug pressure.  
Stage Specific Resistance to Artemisinin Drugs 
The current hypothesis is that artemisinin-resistant parasites have reduced 
susceptibility to drug in the ring-stage of development.  As noted above, artemisinin-
resistant parasites express a prolonged ring phase of development followed by a 
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shortened trophozoite phase; therefore, we next examined the stage specific resistance of 
the clones to DHA following three-hour pulse exposures throughout the asexual life cycle 
of highly synchronized clones.  Following synchronization, parasite aliquots were 
exposed to three hour pulses of DHA (700 nM) followed by three washes with drug-free 
media, then serial dilution into 96-well plates and the cultures allowed to grow out for 14 
days to determine the number of viable parasites remaining following drug exposure 
[131].  For comparison we used W2 and CB132, an artemisinin-susceptible isolate 
collected from Pailin, Cambodia in 1991 [136].  In the first few hours of ring-stage 
development there were no differences in viability of artemisinin-resistant or susceptible 
parasites following exposure to drug and between hour 3 and 9 of development we 
observed hyper-susceptibility to drug in both artemisinin-resistant and susceptible clones 
as previously demonstrated [68]; whereas, from hours 9 through 20 there was a log 
increase in viability of artemisinin-resistant ring-stage parasites as compared to CB132 
(Figure 2.7). As noted above, in the presence of 700 nM DHA a proportion of the 
resistant clones accelerated asexual development from ring to trophozoite (Figure 2.7B). 
Interestingly, when artemisinin-resistant parasites were in trophozoite-stage they were 
equally susceptible to drug, yet during schizogony resistance again was observed with 
approximately a log of increased viability in the resistant parasite compared to CB132 
(Figure 2.7).  These data support the hypothesis that ring-stages are less susceptible to 
drug, yet also for the first time demonstrates accelerated ring to trophozoite transition 
during drug exposure as well as resistance in the later asexual stages of development.   
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Recrudescence Following DHA Exposure 
Previous studies demonstrated a ring-stage arrest following exposure to 
artemisinin derivatives [65, 69].  These ring-stage arrested parasites are known as 
dormant rings due to their ability to persist in culture for days to weeks prior to 
recrudescence of normal growth.  Since all artemisinin-resistant clones eventually 
arrested as dormant ring-stage parasites we next determined the recrudescence patterns 
for the dormant rings following three six-hour pulse exposures to DHA (700 nM).  As 
shown in Figure 2.8, the control clone (W2) remained dormant through day 11 followed 
by recrudescent growth evident on day 12 with subsequent recovery of the parasites with 
greater than initial parasitemia by day 14.  Interestingly, artemisinin-resistant clones 
expressed divergent dormancy recrudescence patterns.  Some resistant clones recrudesced 
2 days earlier than the control W2 clone (e.g., 8A clone of ARCO8-88); whereas, other 
clones were significantly delayed in their recrudescence patterns.  Some clones from 
artemisinin-resistant isolates did not recover from dormancy until well after 20 days 
(Figures 2.8, 2.11-2.13).  These different recrudescence patterns from dormancy were 
consistent between duplicate assays suggesting inherited differences in recrudescence 
following dormancy in different cloned artemisinin-resistant P. falciparum. 
Association of In Vitro and In Vivo Drug Resistance Phenotypes. 
 Previous studies have suggested a strong association of the clinical resistance 
phenotype with mutations in the propeller domains of the Kelch gene (K13) on 
chromosome 13 (Pf3D7_1343700) and ring-stage survival in a modified in vitro assay 
[53]. The presence or absence of K13 mutations was determined by pyrosequence 
analysis for all isolates and clones used in this study (see Table 2.3 for complete list). We 
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compared the phenotypes observed in this study with in vivo parasite clearance half-life 
and found the strongest association was with the in vitro DCA assay (Figure 2.4).  
Interestingly, the reduced rate of parasite clearance in vitro also was observed in parasites 
with C580Y, R539T, Y493H, or A675V mutations in K13 (Figure 2.4B).  In contrast, 
susceptibility to mefloquine was inversely correlated with in vitro clearance half-life 
(PRR12 hr) and with presence of K13 mutations (Figure 2.4C). Despite the reduced 
susceptibility to multiple artemisinin derivatives in the T0 hypoxanthine assays, there was 
no significant correlation with in vivo parasite clearance rates or K13 mutations (Figure 
2.10-2.13).   
Discussion 
Our current understanding of mechanisms of anti-malarial drug resistance have 
emerged from the ability to continuously culture drug-resistant parasites from patients 
and for these parasites to express phenotypes that can be used for phenotype-genotype 
association studies to identify genetic markers of resistance.  Classic examples of this 
approach are the identification of pfcrt mutations that confer chloroquine resistance and 
mutations in dihydrofolate reductase and dihydropteroate synthase that confer resistance 
to antifolate drugs (4-6).  Conversely, for artemisinin resistance, the typical in vitro drug 
assay phenotypes used for previous antimalarial drug resistant studies have not been 
useful (7).  Since these standard in vitro phenotypes have not yielded success, genome 
wide association studies had to be undertaken to identify heritable traits associated with 
clinical resistance [51].  
In this study we demonstrate for the first time multiple new artemisinin resistance 
associated phenotypes that are expressed stably in parasite clones in vitro. These include 
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decreased susceptibility to artemisinin drugs in a T0 
3
H-hypoxanthine assay, altered 
patterns of intraerythrocytic development with prolonged ring-stage and temporally 
compressed trophozoite development, a slow clearance in vitro phenotype in the presence 
of drug, and association of slow clearance in vitro with K13 mutations as well as with 
reduced rate of clearance phenotypes in vivo. These novel in vitro phenotypes offer new 
opportunities for elucidating the role of K13 mutations in artemisinin resistance and for 
identifying additional molecular markers associated with clinical resistance to 
artemisinin. 
 Perhaps the most remarkable phenotype expressed by artemisinin-resistant clones 
was the altered patterns of intraerythrocytic development in the absence or presence of 
artemisinin drugs. In the absence of drug pressure we observed a prolonged phase of 
ring-stage development in artemisinin-resistant clones that lasted up to 30 hr of the life 
cycle; this was approximately 14 hr longer than the control (W2). The prolonged ring 
phase was then followed by a temporally compressed trophozoite-stage (Figure 2.6) prior 
to normal schizont development. Despite the dramatic differences, the overall 
intraerythrocytic life cycle completion of these resistant clones was the same as W2. 
Interestingly we also discovered a resistant clone (5C) that had a significantly abbreviated 
intraerythrocytic life cycle that was completed in only 36 hr. Since we observed no 
differences in intraerythrocytic stage development in drug sensitive clones or isolates 
(e.g., CB132), the prolonged ring and temporally compressed trophozoite development 
phenotype is strongly associated with artemisinin resistance. This result is consistent with 
a recent study of the ex vivo transcriptome of artemisinin-resistant parasites [137] that 
suggested an extended phase of ring-stage development coincident with up-regulation of 
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unfolded protein response (UPR) pathways.  Our results show for the first time this 
phenotype in stable clones and that some resistant isolates have a significantly 
abbreviated asexual life cycle. 
The intriguing question is what advantage does the altered intraerythrocytic 
development pattern provide and how might this phenotype confer resistance? Mok et al 
(23) suggest the prolonged ring phase of development may allow the up-regulated UPR 
pathways to mitigate protein damage caused by drug exposure. Although plausible that 
UPR pathways may be involved, this does not explain why we observed the prolonged 
ring and compressed trophozoite development phenotypes stably expressed in the 
absence of drug pressure. In addition, the accelerated development of the 
intraerythrocytic life cycle of some artemisinin clones (5C) in the absence of drug 
pressure, as well as the accelerated ring-to-trophozoite transition in response to drug 
exposure appear inconsistent with the delayed ring development UPR damage mitigation 
hypothesis.  
Our data in cloned, stably artemisinin-resistant parasites suggest two potential 
advantages of the altered intraerythrocytic development patterns observed; these are 
increased viability of ring-stages and reduced exposure to drug in the most susceptible 
stage of development (trophozoites).  Although most of the resistant clones had a 
prolonged ring phase of development, one resistant clone also had an accelerated 36 hr 
life cycle in the red cell.  One consistency between these phenotypes is the dramatically 
shortened period of development in the trophozoite-stage (Figure 2.6).  Previous studies 
suggest that the trophozoite-stage of development is the most sensitive in the life cycle 
[68] and our studies confirmed trophozoites are the most susceptible stage, even in 
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artemisinin-resistant clones (Figure 2.7).  Therefore, we hypothesize the intraerythrocytic 
development patterns evolved as a mechanism to reduce exposure of the parasite to drug 
in the most susceptible stage of development. The similar AUC(troph hr) for the prolonged 
ring phase phenotype in absence of drug, the accelerated ring-to-trophozoite development 
in presence of drug, and the fully abbreviated life cycle (clone 5C) are consistent with 
this hypothesis.  Secondly, the prolonged ring phase of development offers another 
survival advantage to the parasite.  In previous studies we demonstrated that ring-stage 
parasites are less susceptible to drug due to the ability of ring-stages to arrest 
development following drug exposure; these dormant rings can survive for days to weeks 
before recovering and growing normally.  We hypothesize the prolonged ring phase of 
development is a resistance advantage by extending the period in which the ring-stage 
parasites can be stably arrested in growth with subsequent recovery from dormancy and 
survival.  Evidence that supports this hypothesis is shown in Figure 2.7 where we 
observed significantly increased viability of resistant parasites that were exposed to drug 
in the ring-stages of development.  Since ring-stages were not able to grow continuously 
and complete the life cycle in the presence of 700 nM DHA (Figures 2.2 and 2.3), 
recovery from dormancy was a major component of the ring-stage resistance and long-
term viability differences we observed in artemisinin-resistant clones (Figures 2.7 and 
2.8). Given that drug-induced dormancy is a phenotype expressed in sensitive and 
resistant isolates, this trait appears to be independent of drug resistance selection; 
however, it is plausible the survival advantage conferred by drug-induced dormant rings 
stages factored into the ultimate selection of the prolonged ring phase phenotype in 
artemisinin-resistant P. falciparum.  
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As noted by others, some standard in vitro drug susceptibility assays do not 
correlate with the reduced rate of parasite clearance clinical phenotype (7).  Two 
modified in vitro assays have been shown to correlate to some degree with artemisinin 
resistance in vitro; these are the T0 
3
H-hypoxanthine assay [65] and a ring-stage survival 
assay (RSA) [53].  The RSA is reported to assess the survival of ring-stage parasites 
exposed to a single pulse of 700 nM DHA.  The end point is the percentage of normal 
parasites counted in Giemsa stained blood smears at 72 hours.  The RSA assay was used 
successfully for association studies with clinical resistance and found to have statistically 
significant correlation with in vivo clearance and mutations in the propeller domains of 
K13 [51, 124]. Although the RSA results correlate with the clinical resistance phenotype, 
our data suggest the underlying mechanisms measured in the RSA differ from what has 
previously been described.  For example, in our studies 700 nM DHA was sufficient to 
induce dormancy even in resistant parasites, yet the timing of dormancy induction was 
delayed significantly from sensitive parasites.  The “pyknotic” parasites that were present 
at the 72 hour time point in the RSA were thought to be dead [53, 138], yet clearly the 
results of our study demonstrate parasites remain viable in the dormant stage, thus the 
RSA underestimates viability of resistant parasites. This viability of dormant rings was 
despite exposure to three, six-hour pulse exposures to 700 nM DHA. Conversely, one 
underlying mechanism for the higher “survival” rates in the RSA could be the prolonged 
ring phase of development observed in artemisinin-resistant parasites.  We believe the 
prolonged ring phenotype was incorrectly interpreted as “quiescent” rings in the previous 
study [139] given that we observed the prolonged ring phase in resistant clones in the 
absence of drug.  Interestingly, the clinical phenotype of reduced parasite clearance is 
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primarily due to the presence of ring-stage parasites in the peripheral blood of patients 
following treatment with artemisinin drugs.  The basis of the in vivo slow clearance 
phenotype is likely due to the prolonged ring phase phenotype that we’ve observed.  
Since ring-stages do not sequester in deep vasculature, the prolonged ring phase of 
development probably contributes to reduced parasite clearance rates observed in vivo. 
Regardless of the mechanism(s) involved, these results suggest the common thread 
between the in vivo slow clearance phenotype, reduced rate of parasite clearance in vitro, 
and K13 mutations is the prolonged ring phase phenotype. Therefore the other resistance-
associated phenotypes described herein may be additional traits that contribute to 
artemisinin resistance mechanism(s) that appear to be more complex than resistance to 
other antimalarial drugs.  
The increased prevalence and apparent spread of artemisinin resistance increases 
the urgency for fielding effective tools for epidemiological monitoring of resistance.  
Currently, there are two tools that can be used – presence of K13 mutations and the RSA 
assay phenotype.  In this study, we demonstrate the reduced rate of parasite clearance in 
vivo correlates well with the results of a new delayed clearance assay in vitro.  The main 
advantage over the RSA is the DCA assay can be conducted in as little as 12 or 24 hr, it 
is less reliant upon tight synchronization of cultures, it more accurately assesses the 
prolonged ring phenotype, and the microscopy end point could be rapidly adapted to 
other quantitative measures (e.g., flow cytometry).  The DCA also should be useful with 
ex vivo parasite cultures (directly from patients) and needs to be assessed for potential 
utility in the field.   
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  The resistance phenotypes described herein offer great potential for studies of 
drug resistance mechanisms for artemisinin and related compounds in development.  
Recent advances in rapid, selective integration of mutations in the parasite genome have 
accelerated the confirmation of drug resistance mechanisms.  Several groups have found 
that insertion of specific K13 mutations into susceptible parasites confer an RSA-
resistance phenotype in vitro [52, 140].  These studies did not describe any resistance 
phenotypes other than RSA, thus it would be interesting to know if these transformed 
resistant lines display any of the new resistant phenotypes we observed in artemisinin-
resistant parasite clones from southeast Asia or if there are yet to be identified 
mechanisms that control the unusual cell cycle regulation in artemisinin-resistant 
parasites.   
Artemisinin induced dormancy in ring-stages has been observed in both sensitive 
and resistant parasites in vitro [65, 69]. One of the interesting phenotypes we observed in 
this study was the divergent pattern of recrudescence following dormancy in artemisinin-
resistant clones.  As shown in Figure 2.8, some resistant clones recrudesced earlier than 
the W2 control parasite, whereas others had a significantly prolonged period of dormancy 
followed by recovery after 20 days.  At present, there is no obvious explanation for these 
differences.  The prolonged recovery could be due to differences in the proportion of 
dormant parasites that recover, given the possibility that increased number of viable 
dormant parasites might recover at a faster rate as observed for a lab selected resistant 
line (8).  Conversely, the ability to remain dormant for longer periods of time may be an 
advantageous response to combination drug therapy where the partner drug has 
prolonged systemic exposure; these artemisinin-resistant clones could persist in the 
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dormant ring state until the partner drug exposure is alleviated.  Given that dormant 
parasites remain in drug exposed cultures even after viable parasites start to recover, 
elucidation of the dormancy recovery mechanisms and the true proportion of parasites 
that recover from dormancy will require further studies.   
Previous results suggest that artemisinin resistance is confined to the ring-stages 
of parasite development.  Our data confirms this hypothesis, yet we also observed for the 
first time resistance to artemisinin drugs in mature stages. The mechanisms involved in 
late stage resistance are not known, but this could be a sign that increased levels of 
resistance are developing and thus the phenotype is expressed more broadly in the 
intraerythrocytic development of the parasite.  Another interesting observation from these 
studies is the stable expression of reduced susceptibility to multiple artemisinin drugs in 
vitro as measured by the T0 assay.  This assay captures parasite development within the 
first 24 hours following exposure to drug before ring-stages become arrested and growth 
differences are not able to be measured (as in other in vitro susceptibility assays).  In our 
previous studies, the laboratory derived artemisinin-resistant parasites were most resistant 
to AL and artemisinin with reduced levels of susceptibility observed to DHA [65].  
Surprisingly, we observed the same resistance pattern in the artemisinin-resistant clones 
from Cambodia, despite the fact that AL has never been used in the field.  We 
hypothesize that the resistance mechanism recognizes related compounds and therefore 
these results highlight a significant concern for second and third generation artemisinin 
derivatives in development.  The importance of resistance to artemisinin drugs in the T0 
assay is yet to be determined. In our studies the IC50s obtained did not correlate with slow 
parasite clearance in vivo, yet there was a significant difference in IC50s for many 
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resistant isolates and this phenotype was stable in culture (Figure 2.1). The fact that 
others found similar reduced susceptibility in Cambodia when adding 
3
H-hypoxanthane 
at the beginning of the assay (24) and we found many clones with reduced susceptibility 
in the T0 assay suggests this phenotype may be due to a resistance mechanism unrelated 
to the slow clearance phenotype. 
Resistance to artemisinin drugs and the potential for a selective sweep of these 
parasites in regions outside Southeast Asia is one of the most important threats to malaria 
control and elimination efforts. The novel resistance phenotypes described herein offer 
potential for epidemiological monitoring with the DCA assay and highlight a previously 
unrecognized plasticity of intraerythrocytic development of asexual stages of P. 
falciparum that confers a selective advantage to parasites exposed to artemisinin 
derivatives. The regulatory mechanism(s) involved in altering the cell cycle and 
intraerythrocytic development are unknown, yet seem likely to be due to more than 
mutations in K13. We hypothesize that altered regulation of exit from G1 in the cell cycle 
is the basis for the novel phenotypes observed. The artemisinin-resistant clones that 
stably express these artemisinin resistance associated phenotypes offer an opportunity to 
better understand both the mechanisms of resistance and the mechanisms of cell cycle 
regulation in P. falciparum.  
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Figure 2.1. Reduced Susceptibility of Artemisinin-Resistant P. falcaiprum. A 
modified 
3
H-hypoxanthine assay (T0 assay) was used. A) Fifty percent inhibitory 
concentrations (IC50s) of isolates and clones from Cambodia and Thailand to artemisinin, 
dihydroartemisinin, artelinic acid, and mefloquine were determined in the T0 assay in 
which the label was added at the same time as drug. The largest shift in dose response 
was to artelinic acid and artemisinin. B) Clones from isolates exhibited a range of 
responses to artemisinin drugs. For example, several clones of ARC08-88  (11H, 10G, 
and 9D) exhibited higher tolerance to artemisinin than the parent isolates. In addition 
sensitive clones (5C and 7E) were isolated. Following initial drug susceptibility testing of 
clones, at least three clones from each isolate were selected for more detailed evaluation 
and repeat drug susceptibility testing (see Figures S3-S5). C) Drug resistance phenotypes 
in the T0 assay were stable over 1 year of continuous culture including several rounds of 
freeze and thaw cycles. The results shown are an average of three independent replicates 
conducted at the start of culture and after a year in (mostly) continuous culture with 
multiple cryopreservation and thaw cycles. ARC08-88 clones are listed in descending 
order of IC50 to artemisinin for each graph. 
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Figure 2.2. Delayed Parasite Clearance of P. falciparum Clones Following 
Dihydroartemisinin (DHA) Exposure. Three clones per each isolates plus the control 
W2 clone were tested in duplicate. Highly synchronous ring-stage parasites were exposed 
to three, six-hour pulses of 700 nM DHA (indicated in grey) in the delayed clearance 
assay (DCA). Delayed parasite clearance of morphologically normal rings, trophozoites, 
or schizonts was observed for all artemisinin-resistant clones as compared to artemisinin-
susceptible W2. In contrast parasite clearance of W2 was observed by hour 18 of the 
experiment, whereas resistant clones took as long as 48 hours to clear parasites. Dead and 
dormant parasites were excluded from this analysis. 
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Figure 2.3. Parasite Development Monitored Following Exposure to DHA. Parasites 
(n=100) were categorized as ring, trophozoite/schizont, or dormant/dead for each time 
point. In the delayed parasite clearance (DCA) assay P. falciparum clones were exposed 
to three, six-hour pulses of 700 nM DHA. A, C, E, G) Only ring-stage parasites were 
observed in W2, whereas mature-stage parasites were observed in artemisinin-resistant 
clones following exposure to DHA. DCA results for additional clones are shown in 
Figure S1. B, D, F, G) In similar studies the clones were exposed to one, six-hour pulse 
of 30 nM DHA (10X IC50 for W2) and monitored for parasite development. W2 
progressed to mature stages yet after one asexual cycle all parasites remaining were either 
dead or in a ring-arrested dormant state. In contrast the artemisinin clones progressed 
through two cycles at an accelerated rate, especially as compared to 4G in the absence of 
drug (see Figure 5).  
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Figure 2.4.  Correlation of In Vitro Artemisinin Resistance Phenotypes with In Vivo 
Parasite Clearance Half-Lives and Mutations in the Kelch (K13) Propeller Domains 
of Pf3D7_1343700. A) The results from the delayed clearance  (DCA) assay were used 
to determine parasite reduction ratios (PRR) during the first 12 hr following exposure to 
700 nM DHA. There was a significant correlation between the in vitro phenotype (PRR0-
12 hr) and in vivo parasite clearance half-life. B) The delayed clearance phenotype in vitro 
also was positively correlated with mutations in Pf3D7_1343700 that were previously 
shown to be markers for artemisinin resistance. C) Although mefloquine resistant clones 
were prevalent (see Figure 1), there was an inverse correlation between mefloquine 
resistance and the delayed clearance phenotype in vitro (PRR0-12 hr). Color symbols in 
each panel correspond to absence or presence of Pf3D7_1343700 (K13) mutations as 
annotated in panel B. 
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Figure 2.5. Altered Patterns of Intraerythrocytic Development of Artemisinin-
Resistant Clones in the Absence of Drug Pressure. Tightly synchronized parasites 
were prepared for artemisinin-resistant clones and the timing of asexual stage 
development compared with the control clone W2. A) ARC08-22 (4G) exhibited a 
prolonged ring phase phenotype with rings observed up to 30 hr of development. B) The 
trophozoite-stages of 4G were temporally compressed and schizogony of 4G was 
completed simultaneous with W2. C) Microscopic examination of Giemsa-stained blood 
smears revealed the rings of 4G were smaller and persisted ~14 hr longer than W2. This 
prolonged ring phase was then followed by rapid progression through trophozoite-stage. 
Although most artemisinin-resistant clones expressed the prolonged ring phase 
phenotype, one clone (5C) from PL08-009 completed it full asexual life cycle in only 36 
hr.  
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Figure 2.6. Rapid Progression Through Trophozoite-Stage in Artemisinin-Resistant 
P. falciparum. The unusually rapid progression of artemisinin-resistant clones through 
trophozoite-stage was examined by quantifying the percentage of rings, trophozoites and 
schizonts present throughout the asexual life cycle. The trophozoite prevalence data from 
two independent experiments were then fit to a polynomial function and for comparison 
purposes, plotted with time = 0 hr as the peak of trophozoite prevalence. A, B) In these 
data both of the artemisinin-resistant clones obviously progressed through trophozoite-
stage at an accelerated rate as compared to sensitive parasites (W2 and CB132). C) These 
trophozoite prevalence data were then used to estimate the AUC(Troph hr); both artemisinin-
resistant clones had similar AUCs and were approximately half the time that W2 and 
CB132 were in trophozoite-stage per asexual life cycle. CB132 is an artemisinin-sensitive 
isolate from Pailin, Cambodia that was adapted to culture in 1992 [136]. 
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Figure 2.7. Stage Specificity of Artemisinin Resistance in P. falciparum.  The relative 
susceptibility of each stage of asexual parasite development was assessed by exposing 
tightly synchronous parasites to three-hour pulses of 700 nM DHA at three-hour 
increments throughout one cycle (duplicate experiments). Resistance was then assessed 
by parasite viability of each stage of development, with viability defined as the ability to 
grow logarithmically within 14 days of drug exposure. Initially there were no differences 
in viability of 4G and CB132 and a brief window of hyper-susceptibility was observed 
for both clones. In the presence of drug the ring-to-trophozoite transition for 4G was 
accelerated and in this brief trophozoite window both clones were equally susceptible. 
Resistance to artemisinin was observed in both ring-stages and throughout schizogony in 
the artemisinin-resistant 4G clone and this was expressed as ~ one log increase in 
viability. 
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Figure 2.8. Recrudescence from DHA-Induced Ring-Stage Dormancy in P. 
falciparum. Three, six-hour pulses of 700 nM DHA induced dormant ring-stages in both 
susceptible (W2) and artemisinin-resistant clones (also see Figures S3-S5). There was a 
divergent pattern of recrudescence observed with some clones recovering up to 2 days 
prior to W2, whereas other resistant clones remained dormant and only recovered later 
than 20 days (n=2; bars represent + 1SD). 
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Figure 2.9. Parasite Development was Monitored Following Exposure to DHA. 
Parasites (n=100) were categorized as ring, trophozoite/schizont, or dormant/dead for 
each time point. In the delayed parasite clearance (DCA) assay P. falciparum clones were 
exposed to three, six-hour pulses of 700 nM DHA. 
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Figure 2.10. The In Vitro Response (IC50s) as Determined in the T0 
3
H-hypoxanthine 
Assay Were Not Correlated Directly to the In Vitro Parasite Reduction Ratio (PRR). 
The PRR data were determined from the delayed clearance assay as outlined in the 
methods. The presence of mutations in Pf3D7_1343700 are noted by the symbol color 
(WT; C580Y; R539T; Y493H; A675V) (DHA = dihydroartemisinin; QHS = 
artemisinin; AS = artesunate; AL = artelinic acid). 
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Figure 2.11. Clearance, Recrudescence, and Susceptibility of ARC08-22 Clones 
Compared to W2. ARC08-22 (4G) recrudesced before W2 reaching initial parasitemia 2 
days before W2. ARC08-22 (5G) and (7C) recrudesced after W2 and grew to initial 
parasitemia 3 and 6 days after W2, respectively. In vitro susceptibility to artemisinin 
derivatives was determined in the T0 assay (n > 2 biological replicates). The time to reach 
starting parasitemia did not correlate with IC50 values to artemisinin derivative or 
mefloquine. 
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Figure S3. Clearance, recrudescence, and susceptibility of ARC08-22 clones 
compared to W2. ARC08-22 (4G) recrudesced before W2 reaching initial parasitemia 2 
days before W2. ARC08-22 (5G) and (7C) recrudesced after W2 and grew to initial 
parasitemia 3 and 6 days after W2, respectively. In vitro susceptibility to artemisinin 
derivatives was determined in the T0 assay (n > 2 biological replicates). The time to reach 
starting parasitemia did not correlate with IC50 values to artemisinin derivative or 
mefloquine. 
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Figure 2.12. Clearance, Recrudescence, and Susceptibility of PL08-09 Clones 
Compared to W2. PL08-09 (6B) cleared up to 24 hours slower than PL08-09 (5C) and 
(9H). PL08-09 (5C) and (9H) recrudescence following dormancy was not significantly 
delayed as compared to W2. PL08-09 (6B) took 7 days longer than W2 to reach initial 
parasitemia. In vitro susceptibility to artemisinin derivatives was determined in the T0 
assay (n > 2 biological replicates). The time to reach starting parasitemia did not correlate 
with IC50 values to artemisinin derivative or mefloquine. 
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Figure 2.13. Clearance, Recrudescence, and Susceptibility of NHP2065 Clones 
Compared to W2. NHP2065 (7C) cleared at a similar rate as W2 and began to 
recrudesce around the same time as W2. NHP2065 (6H) and (4A) cleared 18 hours after 
W2 and recrudesced 2 and 7 days after W2 respectively. In vitro susceptibility to 
artemisinin derivatives was determined in the T0 assay (n > 2 biological replicates). All 
NHP2065 clones tested are more susceptible to artemisinin derivatives compared to other 
patient clones tested but are resistant to mefloquine. NHP2065 is the only isolate in this 
study with the A675V mutation in K13 (Francois Nosten, personal communication). 
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Figure S5. Clearance, recrudescence, and susceptibility of NHP2065 clones 
compared to W2. NHP2065 (7C) cleared at a similar rate as W2 and began to 
recrudesce around the same time as W2. NHP2065 (6H) and (4A) cleared 18 hours after 
W2 and recrudesced 2 and 7 days after W2 respectively. In vitro susceptibility to 
artemisinin derivatives was determined in the T0 assay (n > 2 biological replicates). All 
NHP2065 clones tested are more susceptible to artemisinin derivatives compared to other 
patient clones tested but are resistant to mefloquine. NHP2065 is the only isolate in this 
study with the A675V mutation in K13 (Francois Nosten, personal communication). 
*
*
*
*
IC50,*nM*(+SD)*
!! QHS$ AL$ ART$ DHA$ MFQ$
W2$ 10.42!(±3.22)! 22.57!(±8.62)! 4.92!(±1.69)! 3.74!(±2.24)! 8.18!(±3.87)!
NHP2065$ 19.62!(±9.78)! 27.77!(±16.79)! 10.02!(±5.95)! 11.17!(±6.07)! 61.21!(±13.73)!
NHP2065$4A$ 15.19!(±4.03)! 25.14!(±7.65)! 3.43!(±1.33)! 5.11!(±1.04)! 48.11!(±5.25)!
NHP2065$7C$ 14.64!(±0.97)! 19.04!(±3.65)! 3.36!(±0.68)! 5.36!(±1.52)! 61.42!(±18.15)!
NHP2065$6H$ 16.64!(±8.16)! 18.39!(±5.48)! 2.65!(±0.88)! 3.68!(±0.82)! 33.88!(±21.82)!
* 
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Table 2.1. Characterization of P. falciparum Ssolates and Clones Used in this Study. 
In vitro susceptibility was assessed in the T0 assay for artemisinin drugs and by using 
standard methods for mefloquine. Results represent ≥ 2 biological replicates for the drug 
susceptibility assays. 
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Table S1. Characterization of P. falciparum isolates and clones used in this study. In vitro susceptibility was assessed in 
the T0 assay for artemisinin drugs and by using standard methods for mefloquine. Results represent > 2 biological 
replicates for the drug susceptibility assays. 
!
TF!=!Treatment!Failure!
Thailand!
Cambodia!
!
 
! ! ! ! ! ! ! ! !
SNPs!Associated!with!Resistance!
Parasite!Information! !! !! IC50,!nM!(±SD)!!! !!
TakalaBHarrison!et!
al,!2013! Cheeseman!et!al,!2012!
Parasite!ID!
Collection!
site!
Date!of!
Collection!
In!vivo!
clearance!
1/2!life!(hr)! Artemisinin! Artelinic!Acid! Artesunate!
DihydroB
artemisinin! Mefloquine!
MAL10!
(688956)!
MAL13!
(1718319)!
MAL13B220!
(660)!
MAL13B
239!(1646)!
MAL13B405!
(3142)!
W2# !! !! !! 10.4!(±3.2)! 22.6!(±8.6)! 4.9!(±1.7)! 3.7!(±2.2)! 8.2!(±3.9)! T! T! A! T! G!
D6# !! !! !! 3.3!(±0.4)! 6.7!(±1.6)! 1.0!(±0.3)! 0.5!(±0.1)! 2.5!(±0.5)! T! T! A! T! G!
ARC08B19! Tasan! 9BSepB08! 4.09! 14.6!(±5.5)! 33.5!(±10.7)! 3.8!(±0.6)! 2.7!(±1.4)! 38.2!(±3.3)! !! !! A! T! G!
ARC08B22! Tasan! !! 6.92! 27.9!(±11.6)! 50.6!(±9.4)! 6.8!(±2.1)! 6.6!(±1.9)! 49.0!(±22.3)! A! A! A! T! G!
ARC08B32! Tasan! !! 2.58! 35.5!(±12.2)! 59.6!(±14.3)! 10.6!(±1.7)! 13.3!(±11.9)! 52.8!(±18.2)! T! A! A! T! G!
ARC08B34! Tasan! 27BOctB08! 3.60! 15.4!(±2.1)! 22.2!(±4.1)! 4.0!(±0.6)! 3.2!(±0.5)! 23.6!(±19.2)! !! !! A! T! G!
ARC08B36! Tasan! !! 7.21! 9.9!(±1.1)! 24.3!(±3.1)! 6.1!(±0.5)! 4.0!(±0.4)! 9.4!(±1.8)! !! !! !! !! !!
ARC08B39! Tasan! 10BNovB08! 1.48! 14.1!(±1.1)! 28.7!(±1.0)! 4.1!(±0.4)! 3.4!(±0.2)! 53.4!(±6.6)! T! A! A! T! G!
ARC08B63! Tasan! !! 7.60! 28.1!(±19.9)! 42.6!(±24.2)! 7.6!(±1.1)! 6.5!(±1.5)! 44.9!(±24.4)! !! A! A! T! G!
ARC08B88! Tasan! !! TF*! 18.8!(±8.0)! 43.7!(±16.6)! 6.2!(±2.1)! 5.7!(±3.1)! 44.5!(±29.8)! !! A! A! T! G!
PL08B004! Pailin! 18BAprB08! 4.04! 20.2!(±8.4)! 25.4!(±4.4)! 6.4!(±0.9)! 6.0!(±1.8)! 49.7!(±37.8)! !! !! A! T! G!
PL08B009! Pailin! !! 5.30! 38.7!(±11.9)! 74.0!(±9.1)! 12.0!(±4.0)! 8.0!(±4.8)! 67.1!(±20.4)! A! A! A! T! G!
PL08B015! Pailin! 21BAprB08! 5.15! 16.7!(±6.7)! 15.9!(±8.7)! 4.7!(±1.5)! 4.7!(±4.0)! 43.6!(±20.5)! !! !! A! T! G!
PL08B025! Pailin! !! 13.07! 17.0!(±4.8)! 34.9!(±6.0)! 9.0!(±2.8)! 7.0!(±2.4)! 9.3!(±1.3)! T! A! A! T! G!
Cam5!(SC031)! Pailin! 1BAugB07! N/A! 9.7!(±4.1)! 14.6!(±7.2)! 3.4!(±1.3)! 3.1!(±1.2)! 36.3!(±20.5)! T! T! A! T! G!
NHP2065! Mae!Sot! !! 6.67! 19.6!(±9.8)! 27.8!(±16.8)! 10.0!(±6.0)! 11.2!(±6.1)! 61.2!(±13.7)! T! T! G! T! G!
NHP4197! Mae!Sot! !! 2.18! 39.9!(±8.8)! 57.5!(±12.8)! 6.9!(±0.7)! 5.0!(±1.3)! 70.7!(±13.3)! T! T! !! !! !!
NHP4306! Mae!Sot! !! 1.83! 17.3!(±10.4)! 33.5!(±8.1)! 5.1!(±2.7)! 3.2!(±1.5)! 65.1!(±21.6)! T! T! A! T! G!
Thai!13!(FARS012)! Mae!Sot! 1BFebB08! 3.18! 23.5!(±3.7)! 43.6!(±8.8)! 4.6!(±1.9)! 3.8!(±0.6)! 125.2!(±27.6)! !! !! A! T! G!
Thai!14!(ARS40)! Mae!Sot! 1BAprB08! 1.90! 22.7!(±8.6)! 30.0!(±1.0)! 4.3!(±0.8)! 3.9!(±0.1)! 113.3!(±25.8)! !! !! A! T! G!
Thai!22!(ARS014)! Mae!Sot! 1BFebB08! 3.63! 20.5!(±7.4)! 34.8!(±1.3)! 4.9!(±1.4)! 4.2!(±1.6)! 100.1!(±18.6)! A! T! A! T! G!
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Table 2.2. Description of Primers and Conditions Used in this Study. 
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Table S2. Description of primers and conditions used in this study.!
 
Gene SNP Forward Primer Reverse Primer Sequencing Primer TM 
(
o
C) 
PF3D7_1343700 C580Y GTCAACAATGCYGGCGTAT  TCACCATTAGTTCCACCAATGACA 
(BIO)  
CCAATGACATAAATTTTATT  63.0 
PF3D7_1343700 R539T TTAGTCAACAATGCTGGCGTAT 
(BIO) 
CTCCCATTAGTTCCACCAATG AGTGGAAGACATCATGTAA 58.0 
PF3D7_1343700 Y493H TTAGTCAACAATGCTGGCGTAT 
(BIO) 
CTCCCATTAGTTCCACCAATG  GTGCTGTATTGAATAATTTC  58.0 
PF3D7_101700 MAL10 
(688956) 
TGGATTGGTGAAAAGGAAAATGTA  GGAAACATTTATGCCATCAACATT 
(BIO) 
TTTTTATAAAAGAACTATGC  61.8 
PF3D7_1343400 MAL13 
(1718319) 
AAGACAACGGTGACGATCTAAAA 
(BIO) 
CGTCTGCACATTTTTTACACATAA  ATTATTTCCTATATTATTCT  58.6 
PF3D7_1344600 MAL13 
(660) 
CCGTATGTGAAGAAGCACAATGT 
(BIO) 
CTAGCTCCACCATCTGGTAAATCA  GGTAAATCATCTCTATCAAC  63.4 
PF3D7_1344700 MAL13 
(1646) 
TTGATAAACCTGAATGGGGACTTA 
(BIO) 
TTGATCACTCATGGGATGAAAATA  ACTCTAATGTTTGTTTCAAT  61.6 
PF3D7_1344300 MAL13 
(3142) 
TTTTTCATCGTGCATCTCAAAC 
(BIO) 
TTCCTAGTTGGCGTATCCTTAAAT  TTTGATTAGGGTACACATAA  59.0 
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Table 2.3. Compilation of Pf3D7_1343700 (K13) Sequence Results for P. falciparum 
Isolates and Clones Used in this Study. 
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Chapter 3 
Fitness of Artemisinin-Resistant Plasmodium falciparum In Vitro 
Abstract 
 Drug resistance confers a fitness advantage to parasites exposed to frequent drug 
pressure, yet these mutations also may incur a fitness cost. We assessed fitness 
advantages and costs of artemisinin resistance in Plasmodium falciparum in vitro to 
understand how drug resistance will spread and evolve in a competitive environment. 
Genotyping of single nucleotide polymorphisms (SNPs), drug susceptibility assays, and 
copy number determination were used to assess the impact of artemisinin-resistance on 
parasite fitness. An artemisinin-resistant clone (C9) selected from an isogenic parental 
clone (D6) was used to conduct fitness experiments in the presence and absence of drug 
pressure (dihydroartemisinin or pyrimethamine) and to quantify the rate at which 
artemisinin-resistance was gained or lost in competitive growth studies. We 
experimentally demonstrate for the first time that artemisinin resistance incurs a fitness 
advantage that is selected for with infrequent exposure to drug, but is lost in the absence 
of exposure to artemisinin drugs. The best correlations with artemisinin resistance were 
decreased in vitro drug susceptibility to artemisinin derivatives, increased copy number 
of PF3D7_1030100 and a SNP in PF3D7_0307600. A SNP conferring an E208K 
mutation in the kelch gene (PF3D7_1343700) was not associated with resistance. 
Furthermore we observed second cycle ring-stage dormancy induced by pyrimethamine, 
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suggesting that dormancy is a fitness trait that provides an advantage for survival from 
antimalarial drug stress. Artemisinin-resistant P. falciparum have a fitness advantage to 
survive and predominate the population even in the face of infrequent exposure to 
artemisinin drugs. 
Introduction 
Artemisinin-resistant Plasmodium falciparum appears to have emerged 
independently many times in Southeast Asia [47]. First described in Cambodia and along 
the Thai-Myanmar border as a prolonged parasite clearance phenotype following 
treatment with an artemisinin drug combination [49, 141], artemisinin resistance appears 
to be spreading throughout Southeast Asia [124]. Multiple point mutations in the 
propeller domains of PF3D7_1343700, the kelch gene on chromosome 13 (K13), have 
been associated with the delayed parasite clearance phenotype in vivo and have provided 
a molecular marker for tracking the spread of artemisinin resistance [51, 52]. While 
evidence suggests independent emergence of artemisinin resistance across geographic 
locations in Asia, emergence appears to be dependent on the genetic background of 
preexisting mutations in the parasite [54]. Parasites in Southeast Asia have historically 
been associated with multidrug resistance and given that artemisinin combination therapy 
(ACT) has been the primary treatment option globally for more than a decade, parasites 
have most likely evolved mechanisms to resist multiple classes of antimalarial drugs.  
Selection of antimalarial drug resistance often occurs early and can be conferred 
by a single point mutation [97, 142]. In contrast a complex series of mutations may be 
required as compensation for fitness costs or to enhance higher levels of resistance. For 
instance antifolate resistance is associated with a sequential accumulation of point 
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mutations in dhfr or dhps that are associated with reduced susceptibility to antifolate 
drugs [143]. Resistance arose from a single point mutation that was followed by multiple 
compensatory point mutations that increased resistance levels. Similarly for chloroquine 
resistance at least four mutations in Pfcrt are necessary for resistance, with the pivotal 
mutation being K76T. Once these resistance-associated mutations are present in a 
population, they can spread rapidly due to fitness advantages over wild type parasites in 
the presence of drug pressure. For both chloroquine and pyrimethamine resistance 
selective sweeps occurred that rapidly spread across malaria endemic regions [9, 126, 
144].  
 Although drug resistance confers a fitness advantage to parasites exposed to 
frequent drug pressure, these mutations also may incur a fitness cost [97]. For example, 
after chloroquine efficacy fell to low levels in Malawi, chloroquine use was discontinued 
and sulfadoxine-pyrimethamine was used as the primary therapy. Remarkably 
chloroquine susceptibility in Malawi returned a decade later [145] and this was attributed 
to re-expansion of susceptible parasites when chloroquine drug pressure was removed 
[146]. 
The selection process for artemisinin resistance appears to be more complicated 
than was observed with chloroquine and antifolate resistance; therefore, it is not well 
understood how resistance to ACTs will spread and how long it will take for resistance to 
emerge in Africa. Natural selection is likely to be the determinant of combination therapy 
resistance due to the parasite’s requirement to survive two antimalarials simultaneously, 
including a long-lasting partner drug [96]. Therefore, the subsequent spread of resistance 
to ACTs must include mutations beneficial to resist multiple antimalarials and therefore 
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may be associated with a significant fitness cost. These fitness costs are hypothetical at 
present since fitness associated with artemisinin resistance has not been determined 
experimentally.  
Fitness costs of drug resistance can be measured in vitro to understand how drug 
resistance will spread and evolve in a competitive environment [97]. In vitro models 
allow for more precise control and higher throughput to predict the spread of resistance in 
the field [147]. In vitro models of fitness can more easily project the spread of 
antimalarial drug resistance due to the selective nature of antimalarial drug resistance and 
the large role intraerythrocytic-stage parasites have in the spread of drug resistance [71, 
148]. While host and environmental factors play a role in the dissemination of 
antimalarial drug resistance in the field, in vitro models provide significant insights into 
the relative advantages of parasite resistance versus fitness costs.   
 In this study we used in vitro genotyping of SNPs, drug susceptibility assays, and 
copy number determination to assess the impact of artemisinin-resistance on parasite 
fitness. We used an artemisinin-resistant clone selected from an isogenic parental clone to 
conduct fitness experiments in the presence and absence of drug pressure and to quantify 
the rate at which artemisinin-resistance can be gained or lost in a competitive 
environment. By using a combination of pyrosequence analysis of multiple SNPs, copy 
number determination, and in vitro drug susceptibility we experimentally demonstrate for 
the first time that artemisinin resistance incurs a fitness cost that is selected for with 
infrequent exposure to drug, but is lost in the absence of artemisinin drug pressure.  
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Materials and methods 
Artemisinin-Resistant Plasmodium falciparum Culture In Vitro 
 P. falciparum clone D6 (Sierra Leone) and an in vitro selected artemisinin-
resistant clone derived from D6 were cultivated using previously described methods 
[127]. The artemisinin-resistant progeny were initially selected with small increments of 
artelinic acid (AL) up to 80 ng/ml (D6.AL80) [37]. D6.AL80 then was subjected to 
artemisinin (QHS) up to 2,400 ng/ml four times and cloned by limiting dilution [65]. The 
most resistant clone was exposed one additional time with 2,400 ng/ml QHS and 
maintained in culture in the absence of drug pressure for over 400 days 
(D6.QHS2400x5). Clone 9 (C9) of D6.QHS2400x5 maintained a stable in vitro resistance 
phenotype in the absence of drug pressure as described in Tucker et al. [65]. 
Fitness Study Design 
 Asynchronous D6 and C9 were co-cultured in a 1:1 (D6:C9) ratio and also 
maintained as monocultures. Parasite cultures were maintained between 2 to 5% 
parasitemia at 4% hematocrit in complete media supplemented with 10% heat-inactivated 
AB+ human plasma. D6:C9, D6, and C9 cultures at 2% parasitemia each were exposed to 
700nM dihydroartemisinin (DHA), 10μM pyrimethamine (PYR), or were SHAM treated 
(0.25% DMSO) for 48 hours. Following treatment, cultures were washed three times with 
RPMI 1640 medium (Invitrogen, Carlsbad, CA) and observed daily for growth. Every 24 
hours following 48-hour drug exposure media was changed and blood smears were made. 
When parasite cultures recovered and parasitemia exceeded 5%, cultures were diluted to 
2% parasitemia. The remaining parasitized blood pellet was frozen at -20°C for genomic 
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DNA extraction and analysis. Parasites were exposed to drug 4 times with a 21-day grow 
out period between each exposure, between exposure 2 and 3 there was a 42-day grow 
out period. As noted above, parasitemia was maintained between 2-5% during the grow 
out period. 
Recrudescence Assay Following Drug Exposure 
 Following a drug exposure cycle parasitemia was determined every 24 hours 
using microscopy. The ratio of ring, trophozoite, and schizont infected red blood 
cells/total red blood cells was used to determine parasitemia for each time point. Dormant 
and dead parasites were not included in the calculation.  
Drug Susceptibility Assay Using Radioisotope Addition at T0  
 Susceptibility to artemisinin derivatives was determined using a modified 
[
3
H]hypoxanthine incorporation assay [65]. [
3
H]hypoxanthine was added to cultures at 
the start of the assay when drug was added and allowed to incorporate for 48 hours. 
Parasites were harvested at 48 hours to determine fifty percent inhibitory concentration 
(IC50). For pyrimethamine, IC50 was determined traditionally, by adding 
[
3
H]hypoxanthine 24 hours after drug exposure [149].  
Genomic DNA Extraction 
 Parasitized red blood cells were frozen at -20°C for at least 24 hours and treated 
with 0.5% saponin to free parasites from red blood cells. Parasite pellet was frozen 12-24 
hours in Tris EDTA buffer. Thawed pellet was treated with 4% SDS and 20 mg/ml 
RNase (Life Technologies, Grand Island, NY).  Equal volumes of 
phenol:chloroform:isoamylalcohol (25:24:1) were added and extracts were spun at 
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14,000 rpm for 5 minutes at room temperature and then the upper aqueous phase was 
transferred to a new tube. This separation step was repeated with 
chloroform:isoamylalcohol (24:1) and chloroform respectively. The final aqueous 
transfer was treated with 3M potassium acetate and 100% ethanol. Pellet was washed 
with 100% ethanol and suspended in Tris EDTA buffer. Genomic DNA was quantified 
using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA). 
Real-Time Quantitative PCR to Determine Gene Copy Number 
 Previously C9 was found to have an amplified region of chromosome 10, whereas 
the parent clone has only one copy of genes in this region [67]. PF3D7_1030100 is in the 
amplicon and C9 has 2 copies, whereas parental D6 maintains one copy.  Therefore in 
this study we used real time quantitative PCR to assess the copy number of D6, C9, and 
the D6:C9 mixed culture following the 2
nd
 and 4
th
 drug exposure cycles. We used the 
previously described methods and primer sequences [67]. In brief, Brilliant II QPCR 
SYBR Green 2x mastermix (Strategene, LaJolla, CA) and 30nM ROX was used to 
amplify PF3D7_1030100 at a final primer concentration of 200 nM. The relative copy 
number was determined by the standard curve method comparing threshold cycle (Ct) 
values of gene of interest to ldh using MX3000P real-time quantitative PCR system 
(Strategene, LaJolla, CA). Average copy number was calculated from three replicates 
with a confidence interval greater than 95% (GraphPad Prism). 
Determination of SNP Frequency by Pyrosequencing 
 PCR and sequencing primers were designed using Biotage Pyrosequencing Assay 
Design software (Charlottesville, VA) to amplify SNP-containing genes. Primer 
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sequences and SNP details are listed in Table 3.1. A 5’ biotin label was added to the PCR 
primer running in the opposite direction of the sequencing primer. Each 50μl PCR 
reaction mixture contained 31.5μl sterile water, 10μl 5X HF buffer, 1μl 10mM dNTPs, 
2μl each of forward and reverse primer (10μM), 0.5μl Phusion Hot Start II DNA 
polymerase (Fisher Scientific, Pittsburg, PA), and 2μl template DNA. Thermal cycling 
conditions were 98°C for 30 seconds (initial denaturation), followed by 40 cycles of 
denaturation at 98°C for 10 seconds, annealing at temperature indicated in Table S1 for 
30 seconds, and extension at 72°C for 50 seconds, followed by a final extension at72°C 
for 7 minutes, and a final hold at 4°C. PCR products (10μl) were visualized using 
QiAxcel (Qiagen, Valencia, CA). 
 Sequencing primer (0.6μM) was diluted in annealing buffer (Biotage, 
Charlottesville, VA) and 40μl of mixture was aliquoted into a 96-well PSQ plate. Binding 
reaction mixture consisted of 4μl of Streptavidin coated sepharose beads (GE Healthcare) 
and 51μl of binding buffer. In each well of a round-bottom PCR plate 55μl of binding 
mixture was added to 25μl of PCR product and mixed at 14,000rpm for 10 minutes. 
Using the Vacuum Prep Workstation (Biotage, Charlottesville, VA) the sepharose-bound 
PCR products were captured with the Vacuum Prep Tool immediately after being mixed 
and washed as follows: 70% ethanol for 10 seconds, denaturing buffer (0.2M NaOH) for 
10 seconds, and washing buffer (10mM Tris-acetate, pH 7.6) for 15 seconds. The vacuum 
was released and the Sepharose-bound PCR products were released into the PSQ plate 
containing sequencing primer. The plate was incubated at 80°C for 2 minutes and 
allowed to cool to room temperature. Plates were read on a Pyromark Q96 ID 
pyrosequencer (Qiagen, Valencia, CA) in AQ mode using Pyromark Gold Q96 reagent 
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kit. Assays were completed 3 times for each DNA template and the average percentage of 
wild-type allele was plotted over time. In addition standard curves were established for 
each SNP by using ratios of D6:C9 gDNA (Figure 3.6). 
Results 
Competitive Fitness of Artemisinin-Resistant and Susceptible Clones 
Understanding fitness costs associated with artemisinin resistance is of extreme 
importance due to the potential spread of resistance globally. An in vitro model to 
determine fitness cost associated with artemisinin resistance has not been previously 
described yet could provide essential information to elucidate how efficiently artemisinin 
resistance will spread.  Therefore in these studies we assessed fitness of artemisinin-
resistance in vitro in competitive growth experiments. We used a stable artemisinin-
resistant clone (C9) derived from a cloned parent (D6) following repetitive pulse 
exposures to artemisinin drugs in vitro [65]. An advantage of using these cloned parasites 
are they are derived from an isogenic background [97] and following resistance selection 
several molecular markers were identified that allowed us to discriminate between the 
resistant and susceptible clones in mixed population growth studies. In preliminary 
studies Tucker [67] identified several SNPs (see Table 3.1) and a copy number variant on 
chromosome 10 that were present in the C9 (resistant) clone. By using these markers we 
were able to quantify the phenotypic responses associated with the prevalence of C9 
genotypes in a heterogeneous population.  
We first assessed fitness in a competitive growth experiment in which an 
asynchronous parent clone (D6) and its artemisinin-resistant progeny (C9) were mixed 
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equally (1:1) at the beginning of the study. In direct comparison with both susceptible 
and resistant clones grown in monocultures, we exposed the cultures to 4 cycles of drug 
pressure (21 or 42 days apart) with dihydroartemisinin (DHA) or pyrimethamine (PYR); 
as a control we also included a SHAM treatment with 0.25 % DMSO. Following the first 
pulse exposure to DHA, the resistant C9 clone recovered from ring-stage drug-induced 
dormancy earlier than D6 (Figure 3.1), as reported previously [65]. Conversely the D6 
and mixed cultures recrudesced a day later, although the mixed culture recovered to 
higher parasitemia faster than D6. Following the first exposure to PYR there was no 
difference in recovery between sensitive, resistant, and the mixed parasite population 
(Figure 3.1). The resistant C9 clone recovered earlier than D6 following DHA pressure in 
all but the third drug exposure cycle. Importantly the parasites were not synchronized at 
any time of the experiment, therefore mixed asexual stages were present and these ratios 
may be different between cultures at the time of drug exposure. Interestingly, the C9 
resistant clone recovered from dormancy earlier than sensitive parasites only following 
exposure to DHA; these results suggest enhanced survival of resistant parasites and the 
potential of resistance to spread when exposed to artemisinin drugs. In contrast, when 
exposed to a drug that acts through a different target (e.g. pyrimethamine), artemisinin-
resistant parasites recover from dormancy similarly to sensitive parasites. In all SHAM 
treated cultures parasites grew normally without any evidence of the dramatic reductions 
in parasitemia seen with DHA or PYR exposure (data not shown). 
Pyrimethamine Induces 2
nd
 Cycle Ring-Stage Dormancy 
Unlike artemisinin that induces ring-stage dormancy immediately when rings are 
exposed to drug, following pyrimethamine exposure the ring-stage parasites continued 
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development into late schizogony where the drug effect was maximal. Interestingly, 
pyrimethamine exposure also reduced parasitemia in the cultures similar to DHA and this 
effect was followed by subsequent recrudescent growth (Figure 3.1). Recrudescence 
following pyrimethamine exposure has been previously described [78, 79], yet the 
mechanism by which the parasite survives pyrimethamine exposure is not known. By 
examining the artemisinin-resistant (C9) or -susceptible (D6) clone morphology 
following drug exposure, we discovered that pyrimethamine induced ring-stage 
dormancy in the subsequent cycle of development after drug exposure. That is the 
parasites were not arrested in the first ring-stage when drug was applied, but following 
development to mature schizonts, some schizonts successfully produced merozoites that 
invaded new erythrocytes and then arrested as dormant ring-stages (Figure 3.2). The 
morphology of pyrimethamine- and DHA-induced dormant rings was similar as was the 
period of dormancy induced by both drugs following 48 hour exposure.  This is the first 
demonstration of drug-induced 2
nd
 cycle dormancy by any antimalarial drug other than 
artemisinin derivatives. 
Drug Susceptibility Assays Confirm Resistance Phenotypes in Competitive Growth 
Studies 
The artemisinin resistance phenotype in vitro was measured by using a modified 
assay that includes addition of [
3
H]hypoxanthine at the start of assay when drug is added 
[65]; pyrimethamine susceptibility was measured by traditional drug susceptibility 
methods in which [
3
H]hypoxanthine was added 24 hours after drug. By using these drug 
susceptibility methods we were able to assess the prevalence of artemisinin resistance 
phenotypes in the fitness competitive growth studies. We found the mixed population 
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was equally resistant to artemisinin derivatives as the C9 resistant clone by the end of 
study when exposed to four pulse cycles of DHA (Figure 3.3). Conversely, resistance was 
lost and the mixed population was equally susceptible as D6 by the end of study in the 
absence of DHA pressure or following PYR exposures. Pure C9 resistant clones also 
maintained resistance to artemisinin derivatives in vitro in the presence or absence of 
artemisinin drug pressure as expected (Figure 3.3) [65]. Sensitivity to pyrimethamine was 
maintained in this experiment for all parasite cultures.  
Prevalence of SNPs in Competitive Growth Studies  
Next we assessed the relative proportions of resistant and susceptible genotypes in 
the parasite cultures following each drug or SHAM exposure. Resistant and sensitive 
parasites in co-culture were quantified by pyrosequencing SNPs previously identified in 
artemisinin-resistant C9 (Figure 3.6) [67]. In this study we quantified SNPs on 
chromosome 3 (Pf3D7_0307600; conserved protein with unknown function), 7 
(Pf3D7_0700900; RESA-like protein, pseudogene) and 13 (Pf3D7_1343700, K13) to 
discriminate between C9 and D6 genotypes in the competitive growth fitness studies. 
When the Pf3D7_0307600 SNP allele frequency of mixed culture was analyzed 
immediately following recovery from DHA exposure, the SNP frequency reached almost 
80% (Figure 3.4). When grown in the absence of DHA pressure following recovery from 
DHA-induced dormancy, the percentage of wild-type allele became increasingly more 
abundant over time until the subsequent DHA exposure cycle. This is most likely due to 
artemisinin-resistant parasites recovering from DHA-induced dormancy faster than 
sensitive parasites [65, 69]; however, due to the fitness cost associated with artemisinin 
resistance, wild-type parasites outgrew resistant parasites over time in the absence of 
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DHA exposure. Artemisinin-resistant C9 is known to produce fewer merozoites than 
parent D6 [65], thus allowing D6 to outgrow C9 in the absence of artemisinin pressure. 
These results suggest a positive, though not causal association of the Pf3D7_0307600 
SNP with artemisinin resistance. 
The apparent fitness cost of artemisinin resistance was further evident in D6 and 
C9 monocultures treated with DHA compared to pyrimethamine. Artemisinin-resistant 
C9 recovered from drug-induced dormancy earlier than sensitive D6 only when exposed 
to DHA. Furthermore, this was evident in the Pf3D7_0307600 SNP frequency of the 
mixed culture that was examined immediately following recovery from pyrimethamine-
induced dormancy (Figure 3.4). There was 60% wild-type allele in co-cultures tested 
immediately following recovery, reaching 95% when grown in the absence of drug 
pressure until exposed to pyrimethamine again. Artemisinin-resistant parasites did not 
recover from dormancy significantly earlier than sensitive parasites when exposed to 
pyrimethamine and due to fitness costs associated with resistance, they were outcompeted 
in the absence of DHA pressure. Allele frequency associated with artemisinin-resistance 
increased in the mixed population remarkably fast following a DHA exposure cycle yet 
diminished to nearly 100% wild type (D6) after recovery from just one exposure to drug. 
While there remains a large flux in the Pf3D7_0307600 allele frequency of the mixed 
culture when exposed to DHA compared to pyrimethamine or untreated cultures, fitness 
cost associated with artemisinin resistance appears to determine the outcome of the 
competition between parasites very early in drug selection and evolution of resistant 
parasites. We also assessed the prevalence of a SNP in Pf3D7_0700900 that was 
identified in C9. Unlike the other SNP examined, the prevalence of the Pf3D7_0700900 
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SNP was significantly reduced in the mixed culture by the end of the study, with most 
parasites having wild-type sequence.  
The prevalence of a SNP in K13 (Pf3D7_1343700) is of interest given that 
previous studies demonstrated a correlation between mutations in the propeller domains 
(aa>440) of K13 with clinically relevant resistance that is expressed as a slow parasite 
clearance phenotype in vivo. The SNP identified in the artemisinin-resistant C9 clone 
results in a non-synonymous change at amino acid 208 of K13 (E208K) that has not 
previously been observed in the field and is outside the propeller domains associated with 
artemisinin-resistance mutations. Interestingly, the prevalence of Pf3D7_1343700 SNP in 
C9 and the mixed cultures was similar to that observed for Pf3D7_0700900 (Figure 3.4). 
That is, the wild-type allele appeared to increase in C9 or mixed cultures after DHA 
exposures and by the end of the study the K13 SNP was no longer prevalent in any of the 
cultures exposed to DHA. These results suggest that neither the Pf3D7_1343700 nor 
Pf3D7_0700900 SNPs are strongly associated with the artemisinin resistance phenotype 
in vitro. It is important to note the SNP discrimination for the K13 SNP in mixtures of D6 
and C9 was not as good as the other SNPs (see Figure 3.6) thus the SNP calls were binary 
(D6 or C9). 
Pf3D7_1030100 Copy Number and Artemisinin Resistance  
 The artemisinin-resistant C9 clone has two copies of a multigene amplicon on 
chromosome 10 [67], therefore we also assessed the relative proportion of resistant and 
susceptible clones by copy number analysis of Pf3D7_1030100, a pre-mRNA-splicing 
factor ATP-dependent RNA helicase located within the amplified region of chromosome 
10.  In this study, the artemisinin-resistant C9 clone maintained 2 copies of 
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Pf3D7_1030100 in the presence or absence of DHA or PYR drug pressure over the 
course of study (Figure 3.5). Once recovered from the second DHA exposure the mixed 
culture had two copies of Pf3D7_1030100, but only 1 copy when exposed to 
pyrimethamine or no drug pressure. In addition following the 4
th
 drug exposure cycle, 
two copies of Pf3D7_1030100 were found in mixed culture only when exposed to DHA. 
These results suggest a positive association of increased Pf3D7_1030100 copy number 
and the artemisinin-resistance phenotype assessed by drug susceptibility assays.  
Discussion 
Antimalarial drug exposure ultimately leads to emergence of resistant parasites. 
All too often resistance is selected quickly due to SNPs in target genes or transporters or 
via amplification of regions of the genome that confer an advantage for parasites exposed 
to drugs. The ease and speed of resistance development varies with the target, the specific 
chemotype of drug used, the presence of preexisting cross-resistance, and the duration of 
exposure to the drug in vitro and in vivo. As resistant organisms emerge, they have a 
competitive advantage over susceptible organisms when exposed to drug, yet often the 
genetic alterations that confer resistance come at a cost to the parasite in the absence of 
drug pressure.  Therefore without drug pressure, the less fit resistant genotypes can be 
outcompeted by wild-type parasites. In areas of low endemicity and high drug pressure 
(e.g., Southeast Asia), even the less fit resistant genotypes can be selected for at such a 
rate as to reach fixation in a population. An example of this is stable chloroquine and 
pyrimethamine resistance in Thailand where these drugs have not been used for primary 
treatment of falciparum malaria in decades. Conversely, in high transmission areas 
resistance may emerge multiple times, yet the relative absence of drug pressure, plus the 
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massive genetic diversity of susceptible parasites outcompete the resistant parasites. 
Obviously this is a complex, yet critically important issue, specifically for the future 
utility of artemisinin drugs. Resistance has emerged in Southeast Asia and some data 
suggest K13 mutations have emerged independently in both Asia and Africa [47, 150]. 
Clearly the relative fitness of artemisinin resistance traits and the potential for even soft 
selective sweeps of artemisinin-resistant P. falciparum requires urgent attention. 
 In this study we have assessed the fitness of an artemisinin-resistant clone in 
competitive growth experiments with its isogenic parent (D6). The clear advantage of this 
approach is the clones are genetically homogenous with the exception of SNPs and CNVs 
that arose during selection of resistance. In addition we were able to use three SNPs and a 
CNV on chromosome 10 to quantify the resistant C9 genotype in relation to the 
susceptible D6 parental clone. Finally we had a drug resistance phenotype that allowed us 
to assess the relative shifts in population structure and to correlate with the molecular 
markers. The results of the competitive growth studies demonstrate a fitness advantage of 
the resistant parasite with infrequent pulse exposures to DHA. The period between drug 
exposures was either 21 or 42 days, which is equivalent to approximately 11 or 22 
asexual parasite generations. Conversely, the artemisinin-resistant parasites incurred 
fitness costs and were outcompeted in the absence of drug pressure or with a drug that 
has a different mechanism of action and resistance (pyrimethamine).  These studies 
demonstrate for the first time the relative fitness of artemisinin-resistant P. falciparum 
and provide contextual information about the potential for this resistance to spread. 
 There is no gold standard method for assessing antimalarial drug fitness. The 
competitive growth experiments offer perhaps the most direct comparison of fitness of 
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resistant and susceptible organisms at the level of the parasite [97]. This approach has 
been used successfully to demonstrate fitness of cytochrome b and pfmdr1 mutants by 
using similar approaches [142, 147] and in some cases to correlate with in vivo fitness 
[97, 147]. Despite the advantages of our approach to assess fitness, there are some 
limitations that must be considered. First the resistance mechanism(s) selected in C9 may 
differ from artemisinin-resistant genotypes that have emerged in Southeast Asia. A direct 
comparison of resistant and susceptible clones from Asia would provide an interesting 
comparison to our results, yet given the inherently different growth rates between isolates 
and the fact that some artemisinin-resistant P. falciparum from Cambodia have altered 
asexual life cycles [137] will make competitive growth studies difficult to interpret. More 
importantly the ultimate goal is to understand the relative fitness of artemisinin resistance 
in the clinic and how often and how fast these resistant genotypes can emerge and spread. 
Modeling studies of artemisinin in Southeast Asia suggest that mostly effective drug 
coverage in this hypoendemic region is rapidly selecting for the most resistant parasites 
and that the “last man standing” will be the most resistant genotypes to ACTs [123]. Our 
data support this contention; especially since relatively infrequent drug exposures are 
enough to give a fitness advantage to the resistant parasite. 
 Interestingly the best correlation of artemisinin resistance in our study was with 
three measured phenotypes or genotypes: in vitro drug susceptibility in a modified assay 
format, a CNV on chromosome 10, and a SNP in Pf3D7_0307600. In comparison SNPs 
in two other genes, including K13 in C9 were lost during the competitive growth studies 
and appear to be unrelated to the artemisinin-resistance phenotype. The C9 resistant clone 
was selected from the D6 parent by numerous pulses of artelinic acid and artemisinin, 
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followed by recovery and growth before another drug exposure cycle. During this 
selection process a limited number of mutations were observed in C9 versus D6 [65, 67]. 
These included the three SNPs and the chromosome 10 CNV used to monitor resistant 
genotypes in our study.  It is important to note that SNPs or CNVs can arise in long-term 
culture even in the absence of drug pressure [151]; therefore, the molecular markers we 
used could be neutral and not linked to the resistance phenotype. That appears to be the 
case for the SNPs in Pf3D7_1343700 and Pf3D7_0700900. The prevalence of these 
SNPs decreased over time following exposure to DHA even though the artemisinin 
resistance phenotype persisted. In contrast, the Pf3D7_0307600 SNP was linked to the 
artemisinin resistance phenotype and the CNV on chromosome 10. Further studies are 
required to determine if the SNP in Pf3D7_0307600 is causally associated with 
artemisinin resistance. 
Conversely we identified a strong positive association of artemisinin resistance 
with a duplicated region on chromosome 10, as exhibited by quantitative analysis of 
Pf3D7_1030100 copy number. The C9 clone maintained two copies of Pf3D7_1030100 
throughout the study, either in the absence or presence of DHA or pyrimethamine drug 
pressure. In addition the increased copy number of Pf3D7_1030100 was selected for in 
the mixed culture exposed to infrequent pulses of DHA. Furthermore, this molecular 
marker provided the best correlation with resistance as assessed by in vitro drug 
susceptibility to four different artemisinin drugs (Figure 3.3). The association of this 
CNV and the artemisinin resistance phenotype is intriguing, yet we do not know if any of 
the genes in the amplicon have a direct role in conferring artemisinin resistance. In a 
previous study of clonal variation in transcriptional responses, one stock of 3D7 had a 56 
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kb amplicon on chromosome 10 that covered from Pf3D7_1028700 to Pf3D7_1030300 
and increased expression two-fold of 5 of 6 genes analyzed within the duplicated region 
[62]. This observation is interesting given that in a different study 3D7 was identified as 
having reduced susceptibility to artemisinin drugs in vitro [68], although it is not known 
if that stock of 3D7 had a CNV on chromosome 10. The potential role of chromosome 10 
CNVs in artemisinin resistance and dormancy certainly deserves further study. 
Exposure of ring-stages of P. falciparum to artemisinin derivatives induces a cell 
cycle arrest that is time of exposure and dose dependent. The drug-induced ring stages 
are known as dormant rings given their ability to persist for days to weeks in a non-
replicating state before recovery and normal asexual growth resumes. Previously we have 
confirmed artemisinin-induced dormancy in both drug resistant and drug susceptible P. 
falciparum [65, 69]. These dormant ring-stages have distinct physiological differences 
from normal rings as shown by up-regulation of fatty acid and pyruvate metabolism [152] 
and maintenance of mitochondrial membrane potential that is linked to viability of 
dormant rings [153]. In this study we observed ring stage dormancy with subsequent 
recrudescence following exposure of resistant, susceptible, or mixed cultures to both 
DHA and pyrimethamine. Although recrudescence following pyrimethamine drug 
pressure has been observed previously [78, 79], the mechanism for parasite survival was 
not known. By observing parasite morphology following pyrimethamine drug exposure, 
we observed for the first time induction of 2
nd
 cycle ring stage dormancy.  The difference 
in induction of dormancy between DHA and pyrimethamine is that only artemisinin 
drugs induce dormancy immediately upon exposure to ring stages. Conversely, under 
pyrimethamine pressure the rings progressed through the asexual cycle until late 
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schizogony (segmenters) where development was arrested in most parasites. An unknown 
proportion of these segmenters produced viable merozoites that invaded new erythrocytes 
and then arrested as dormant rings. These observations explain the results of previous 
studies with pyrimethamine [78, 79] and suggest a more broadly adaptive fitness 
advantage of dormancy for parasite survival. We hypothesize that ring stage dormancy is 
a fitness trait that provides an advantage to P. falciparum survival to stress, especially 
from antimalarial drugs. The potential role of 2
nd
 cycle dormancy and recrudescence in 
resistance development should be investigated with additional antimalarial drugs. 
The relative fitness associated with artemisinin resistance is of critical 
importance, given our current reliance on ACTs as the first line therapy for malaria 
worldwide. Although new promising drugs are in clinical trials, there are no new 
therapies that can immediately replace the loss of ACTs; therefore, fitness and its role in 
the emergence and spread of this resistance trait needs additional scrutiny. What our data 
show is the fitness advantage of artemisinin-resistant genotypes to survive and 
predominate the population even in the face of infrequent drug exposure. What we could 
not measure in this study are other important traits that could enhance the spread of these 
genotypes. In particular the transmission potential of artemisinin-resistant P. falciparum 
is of critical importance. Previous studies suggest enhanced transmission potential of 
resistant parasites by earlier commitment to produce gametocytes as well a competitive 
advantage of resistant parasites to survive drug exposure long enough to transmit the 
traits to the next generation. Clearly if artemisinin-resistant parasites are more fit to 
transmit to mosquitos, the effects we observed would be amplified in the field. These are 
intriguing biological questions that more importantly have immediate relevance to the 
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malaria elimination and eradication efforts. Data from these competitive fitness studies 
offer an opportunity to model the fitness of artemisinin resistance and to begin to assess 
these fitness advantages and costs in vivo. 
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Figure 3.1. Recrudescence Following Antimalarial Drug Exposure. Recrudescence 
following 4 exposures to dihydroartemisinin (DHA) or pyrimethamine (PYR) was 
assessed by microscopy of Giemsa stained blood smears. Asynchronous artemisinin-
resistant (C9) and parent D6 ring-stage parasites were co-cultured 1:1 and exposed to 
700nM DHA or 10μM PYR for 48 hours; data for SHAM exposure with 0.25% DMSO 
are not shown. C9 and the mixed culture recovered up to 2-3 days earlier than D6 when 
exposed to DHA. When exposed to PYR mixed culture recrudescence was similar to drug 
sensitive D6 in monoculture. 
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Figure 3.2. Pyrimethamine Induces 2
nd
 Cycle Ring-Stage Dormancy. P. falciparum  
exposed to pyrimethamine (PYR) enter ring-stage dormancy in the subsequent life cycle 
of development. Late-stage parasites were observed 24 hours following 10μM PYR 
exposure to ring-stage parasites progressing the same as untreated parasites. Ring-stage 
dormant parasites were observed 48 hours after starting pyrimethamine treatment. This is 
in contrast to ring-stage induced dormancy by dihydroartemisinin (DHA) in which 
dormant parasites are observed 24 hours following 700nM DHA exposure to ring-stage 
parasites. 
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Figure 3.3. Artemisinin-Resistant Phenotypes Correlate with Prevalence of 
Resistant Genotypes in Mixed Populations.  In vitro drug susceptibility assays  (n=2) 
were performed on the clones before the experiment (pre-treatment) and on the D6, C9, 
and mixed cultures following recovery from the 4
th
 drug or SHAM exposure. Reduced 
susceptibility of C9 to artelinic acid (AL), artemisinin (QHS), and dihydroartemisinin 
(DHA) was observed in the absence of DHA exposure. The mixed culture also 
demonstrated reduced susceptibility to artemisinin derivatives in the DHA-exposed 
groups, but not in the SHAM or pyrimethamine (PYR) exposed group. 
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Figure 3.4. Artemisinin-Resistant Allele Frequency. Allele frequency of single nucleotide polymorphisms (SNPs) was assessed by 
pyrosequence analysis and is plotted as the percent of wild-type (D6) SNP found at each time point in the competitive growth 
experiment. Drug or SHAM exposures were for 48 hr and are denoted as bars (DHA = yellow; pyrimethamine (PYR) = blue; SHAM 
= grey). The SNPS quantified were on chromosome 3 (Pf3D7_0307600; conserved protein with unknown function), 7 
(Pf3D7_0700900; RESA-like protein, pseudogene) and 13 (Pf3D7_1343700, K13). The Pf3D7_0700900 and Pf3D7_1343700 SNPs 
were lost in C9 and the mixed culture in the absence of dihydroartemisinin (DHA) pressure. Conversely, the Pf3D7_0307600 SNP 
persisted throughout the study in C9 and the mixed culture exposed to DHA. , K13maintained in artemisinin-resistant (C9) over 4 
consecutive treatments plotted as proportion of wild-type allele. 
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Figure 3.5. Increased Copy Number of Pf3D7_1030100 is Associated with Artemisinin 
Resistance in P. falciparum. The artemisinin resistant clone (C9) has an amplified region on 
chromosome 10 that include PF3D7_1030100, a pre-mRNA-splicing factor ATP-dependent 
RNA helicase; therefore, copy number of PF3D7_1030100 was analyzed by real-time PCR (n=3) 
following the 2
nd
 and 4
th
 drug or SHAM exposure cycles in the competitive fitness experiment. 
After recovery from the second exposure one copy of PF3D7_1030100 was observed in the 
absence of DHA exposure in mixed cultures. Artemisinin-resistant C9 maintained 2 copies of 
PF3D7_1030100 in the absence of artemisinin exposure. Co-cultured parasites maintained 2 
copies of PF3D7_1030100 only when treated with DHA. 
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Figure 3.6. Standard Curves of Pyrosequencing Data. Mixtures of gDNA from D6 (wild-
type) and C9 (artemisinin resistant) clones were prepared and then analyzed to establish a 
standard curve for each single nucleotide polymorphism (SNP) analyzed in the competitive 
growth studies.  
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Figure S1. Standard curves of pyrosequence data for each 
single nucleotide polymorphism (SNP) analyzed in the 
competitive growth studies. Mixtures of gDNA from D6 (wild-
type) and C9 (artemisinin resistant) clones were prepared 
and then analyzed to establish a standard curve for each 
SNP. 
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Table 3.1. Description of Primers and Conditions Used in this Study. 
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Table S1. Description of primers and conditions used in this study. 
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CHAPTER 4 
Using GFP- and luciferase-expressing artemisinin-resistant P. falciparum to further 
elucidate artemisinin resistance and drug-induced dormancy in vitro 
Rationale for Study 
Artemisinin resistance has been defined in the field as delayed parasite clearance 
following treatment with artemisinin combination therapy (ACT) [49]. A molecular marker, 
several single nucleotide polymorphisms (SNPs) in K13, has been associated with artemisinin 
resistance in vivo and has been used to track the spread of artemisinin resistance across Southeast 
Asia [51]. An in vitro phenotype assay for artemisinin resistance, ring survival assay (RSA), has 
been established that is associated with delayed clearance observed in the field and SNPs in the 
K13 propeller domain [139]. We have established a more robust in vitro phenotype assay, 
delayed clearance assay (DCA), which correlates with delayed clearance observed in the field 
and is associated with the presence of SNPs in the K13 propeller domain. In addition to the 
DCA, we discovered novel phenotypes of artemisinin resistance all involving altering cell cycle. 
Despite these new phenotypes we have discovered and the association with the slow phenotype 
in vivo, there remain numerous questions about the mechanisms of resistance in these parasites. 
In addition, it is important that new drug discovery efforts effectively target the artemisinin 
resistance phenotypes. The only currently available in vitro methods to phenotype dormant 
parasites are laborious and require extensive counts of microscope slides. Therefore we aim to 
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develop reporter strains to further elucidate how altering cell cycle is related to artemisinin-
resistance and resistance to other antimalarials, including the ACT partner drugs. 
 Dormancy has been associated with artemisinin-resistance leading to recrudescence of 
parasites able to survive artemisinin drug pressure [65, 69]. We have shown that additional 
drugs, such a pyrimethamine, having a completely different mechanism of action compared to 
artemisinin can induce ring-stage dormancy and lead to a recrudescent infection. Interesting, 
ring-stage dormancy was induced at the start of the second cycle following exposure to 
pyrimethamine at ring-stage. We hypothesize that many antimalarials induce ring-stage 
dormancy, including ACT partner drugs, causing a recrudescent infection and ultimately 
contributing to treatment failure. 
 We wanted to further understand the complex phenotypes observed with artemisinin 
resistance and possibly multi-drug resistance. In order to do this we generated GFP and 
luciferase based artemisinin-resistant parasites to study these resistant phenotypes in real time 
and develop new tools to find drugs that target ACT-resistant parasites. 
Materials and Methods 
Generation of GFP- and Luciferase-Expressing Artemisinin-Resistant P. falciparum 
Clones of highly characterized artemisinin-resistant Plasmodium falciparum from 
Cambodia [ARC08-22 (4G) and PL08-09 (5C)] and Thailand [NHP4197 (2A)], as well as one 
control parasite, W2, were transfected with GFP and luciferase using transposon-mediated 
mutagenesis (Table 1). piggyBac transposon plasmids were constructed by John Adams lab 
(Hitoshi, Xu, Adams unpublished data) and transfection methods were adapted from Balu et al. 
[130]. GFP (pL-BACII-EDGH) and luciferase (pL-BACII-bEDMH-luc-Pbdhfr) plasmids contain 
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human dihydrofolate reductase (dhfr) and P. berghei dihydrofolate reductase (Pbdhfr) drug 
selectable markers respectively under the control of 5’ calmodulin and 3’ histidine-rich protein 2 
promoter. A transposase-expressing helper plasmid, pDCTH, is also needed to drive integration 
of the transposable element containing GFP or luciferase at TTAA targeted sites randomly in the 
Plasmodium genome. GFP and luciferase expression remained under the control of the 
constitutively expressed elongation factor 1 alpha (ef1α) promoter. 
 GFP, luciferase, and pDCTH helper plasmids were electroporated into fresh uninfected 
erythrocytes using BioRad Gene Pulser Xcell Electroporation System+ CE Module (Hercules, 
CA). Magnetically purified schizonts were cultured with plasmid containing erythrocytes. Once 
culture reached 1% parasitemia, 5nM WR99210 was applied for 24 hours to select for positively 
transfected parasites. WR99210 pressure was applied again 24 hours later. Once surviving 
parasites grew to 1% parasitemia cultures were immediately frozen in glycerolyte and cloned 
using limiting dilution in the absence of WR99210 pressure. Clones that stably express GFP and 
luciferase in the absence of WR99210 were glycerolyte frozen for further elucidation.  
Luciferase- and GFP-Expression Over Intraerythrocytic Life Cycle 
Luciferase expression was determined over the course of the intraerythrocytic life cycle.  
Parasites cultures were synchronized to ring-stage with 5% D-sorbitol and grown in a white 96-
well plate at 2% hematocrit. D-Luciferin substrate (1.5 μg/ml) was added to each well in a 1:10 
dilution and incubated for 20 minutes. Luminescence was measuared on TopCount NXT 
(PerkinElmer, Waltham, MA) over one 48-hour life cycle. Luciferin substrate was added every 
24 hours when media was changed. GFP-expression for three intraerythrocytic life cycle stages 
(ring, trophozoite, and schizont) was determined using the DeltaVision Core imaging system 
(GE Healthcare Life Sciences, Pittsburg, PA). GFP fluorescence intensity was measured for all 
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three stages of selected clones. Clones identified with stable GFP- and luciferase-expression can 
be found in Table 4.1. 
Luciferase-Expression in Artemisinin-Induced Ring-Stage Dormancy 
Synchronous ring-stage parasites were treated with 700nM DHA for 6 hours. Parasite 
cultures were washed three times with RPMI medium and D-Luciferin (1.5 μg/ml) was added to 
culture. Luminescence was measured every 6 hours for the first 48 hours and until parasite 
cultures recovered from ring-stage dormancy as evidence by reaching initial parasitemia level. 
Giemsa-smears were made every time point. TopCount NXT (PerkinElmer, Waltham, MA) was 
used to measure luminescence and log of luminescence measurement was plotted over time.  
GFP-Expression in Artemisinin-Induced Ring-Stage Dormancy  
Ring-stage dormancy was induced in GFP-expressing parasites with 700nM DHA as 
described above. Parasite cultures were stained with 5μM Hoechst (or RNA dye). The Operetta 
high content screening system (PerkinElmer, Waltham, MA) was used to quantify number of 
GFP-expressing ring-stage dormant parasites. Parasite cultures were seeded at 0.5% hematocrit 
in a 96 MicroWell  optical bottom plate, #1.5 coverglass bottom (ThermoScientific, Waltham, 
MA) and incubated in the dark between measurements. DeltaVision Core imaging system (GE 
Healthcare Life Sciences, Pittsburg, PA) was used to visualize dormant parasite and measure 
green fluorescence intensity of dormant parasites. A small amount of culture (10μl) was seeded 
onto a glass slide and sealed with a glass cover slip. Slides were immediately imaged. 
Confirming Artemisinin-Resistant In Vitro Phenotypes 
Delayed clearance assay (DCA) and recrudescence assay was performed with luciferase- 
and GFP-expressing parasites to confirm that the delayed clearance and recrudescence phenotype 
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remained in transfected parasites when exposed to DHA (Chapter 2). Synchronous ring-stage 
parasites were exposed to 700 nM DHA for 6 hours at 1.5% parasitemia. DHA exposure was 
repeated 24 and 48 hours after initial exposure. Parasite cultures were washed with RPMI 
medium three times after each exposure. Giemsa smears were used to quantify parasitemia and 
parasite maturation at hour 0, 6, 12, 18, 24, 36, and 48. Luciferase measurements were made at 
the same intervals with additional luminescence measurements at hour 2 and 4. 
Parasite maturation was determined in DCA by categorizing 100 parasites per Giemsa 
smear by early or late stage normal morphology (ring or trophozoite/schizont). Dormant ring or 
pyknotic, dead forms were counted in one category separately so that parasite clearance could be 
determined. Parasite reduction ratios (PRRs) were determined using microscopy counts of 
transfected parasites. In addition, delayed ring-stage phenotype of ARC08-22 (4G) and 36-hour 
life cycle of PL08-09 (5C) were confirmed in untreated synchronized cultures.  
Drug Resistance and Dormancy Assessments with Reporter Strains of Artemisinin 
Resistant P. falciparum  
Highly synchronous ring-stage parasites were exposed to 10X IC50 and 100X IC50 of 
DHA for 6 hours. Parasite cultures were washed 3 times with RPMI medium to removed drug. 
Clearance and recrudescence rates were analyzed using microscopy counting of Giemsa-stained 
blood smears. Dormant ring-stage morphology and time of dormancy induction were observed. 
Parasite maturation was observed during clearance of each parasite culture. 
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Clearance and Recrudescence of Luciferase-Expressing Parasites Treated with 
Antimalarials 
Parasites were synchronized to ring-stage with 5% D-sorbitol and seeded in a white 96-
well plate at 2.5% parasitemia. Cultures were exposed to 10X or 100X IC50 of antimalarials 
listed in Table 3 for 6 hours. Parasite cultures were washed 3 times with RPMI medium to 
removed drug. D-Luciferin (1.5 μg/ml) was added after drug was washed out at 6 hours and 
every 24 hours after that. Plates were incubated with lid covered in foil to limit light exposure. 
Luminescence readings were taken at hours 2, 4, 6, 12, 18, 24, 36, 48, 60, 72, 84, and 96 directly 
from the 96-well culture plate on TopCount NXT (PerkinElmer, Waltham, MA). Clear adherent 
cover was applied to 96-well plate before each reading and removed after each reading in a 
sterile hood environment to keep 96-well culture environment sterile for continuous parasite 
growth. Luminescence was measured in triplicate and the average measurement was used in 
calculations. Change in luminescence, calculated as % of starting luminescence for each parasite 
culture, was plotted over time and area under the curve (AUC0-96) was measured from hour 0 to 
96 using GraphPad (Prism6). 
 
Results 
Generation of GFP- and Luciferase-Expressing Artemisinin-Resistant P. falciparum 
We used piggyBac transposon to integrate into the genome of Plasmodium falciparum 
lines transgenes expressing GFP (pL-BACII-EDGH) or luciferase (pL-BACII-bEDMH-luc-
Pbdhfr) vectors to successfully integrate into the genome of each Plasmodium falciparum listed 
in figure 4.1 (Figure 4.1, Table 4.1). ARC08-22 (4G) and PL08-09 (5C) have a C580Y mutation 
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in K13 associated with artemisinin resistance. Cloned progeny maintained stable GFP (Figure 
4.3) or luciferase expression (Figure 4.2) across the intraerythrocytic life cycle while Mcherry 
expression was not observed in cloned progeny (data not shown). Luciferase expression of ring-
stage parasites was remarkably high. Early and late stage parasites differed in luciferase 
expression by just 2 logs (Figure 4.2).  
 Using the DeltaVision Core high-resolution confocal microscopy system GFP 
localization was differentiated in transfected clones and novel artemisinin resistance phenotypes 
were confirmed. GFP expression was stable at ring, trophozoite, and schizont stages. 
Interestingly, one GFP-expressing artemisinin-resistant clone had a noticeable increase in 
parasite invasion within a single red blood cell (Figure 4.4). It is possible that the piggyBac 
insertion enhances invasion efficiency. We can associate the phenotypic response observed with 
the silenced gene and ultimately discover the function of novel genes potentially associated with 
antimalarial resistance. Our first goal was to demonstrate the feasibility of using the piggyBac 
transfected parasites for drug discovery and drug resistance studies. Following confirmation of 
phenotypic response as outlined about our next goal is to confirm insertion sites in each of these 
clones. This work is currently underway and includes whole genome sequencing of these 
parasites.  
Confirmation of In Vitro Phenotypes of Artemisinin Resistance 
Ring-Stage Dormancy is Induced by DHA 
Clones of transformed parasites entered ring-stage dormancy when treated with 700nM 
DHA. GFP expression was observed in DHA-induced ring-stage dormant parasites and parasites 
that recrudesced (Figure 4.5). GFP expression was localized to the cytoplasm of dormant ring-
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stage parasites and was not co-localized with DNA stain (Hoechst 33258 dye). Luciferase 
expression was not observed above background in dormant parasite cultures (Figure 4.6). Once 
parasite cultures recrudesced, luciferase expression increased to detectable levels.  
Prolonged-Ring Phenotype and 36-Hour Life Cycle Confirmed in Transfected Isolates 
In the absence of drug pressure, growth of GFP and luciferase transfected parasites was 
unaffected and artemisinin resistance growth phenotypes were maintained (Figure 4.7 & 4.8). 
Artemisinin-resistant ARC08-22 (4G) clones tested maintained a prolonged-ring phenotype with 
parasites remaining in ring-stage for approximately 6 hours longer than W2. Artemisinin-
resistant PL08-09 (5C) clones maintained 36-hour life cycle with equal distribution of time spent 
in each stage. More experiments with tightly synchronized transfected clones across more time 
points would determine if cell cycle progression is equal to clones that have not been transfected. 
Delayed Clearance and Recrudescence Phenotype in Luciferase Transfected Parasites 
Delayed clearance phenotype was observed in artemisinin-resistant isolates when the 
delayed clearance assay (DCA) was performed with luciferase-transfected parasite clearance rate 
was slow for artemisinin-resistant parasites and fast for susceptible parasites following exposure 
to DHA (Figure 4.9). The percent of starting luciferase expression following exposure to DHA 
was determined and clones of PL09-09 (5C) and ARC08-22 (4G) had a larger amount of 
luciferase expression over time when compared to W2. In contrast to microscopy observations, 
luciferase expression was reduced at a faster rate than parasite density determine by (Figure 4.9). 
Despite this the parasites had a reduced rate of clearance in the luciferase assay just as they did in 
the microscopy assay. Change in luciferase expression was only detectable at hour 2 of the 
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experiment. Luciferase expression reduced to nearly 0 by hour 4 of the experiment yet ring-stage 
parasites remained present in culture.  
Using GFP- and Luciferase-Transfected Parasites to Further Elucidate Mechanisms of 
Drug Resistance 
Revisiting 2
nd
 Cycle Ring-Stage Dormancy 
For reasons we do not understand dormancy can be induced in the first or second life 
cycle once exposed to drug. After exposure to DHA synchronous ring-stage parasite cultures 
enter dormancy. When exposed to pyrimethamine the ring-stage parasites progress through 
schizogony and enter ring-stage dormancy at the start of the second cycle (Chapter 3). It remains 
unclear what factors contribute to a parasite entering 1
st
 vs 2
nd
 cycle ring-stage dormancy. When 
artemisinin-resistant P. falciparum clones and W2 were exposed to the same concentration of 
drug there were a small population of parasites in artemisinin-resistant isolates that progressed to 
late-stage before clearance was observed (Chapter 2). Only ring-stage parasites were observed 
before clearance was observed with W2. It is possible that resistant parasites tolerate drug, 
progress through one life cycle, and enter dormancy at the start of the second cycle. Therefore, 
we wanted to look at the dose-dependent effects of artemisinin and other antimalarials on 
parasite survival and progression through the intraerythrocytic life cycle in artemisinin-resistant 
and sensitive P. falciparum. This will help us better understand parasite commitment to 1
st
 vs. 2
nd
 
cycle ring-stage dormancy. 
Assessing the Effects of Low-Dose Antimalarials on Parasite Growth  
Artemisinin-resistant P. falciparum synchronize cell cycle and more resistant parasites 
complete 1
st
 cycle in the presence of low levels of DHA and other endoperoxides. Artemisinin-
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resistant P. falciparum clones from Cambodia maintained intraerythrocytic development 
following exposure to 10X IC50 DHA while W2 parasites were dormant by hour 36. Both 
artemisinin-resistant clones from Cambodia matured through the intraerythrocytic life cycle at a 
similar rate when synchronous ring-stage parasites were exposed to low levels of DHA 
regardless of the differences in progression observed in the absence of drug pressure (Figure 
4.10). This was determined by parasite maturations assays, number of early-stage (ring), late-
stage (trophozoite and schizont), and dormant/dead following exposure to DHA. Artemisinin-
resistant cultures maintained majority late-stage parasites by hour 30 when treated with 10X IC50 
(Figure 4.10). A peak in ring-stage parasites following drug exposure occurred at hour 42 for 
both artemisinin-resistant parasites. 
We were able to compare the amount of resistant and sensitive parasites that mature 
through the first cell cycle, producing multiple merozoites that can enter dormancy at the start of 
the second cycle once invading a new parasite. Artemisinin-resistant cultures had more parasites 
completing 1
st
 cycle of development compared to W2 control when exposed to DHA (Figure 
4.10). This was observed with other endoperoxide compounds tested such as the OZ compounds 
in clinical trials. Conversely W2 did not enter dormancy and continued the intraerythrocytic 
cycle when treated with 10X IC50 OZ439. When parasite cultures were exposed to 100X IC50 of 
DHA and OZ439, artemisinin-resistant parasite cultures had more parasites progress to late-stage 
parasites after drug exposure compared to W2. This suggests that more parasites completed the 
first life cycle following drug exposure in artemisinin-resistant parasite cultures compared to 
sensitive cultures.  
Using the T0 drug susceptibility assay, OZ compounds and methylene blue show reduced 
susceptibility to artemisinin-resistant patient isolates compared to W2 suggesting resistant 
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parasites isolated from southeast Asia might tolerate all endoperoxide compounds, and all 
compounds thought to act through redox metabolism, through a similar mechanism (Table 4.2).  
Parasitemia and luminescence relative to the start of the experiment was measured for 
each parasite during clearance and recrudescence for each parasite exposed to 10X and 100X 
IC50 (Figure 4.10 and 4.11). Resistant parasites maintained higher luciferase expression even 
when parasites were undetected in culture and only dormants were observed. Artemisinin-
resistant parasites recrudesced reaching starting parasitemia before W2 control following 
clearance by 100X IC50 of DHA (Figure 4.11). The same recrudescence patterns were observed 
when treating parasites with 700nM. ARC08-22 (4G) having a delayed-ring phenotype in the 
absence of drug pressure has more rings survive during the course of drug treatment compared to 
PL08-09 (5C) and W2 control. Recrudescence is observed with visible ring-stage parasites in 
ARC08-22 (4G) first and both artemisinin-resistant parasites reach starting parasitemia before 
W2.  
The change in luciferase expression at low concentrations of DHA provided interesting 
results. When observing changes beyond the first life cycle following drug exposure a distinct 
pattern emerges in which increasing luminescence relative to the start of the experiment 
correlates to a rise in parasitemia. There appears to be a lag in time to reach starting 
luminescence compared to parasitemia. This was also observed when cultures were treated with 
700nM. Small changes in luciferase expression were observed in dormant parasite cultures over 
time after exposure to 100X IC50. Larger changes are observed with artemisinin-resistant 
parasites; however, W2 displays small changes in luciferase expression during dormancy as well. 
Increases in low amounts of luciferase expression occur at the same time for resistant parasites. 
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Future studies and determining insertion sites of each luciferase-transfected parasite will help us 
understand this observation further. 
Artemisinin-Resistant Clones from Cambodia Display Increased Tolerance to ACT 
Partner Drugs and Additional Antimalarials Tested 
Since recrudescence caused by drug induced dormancy has been observed with other 
drugs besides artemisinin derivatives, such as pyrimethamine (Chapter 3), a variety of 
antimalarials were tested for drug-induced dormancy at concentrations relative to published IC50 
data for W2 control strain to study their contribution to drug tolerance and development of 
artemisinin combination therapy (ACT) resistance. 
When luciferase-transfected parasites were treated with 10X and 100X IC50 for 
antimalarials listed in Table 4.3, artemisinin-resistant ARC08-22 (4G) and PL08-09 (5C) 
displayed patterns of increased growth rates under drug pressure compared to W2 control for 
many classes of antimalarials. In addition, ARC08-22 (4G) having an extended ring-stage and 
PL08-09 (5C) having a 36-hour life cycle in the absence of drug pressure progressed through the 
intraerythrocytic cycle at the same rate when exposed to 10X and 100X IC50 for all antimalarials 
tested. Parasite cultures had similar changes in luciferase expression and morphology over time. 
Change in luciferase expression of treated luciferase-transfected clones was compared over two 
life cycles (96 hours) and plotted over time relative to % starting luminescence. Area under the 
curve (AUC0-96) was determined for each parasite culture using GraphPad Prism 6 (Figure 4.12).  
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Parasites Display Signs of Increased Growth when Exposed to 10X and 100X IC50 ACT 
Partner Drugs  
 The largest increases in AUC0-96 were observed with mefloquine and lumefantrine. 
Piperaquine showed patterns of increased growth but did not have as high of AUC0-96 as 
mefloquine and lumefantrine (Figure 4.11). There was also a significant increase in AUC0-96 
when artemisinin-resistant parasites were treated with primaquine compared to W2. Artemisinin-
resistant parasites displayed patterns of increased sensitivity to chloroquine compared to W2. 
These trends were not observed when determining AUC0-96 of fast acting antimalarials at 
concentrations tested. AUC0-96 was reduced in all parasite cultures treated with amodiaquine, 
doxycycline, and dihydroartemisinin due to the lack of parasites maturing during the first cycle 
of development. 
When Giemsa-stained blood smears were examined following mefloquine exposure to 
synchronous ring-stage cultures, the majority of ARC08-22 (4G) parasites had progressed to 
late-stage schizogony by hour 24 while W2 parasites remained in ring-stage (Figure 4.13). By 
hour 48, merozoites had survived to the second cycle and successfully invaded new red blood 
cells in ARC08-22 (4G) culture while W2 parasites arrested at ring-stage and entered ring-stage 
dormancy in the first cycle when drug was added. Therefore the increase in luciferase expression 
of artemisinin-resistant ARC08-22 (4G) compared to W2 over the first 36 hours of the 
experiment is due to a high proportion of parasites completing schizogony following mefloquine 
exposure and entering dormancy at the start of the second cycle. The proportion of parasites 
completing the first life cycle is dose dependent when comparing 10X and 100X IC50 of 
mefloquine. Parasite cultures had a larger AUC when treated with 10X IC50 compared to 100X 
IC50. Interestingly, ARC08-22 (4G) sped through the first life cycle following mefloquine 
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exposure having cultures with majority schizonts and highest luciferase expression around 24 
hours which is associated with late-stage parasites. This matched PL08-09 (5C) fast life cycle 
and both resistant patient isolate clones had the same changes in luciferase expression across the 
entire experiment in the presence of 10X and 100X IC50. However, more experiments are needed 
to determine the life cycle time of resistant and sensitive parasites under low exposure to drug in 
order to determine if this observation is significant and at what rate each antimalarial changes 
life cycle progression. This could provide insight into the development of resistance to multiple 
antimalarials through a similar cell cycle regulatory process. 
4-Aminoquinolones 
The artemisinin-resistant parasites tested did not have as high of a shift in AUC to 4-
aminoquinolones tested compared to W2 as was observed with amino alcohols and primaquine. 
In fact, AUC for chloroquine treatment was reduced in artemisinin-resistant parasites compared 
to W2 (Figure 4.12). This suggests artemisinin-resistant parasites do not resist chloroquine like 
W2, a southeast Asian derived chloroquine-resistant parasite line. A small shift in AUC was 
observed with artemisinin-resistant parasites treated with piperaquine compared to W2 and an 
almost undistinguishable difference when treated with amodiaquine. Piperaquine displays 
patterns of increased growth during the first intraerythrocytic development compared to 
amodiaquine and chloroquine and interestingly is the most common 4-aminoquinolone used as a 
partner drug for ACTs. Thus contributing to the hypothesis that parasites isolated from 
Cambodia resist antimalarials given in combination with artemisinin and have more parasites 
progress through the first life cycle following drug exposure. However, luciferase expression is 
reduced in artemisinin-resistant parasites to undetectable levels at a much faster rate with 4-
aminoquinolone treatment compared to treatment with amino alcohols (Figure 4.14). This 
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suggests parasites complete one life cycle and enter ring-stage dormancy in a shorter period of 
time when treated with 4-aminoquinolones compared to amino alcohols. How this contributes to 
recrudescence of parasites and the generation of ACT resistance needs to be studied further. 
Primaquine 
The results observed with primaquine may shed light on different drug tolerance 
phenotypes observed. A larger shift in AUC was observed in artemisinin-resistant isolates treated 
with primaquine (Figure 4.12). More late-stage parasites were present after 48 hours compared to 
4-aminoquinolones tested (Figure 4.15). However, this trend was not consistent when resistant 
parasites were treated with 100X IC50. Dormant parasites were observed in culture 24 hours after 
drug exposure and following an increase in luciferase expression. Late-stage schizonts were 
present in all other cultures at 24 hours. By hour 48 resistant parasites had progressed with 
majority ring-stage parasites in culture and little ring-stage dormancy induction. All W2 parasites 
remained in schizont stage. When resistant parasites were exposed to a higher concentration of 
primaquine (100X IC50) parasites arrested by hour 24 and appeared to already be entering a state 
of dormancy (Figure 17). Interestingly, luciferase expression remained higher than starting 
luciferase expression and dormant parasites appeared to have a difference in Giemsa stained 
morphology. It is critical to repeat this experiment and observe the morphology of resistant 
parasites during the first 24 hours to understand how dormancy was induced and how these 
changes in luciferase expression relate to the dormant morphology observed. At 10X IC50 more 
ring-stage parasites persisted in the second cycle of artemisinin-resistant isolates compared to 
parasites entering into dormancy. This was consistent with what was observed with the amino 
alcohol. The response observed with 100X IC50 was more consistent with what was observed 
with piperaquine at both 10X and 100X suggesting the two phenotypic responses observed with 
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resistant parasites could be dose dependent at different rates for different antimalarials. It 
remains that Cambodian isolates have more parasites progress through first cycle following 
exposure to drug compared to W2 control and at increasing concentrations of drug more resistant 
parasites enter dormancy earlier during the first 48 hours of development. This is observed by a 
peak increase in luciferase expression during the first 24 hours of development followed by a 
drastic decline and morphology of parasites at hour 24 and 48 following antimalarial treatment. 
Atovaquone and Antibiotics  
All parasites, sensitive and resistant, had the same growth patterns when exposed to 
atovaquone or doxycycline at concentrations tested in our luciferase assay (Figure 4.16). When 
exposed to atovaquone all parasites were stalled in late-stage when slides were examined at 24 
and 48 hours of the experiment. Parasites treated with doxycycline had a drastic decline in 
luciferase expression immediately following drug exposure with similar AUC as 
dihydroartemisinin. Both doxycycline and dihydroartemisinin are the only two antimalarials 
tested that continue to act on early-stage parasites.  
Discussion 
Our most effective antimalarial treatment strategies, artemisinin combination therapies 
(ACTs), are being threaten by the potential spread of multidrug-resistant Plasmodium and we are 
in dire need of new antimalarials to combat these resistant parasites. Resistance to ACTs 
emerged independently in multiple geographic locations in Cambodia and along the western 
Thailand border [47, 124]. Resistance in vivo is defined as delayed parasite clearance following 
3-day treatment with an ACT [49]. A molecular marker, multiple SNPs in kelch, have been 
associated with delayed clearance in vivo [51]. Only one SNP is required to confer resistance and 
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very rarely are 2 SNPs found in kelch gene of artemisinin-resistant parasites. Recent reports 
suggest spread of resistance across Burma as far as the western border of India determined by 
sequencing kelch mutations [48].  
The mechanism of artemisinin resistance remains elusive and has proven to be complex. 
Multiple sub-populations of parasites conferring resistance have emerged unrelated to 
geographical origin and exist across geographical locations [135]. Multiple in vitro phenotype 
assays have been established to confirm artemisinin resistance observed in vivo associated with a 
molecular marker of resistance (Chapter 2; [132, 139]). All phenotypic responses have been 
linked to decreased sensitivity and increased survival at the ring-stage, a uniquely targeted stage 
by artemisinin derivatives that were thought to be responsible for the rapid action of the drug. In 
addition, we have shown that resistant parasites have altered their cell cycle to reduce the amount 
of time spend at the most vulnerable stage of intraerythrocytic development, trophozoite-stage. 
Looking at the contribution of these cell cycle associated phenotypes to the generation and 
spread of artemisinin resistance in real-time became the next logical step.  
In addition, we hypothesized that partner drugs contribute to the complex mechanism of 
action and spread of ACT resistance observed across southeast Asia since partner drugs are used 
in combination with artemisinin as the current treatment strategy. Our most successful treatment 
strategies against malaria are being threatened by the spread of artemisinin-resistance and 
potentially multi-drug resistance; thus there is a dire need to find new antimalarials that are 
effective against parasites resistant to ACTs. 
With current increases in treatment failure rates following 3-day ACT regimens, it is 
incredibly alarming that we are selecting for parasites capable of resisting multiple drugs thought 
to act through different mechanisms. Since artemisinin-resistant parasites have been shown to 
  116 
have a fitness advantage in the presence of artemisinin treatment (Chapter 3) and lead to an 
earlier recrudescent infection in vitro following DHA exposure, could we be selecting parasites 
that are capable of resisting exposure to multiple classes of antimalarials in the field through a 
common mechanism?  
piggyBac Transposon Mutagenesis is an Effective System to Stably Integrate GFP and 
Luciferase into the Genome of Drug Resistant Field Isolates without Changing Drug 
Resistance Phenotypes 
We have successfully transfected green fluorescent protein (GFP) and luciferase into the 
genome of three artemisinin-resistant P. falciparum clones from Thailand/Cambodia and one 
control parasite, W2. Phenotypes associated with artemisinin resistance were maintained in 
stably transfected clones. We selected resistant parasites with different phenotypic profiles so 
that we could compare each phenotype and its contribution to resistance of antimalarial drugs. 
Each resistant parasite selected maintained a different phenotypic profile in order to compare 
each phenotype contributed to tolerance of antimalarial treatment. Specifically, ARC08-22 (4G) 
maintained a prolonged-ring phenotype in vitro with rings present in culture up to 6 hours longer 
than control and PL08-09 (5C) maintained a 36-hour life cycle. Delayed clearance and 
recrudescence caused by 700nM DHA-induced ring-stage dormancy remained unchanged. While 
clearance was delayed in resistant isolates when exposed to DHA, luciferase expression 
diminished at a faster rate than parasitemia determined by morphology.  Therefore, delayed 
clearance determined by luciferase expression was observed to a lesser degree compared to 
microscopy. By hour 4 following exposure to DHA luciferase expression had reached nearly 0; 
however, low levels of expression remained in resistant isolates compared to W2 after hour 4. 
PL08-09 (5C) maintained a consistently higher luciferase expression compared to ARC08-22 
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(4G) when diminishing to nearly 0 and dormant parasites were observed in culture. The 
reduction in luciferase expression we observed following exposure to DHA was consistent with 
previous reports [154]. Therefore, delayed parasite clearance will not be observed with 6-hour 
time points in a luciferase clearance assay when parasites are exposed to 700nM DHA.  
Green fluorescence was maintained in parasites having dormant morphology several days 
after DHA exposure. However, some parasites, visible by Hoechst stained nuclei, did not 
maintain a green fluorescence signal in the cytoplasm. Interestingly, this difference could be 
observed within one red blood cell. Little progress has been made on GFP expression in dormant 
parasites. Better methods to observe changes in GFP expression in real-time are needed. 
Development in new technologies is helping us achieve these goals.  
piggyBac System Can be Used to Identify Genes Associated with Phenotype of Artemisinin-
Resistance and Multidrug-Resistance 
piggyBac has been used to find genes associated with drug resistance in many biological 
systems, such as cancer [155], as well as Plasmodium falciparum (unpublished). piggyBac 
preferentially inserts into AT-rich, actively transcribed portions of the genome where chromatin 
is open and avoids closed chromatin structures. Hot spots have been located to promoter regions 
of highly expressed mRNA in mouse embryonic stem cells [156]. Integration is biased toward 
transcription start sites and DNase I-hypersensitive sites. Phenotypic responses to drug pressure 
can be associated with a silenced gene where piggyBac element has been inserted. While in vitro 
artemisinin resistance phenotypes were maintained in many stably transfected clones, phenotypic 
changes were observed in other stably transfected artemisinin-resistant clones that could uncover 
genes associated with the phenotypic responses observed with artemisinin resistance and 
potentially multidrug resistance. However, the main focus of this study was to establish GFP- 
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and luciferase-expressing field isolates that maintained their artemisinin resistance phenotypes in 
order to further understand these complex phenotypes in real-time. Since all artemisinin 
resistance phenotypes discovered by our lab and others involve changes in cell cycle we wanted 
to understand how these changes contributed to artemisinin resistance. We also wanted to assess 
our phenotypes with other antimalarials potentially contributing to multidrug resistance with the 
use of ACTs. 
Luciferase-Based Drug Assays 
Luciferase-based reporter assays have proven to be good ways of determining killing 
rates and modes of action of antimalarial compounds in high throughput screening (HTS) 
methods for all stages of the malaria life cycle [154, 157]. Compounds targeting apicoplast of 
Plasmodium have been identified [158], as well as drugs that target gametocytes, the sexual form 
of the parasite [159]. Luciferase-based screening methods have been used to determine IC50 of 
active antimalarials against drug resistant parasites, including multidrug resistant parasites [157, 
160]. We have developed a luciferase-based reporter assay to look at kill rate and mode of action 
of artemisinin and other antimalarials in drug resistant parasites.  
2
nd
 Cycle Dormancy Contributes to Delayed Parasite Clearance Phenotype Observed with 
Artemisinin Resistance and Resistance to Other Endoperoxide Compounds In Vitro 
Drug-induced ring-stage dormancy has been attributed to parasite survival following drug 
exposure and the subsequent recrudesecent infection in vitro ([65, 69]; Chapter 3). While 
artemisinin induced ring-stage dormancy immediately following exposure to drug, 
pyrimethamine was shown to induce ring-stage dormancy after completing one life cycle 
following exposure to drug. The differences observed are thought to be due to different modes of 
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action of each antimalarial. Artemisinin acts on early stage parasites of intraerythrocyctic 
development while pyrimethamine acts on later stages interfering with DNA synthesis. Therefore 
we wanted to assess time of dormancy induction and how it contributes to parasite clearance and 
survival in sensitive and resistant Plasmodium falciparum. 
 As described by many, Plasmodium falciparum has been shown to progress through the 
life cycle following exposure to drug. Antibiotics and drugs that target the apicoplast have been 
shown to produce a delayed death effect in which parasites complete one life cycle and do not 
show signs of death until the second cycle[161-163]. However, growth is delayed in treated 
parasites compared to untreated parasites. In addition, this phenotypic response is shown to be 
variable with antibiotics. A portion of parasites will experience the effect of the drug in the first 
cycle while another portion continue growth relative to the concentration of drug they are 
exposed to. A similar effect on parasites has been described with mefloquine [164, 165]. 
Parasites were continuously exposed to IC50 and IC99 of mefloquine for 48 hours and a dose 
dependent delay in death was observed. Mature-stage parasites were observed when treated with 
IC50 and not when treated with IC99. Delayed death effect was enhanced with increased 
expression of pfmdr1. After mefloquine treatment parasites with increased expression of pfmdr1 
remained in ring-stage longer than when treated with atovaquone. 
A variable phenotypic response to drug pressure in clonal populations has been observed 
in enhancing the development of resistance to drug by many different microbes and cancer [91, 
166]. Even wild-type organisms have the ability to produce variable phenotypic responses to an 
environmental perturbation [86]. However, the most fit organism in the environment will 
outcompete the others and saturate the biological system. The variability in phenotypic response 
is attributed to epigenetic regulators that modulate gene expression resulting in the 
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diversification of cells; ultimately regulating cell cycle in response to external cues from the 
environment. Drug affected, drug resistant, and persistent populations begin to emerge. The 
diversification of cell cycles of these subpopulations has been attributed to the generation of drug 
resistance [91, 167]. Increased fitness of resistant populations is associated with organisms that 
are able to regulate this phenotypic variability in response to drug the best [86, 88, 168]. 
Persistent populations, characterized by a growth arrest, consist of organisms with 
unchanged morphology stalled in development and remain distinctly different from dormant, 
condensed forms. The difference in these two populations has mostly been described in bacteria 
[169]. Plasmodium falciparum has the ability to enter dormancy during the intraerythrocytic 
cycle and this phenomenon has been attributed to artemisinin resistance in vitro [65, 69]. 
Artemisinin has been shown to induce ring-stage dormancy immediately following drug 
exposure while pyrimethamine induces ring-stage dormancy after completing one life cycle 
following drug exposure (Chapter 3). While observing parasite clearance in artemisinin-resistant 
isolates from the field, there was a portion of parasites that progressed through the first life cycle 
following DHA exposure only in resistant parasites (Chapter 2). Therefore, we wanted to 
understand the effects of dose on dormancy induction in resistant and sensitive parasites. 
1
st
 vs 2
nd
 Cycle Dormancy At Low Levels of DHA 
We assessed the induction of 1
st
 vs 2
nd
 cycle ring-stage dormancy in artemisinin-resistant 
and sensitive parasites exposed to differing concentrations of DHA. At low concentration of 
drug, 10X IC50, sensitive parasites entered ring-stage dormancy with all intraerythrocytic stages 
absent by hour 36 while resistant parasites complete the first cycle of development and continue 
to grow beyond the second cycle following drug exposure. Thus, a higher concentration of DHA 
is required to induce dormancy in resistant field isolates.  
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By hour 36 following treatment with 10X IC50 DHA parasites had entered dormancy and 
late-stage parasites were no longer present. Late-stage parasites were present starting at hour 6 
and remained in culture until clearance was observed at hour 36. The amount of late stage 
parasites present in culture during the time course of one life cycle decreased with increasing 
concentration of DHA (100X IC50). This decrease in late-stage parasites with increasing 
concentrations of DHA is further noticed when cultures were treated with an even higher dose of 
DHA, 700nM, in the previous chapter (Chapter 2). These results suggest parasites enter 1
st
 and 
2
nd
 cycle dormancy in a dose-dependent manner. In addition, resistant parasites have a larger 
amount of late-stage parasites in culture before clearing at 100X IC50 suggesting more parasites 
commit to second cycle dormancy compared to entering in the 1
st
 cycle. This is most likely 
attributed to their ability to tolerate drug better than sensitive parasites. 
Interestingly, artemisinin-resistant parasites life cycle synchronized following exposure 
to low levels of artemisinin even though they have remarkably differing life cycles in the 
absence of drug pressure. Rise in amount of ring-stage parasites occurred between hour 36 and 
42 for both parasite cultures followed by a simultaneous decline. It remains unclear how this 
would contribute to the resistance mechanism associated with artemisinin however additional 
endoperoxide compounds produce the same response at low doses. All parasites, including W2, 
progress through the first and second life cycle following 10X IC50 OZ439. Highest percent of 
ring-stage parasites after the first cycle occurred at hour 42 for all parasite cultures followed by a 
simultaneous reduction in ring-stage parasites suggesting all parasites synchronize, including W2 
control, in the presence of low levels of OZ439. How synchrony contributes to artemisinin and 
potentially antimalarial drug resistance is discussed further as it become more evident in later 
experiments. 
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Dormancy and Multidrug Resistance 
 We are beginning to shed light on to how dormancy is involved in artemisinin resistance 
but also how parasites have exploited a stress response pathway in order to combat the arsenal of 
antimalarial drugs parasites are exposed to most of which are derived from natural products that 
have been used as antimalarial remedies for centuries. Current field isolates are progeny of 
parasites that have been exposed to active components of these natural products and survived 
treatment for centuries.  
Combination therapy has been associated with the development of multidrug resistance in 
other organisms and becomes difficult to overcome [170]. Changing combination partners based 
on different modes of action and adding a 3
rd
 partner drug has been a popular option and offers 
quick solutions to managing diseases with multidrug resistance mechanisms against combination 
therapies, however resistance continues to develop and multidrug resistance mechanisms evolve. 
Is that a viable option with artemisinin-resistant parasites maintained in the field today?  
 Persistence and dormancy of many different organisms have been associated with 
multidrug resistance, however they are thought to contribute to drug resistance by aiding in drug 
tolerance during exposure to drug, enhancing the effects of resistance that emerge rather than 
being responsible for the mechanism of resistance [84, 91, 171]. This has profound effects on 
increasing fitness cost of drug resistant organisms. In bacteria, reduced fitness cost was 
associated with increased persistence of resistant bacteria. This was thought to be driven by 
evolution of compensatory resistance mutations that enhance fitness of drug resistant bacteria 
and increase persistence in E. coli, Mycobacterium tuberculosis, and Streptococcus pneumonia 
[172-174]. This is alarming for the spread of drug resistance because enhanced fitness leads to 
increased survival when drug pressure is not around ultimately leading to saturation of drug 
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resistant organisms in the environment. We wanted to starting looking at multidrug resistance 
responses in our artemisinin-resistant field isolates from Cambodia that developed artemisinin 
resistance under combination therapy antimalarial treatment and the contribution of dormancy to 
tolerance of antimalarials other than artemisinin. 
Artemisinin-Resistant Isolates from Cambodia Show Increased Survival When Exposed to 
ACT Partner Drugs and Other Antimalarials 
Artemisinin-resistant and sensitive isolates were treated with low doses of antimalarials 
relative to IC50 (10X or 100X) for 6 hours. Luciferase expression relative to the start of the assay 
was determined over 2 life cycles following antimalarial exposure. Luciferase-expressing 
artemisinin-resistant isolates had an increase in luciferase expression over time following drug 
exposure compared to W2, determined by area under the curve (AUC) for many antimalarials 
tested. This increase in luciferase expression was due to an increase in parasites progressing 
through the first life cycle following drug exposure in artemisinin-resistant isolates compared to 
W2 determined by microscopy. At hour 24 ARC08-22 (4G) maintained majority schizonts while 
W2 maintained ring-stage parasites. By hour 48 parasite cultures maintained parasites with 
dormant-like morphology distinguished by a condensed cytoplasm. Parasite progression was 
similar to that reported by others who observed delayed death effects with mefloquine [164, 
165]. Interestingly, both resistant parasites maintained the same response to all antimalarials 
tested regardless of the cell cycle differences in the absence of drug exposure. 
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Under Low Levels of Antimalarial Drug Pressure Artemisinin-Resistant Parasites 
Synchronize Their Progression Through the Life Cycle 
Artemisinin-resistant parasites, having strikingly different cell cycles, synchronized their 
life cycles in the presence of all antimalarials tested. This was observed in change in luciferase 
expression across the life cycle as well as changes in morphology observed at hour 24 and 48.  
 Synchrony of Plasmodium has been observed in many Plasmodium species. The 
circadian rhythms observed naturally by Plasmodium falciparum and the mouse parasites 
Plasmodium chabaudi provide a fitness advantage to the parasite and when disrupted lead to a 
reduction in parasite production [175]. Synchrony is thought to be driven by changes in 
concentration of host melatonin levels sensed by the parasite [176, 177]. Melatonin treatment in 
vitro synchronizes Plasmodium falciparum by activating specific receptors of melatonin coupled 
to phospholipase-C activation and an increase in cytosolic free Ca
2+
. Regulated by tryptophan 
catabolism, this occurs independently of extracellular Ca
2+ 
concentration [178, 179]. Synchrony 
can be achieved with many molecules involved in tryptophan metabolism, including serotonin 
and effects are abrogated when an antagonist of melatonin receptor, luzindole, is added to 
culture. Further, P. berghei and  P. yoelii cannot by synchronized with melatonin in vitro while 
P. chabaudi can [180]. These results suggest parasites use exogenous cues sensed from their host 
environment by surface receptors to regulate cell cycle and ultimately control infection in the 
human host.  
 In addition to molecules interacting with receptors involved in tryptophan metabolism, 
temperature synchronizes parasite populations in vitro. Febrile temperatures, refrigeration, and 
temperature cycling have been shown to synchronize Plasmodium falciparum in vitro [181-183]. 
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This suggests Plasmodium falciparum uses stress response mechanisms, in addition to receptor-
mediated metabolic pathways to regulate cell cycle and control infection in the human host.  
Other organisms, such as bacteria and cancer, regulate cell cycle through both stress 
response and receptor-mediated metabolic pathways in disease pathogenesis of the human host. 
Dysregulation of cell cycle has been associated with enhanced treatment outcomes in cancer. 
Cancer cell or bacterial populations use exogenous cues to enhance survival in response to drug 
pressure or host immunity. Regulating cell cycle in response to environmental stress has been 
implicated in drug tolerant bacteria and cancer. 
Subpopulations of drug tolerant bacteria are known to increase production and secretion 
of indole in response to drug pressure [87]. Indole molecules, will turn on drug efflux pumps and 
oxidative-stress protective mechanisms in bacteria thus contributing to increased survival during 
drug exposure. Indole derivatives, melatonin derived molecules, have been implicated in cell 
cycle regulation in Plasmodium by activating tryptophan catabolism to synchronize parasite cell 
cycle [59, 184]. It is possible that Plasmodium uses similar regulatory cell cycle mechanisms to 
tolerate drug pressure and oxidative stress associated with drug insult.  
Cancer cells resist chemotherapy and radiation therapy by constitutively expressing genes 
involved in antioxidant pathways to better tolerate redox imbalance associated with cancer 
therapy. Human kelch, KAEP1, is prevented from interacting with Nrf2 transcription factor 
leading to Nrf2 translocation to the nucleus and constitutive activation of antioxidant response 
elements (AREs) driven transcription [57, 185, 186]. KAEP1 is part of one of three major signal 
transduction pathways implicated in the regulation of ARE driven transcription that is thought to 
be a highly ordered signaling network [56, 58]. Three major kinases are involved: protein kinase 
C, the driver of Nrf2 nuclear translocation; phosphatidylinositol 3-kinase (PI3K) and MAP 
  126 
kinase cascade. The intracellular redox state plays an important role in ARE driven transcription. 
Nrf2 is translocated to the nucleus by releasing cysteine residues associated with KAEP1 in the 
presence of oxidative stress in the cytoplasm. It is also thought that protein phosphorylation is 
important for regulating ARE driven transcription.  
Nrf2 enhances cancer growth by promoting activation of antioxidant response pathways 
and also by upregulating expression of many different regulatory elements of cell growth 
pathways [187]. Therefore, KAEP1/Nrf2 remains part of a key regulatory interaction that 
promotes cancer survival and proliferation in a highly coordinated manner.  
In Arabidopsis, kelch repeat protein is part of a complex that coordinates the precise 
timing of constans (CO) gene expression, in which the highly regulated expression is necessary 
for photoperiodic flowering [188].  The interaction of, flavin-binding, kelch repeat, F-box 1 
(FKF1) with gigantea (GI) is formed in the late afternoon on the CO promoter and induces day-
length specific expression of flowering locus T (FT) gene [189]. The coordinate timing of 
expression is induced by photoreceptors and temperature receptors and interaction with circadian 
clock genes that have been demonstrated to regulate a transcriptional clock [190-192].  These 
photoperiodic expression pathways regulated by photoreceptors and temperature receptors also 
coordinate seed dormancy in winter and drought.  
Therefore, we hypothesize that Plasmodium falciparum artemisinin-resistant parasites 
being selected for in southeast Asia by the use of ACTs could be acting through a second 
messenger receptor-mediated and/or stress response pathway to regulate cell cycle in response to 
many different antimalarials. While genetic mutations are necessary to confer resistance to 
artemisinin, the potential reduced fitness cost associated with phenotypic variability in cell cycle 
regulation is selecting for resistant parasites that are able to tolerate combinations of drugs. 
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Future studies are needed to determine the fitness cost associated with cell cycle regulation of 
Plasmodium falciparum resistant parasites since this phenotypic variability has only been 
associated with drug resistant bacteria and cancer.  
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Figure 4.1. GFP- and Mcherry/Luciferase Plasmid Constructs Used in Transfection 
Experiments. GFP (pL-BACII-EDGH) and Mcherry/luciferase (pL-BACII-bEDMH-luc-Pbdhfr) 
piggyBac plasmid constructed by John Adams lab. GFP and luciferase expression were 
maintained under the constitutively expressed elongation factor 1 alpha (ef1α) promoter. 
Plasmids contain dihydrofolate reductase (dhfr) drug selectable markers. WR99210 (5nM) drug 
selection was applied twice before cloning. 
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Table 4.1. Artemisinin Resistance Phenotypes and K13 Mutations Identified in GFP and 
Luciferase Transfected P. falciparum Clones. P. falciparum clones with stable GFP and 
luciferase expression. Artemisinin resistance phenotypes have been confirmed in select clones of 
ARC08-22 (4G) and PL08-09 (5C) Cambodian isolates. W2 clones selected have maintained a 
wild-type phenotype. Kelch (K13) mutations identified in artemisinin-resistant clones will be 
confirmed in piggyBac transfected clones by whole genome sequencing.  
  
	
Parasite Phenotypes K13 mutation Life cycle Reporter 
expression W2 ART sensitive 
CQ resistant 
WT 48-hour GFP or 
Luciferase ARC08-22 (4G) ART resistant C580Y 48-hour, 
prolong-ring 
GFP or 
Luciferase PL08-09 (5C) ART resistant C580Y 36-hour GFP or 
Luciferase NHP4197 (2A) ART resistant WT 48-hour GFP or 
Luciferase 
  130 
 
 
 
Figure 4.2. Stable Luciferase Expression Across Intraerythrocytic Life Cycle. Raw 
luminescence measurements of W2_6G, ARC08-22 (4G)_5F, and PL08-09 (5C)_11E are shown. 
Luciferase expression of synchronous ring-stage cultures was measured for 48 hours (one 
intraerythrocytic life cycle).  
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Figure 4.3. Stable GFP Expression Across Intraerythrocytic Life Cycle. Stable GFP 
expression was observed in clones of W2, ARC08-22 (4G), and PL08-09 (5C). GFP signal in 
ring, trophozoite, and schizont stages visualized using DeltaVision CORE. GFP signal remained 
well distributed throughout the cytoplasm.  
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Figure 4.4. Clones with GFP Localization Patterns. Clones not selected for further 
characterization due to phenotypic changes and GFP localization patterns. One clone maintained 
an increased number of parasites within one red blood cell. Subcellular localization was observed 
in clones and would not be good candidates for antimalarial drug assays. However, these clones 
might lead to discovery of new gene functions and provide new drug targets. 
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Figure 4.5. GFP-Expressing DHA-Induced Dormant Parasites Counter Stained with 5μM 
Hoechst 33258 Nuclear Stain. Parasite cultures were treated with 700nM DHA for 6 hours and 
visualized on DeltaVision CORE with micro-well chambers to isolate single parasites 48 hours 
later. GFP signal remained opposite of the nuclear stain localizing in cytoplasm. 
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Figure 4.6. Dormancy and Recrudescence Phenotype Observed in Luciferase-Transfected 
P. falciparum. Luciferase expression (A) and parasitemia (B) of transfected P. falciparum are 
shown following 6-hour exposure of 700nM DHA to synchronous ring-stage cultures. 
Artemisinin-resistant clones reach starting parasitemia up to 2 day before W2. Parasite 
morphology of ARC08-22 (4G) is shown every day following 700nM DHA exposure(C). 
  
0 2 4 6 8 10
0.01
0.10
1
10
100
1000
Day
lo
g
 (
%
 o
f 
s
ta
rt
in
g
 l
u
m
in
e
s
c
e
n
c
e
)
W2
4G
5C
0 2 4 6 8 10
0
20
40
60
80
100
Day
P
a
ra
s
it
e
m
ia
 (
%
 o
f 
s
ta
rt
in
g
)
 
A B 
C 
0     1        2             3  4    5 
Day 
  135 
 
Figure 4.7. Prolonged Ring Phenotype and 36-Hour Life Cycle Confirmed in Luciferase-
Expressing P. falciparum. Giemsa smears of synchronous ring-stage parasites were examined 
for morphology every 6 hours in the absence of drug pressure. W2 clone maintained wild-type 
intraerythrocytic development having equal distribution of time spent in ring, trophozoite, and 
schizont stages. ARC08-22 (4G) and PL08-09 (5C) maintained altered cell cycle phenotypes 
associated with artemisinin resistance. ARC08-22 (4G) parasites maintained a prolonged ring 
phenotype and shortened trophozoite stage having parasites completing schizogony by hour 48. 
PL08-09 (5C) parasites maintained 36-hour life cycle having parasites spend equal amounts of 
time in ring, trophozoite, and schizont stages. 
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Figure 4.8 Prolonged Ring Phenotype and 36-Hour Life Cycle Confirmed GFP-Expressing 
P. falciparum. Giemsa smears of synchronous ring-stage parasites were examined for 
morphology every 6 hours in the absence of drug pressure. W2 clone maintained wild-type 
intraerythrocytic development having equal distribution of time spent in ring, trophozoite, and 
schizont stages. ARC08-22 (4G) and PL08-09 (5C) maintained altered cell cycle phenotypes 
associated with artemisinin resistance. ARC08-22 (4G) parasites maintained a prolonged ring 
phenotype and shortened trophozoite stage having parasites completing schizogony by hour 48. 
PL08-09 (5C) parasites maintained 36-hour life cycle having parasites spend equal amounts of 
time in ring, trophozoite, and schizont stages. 
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Figure 4.9. Delayed Parasite Clearance Phenotype Observed in Luciferase-Expressing P. 
falciparum. A) Top panel: Delayed parasite clearance of artemisinin-resistant ARC08-22 (4G) 
and PL08-09 (5C) compared to W2 determined by microscopy. Synchronous ring-stage cultures 
were exposed to 700nM DHA for 6 hours and parasitemia was determined by microscopy 
(Chapter2). Bottom panel: Delayed parasite clearance of luciferase-expressing ARC08-22 
(4G)_5F and PL08-09 (5C)_11E compared to W2_6G following 700nM DHA exposure 
determined by luminescence measurements. Luminescence measurements were plotted as 
percent of luminescence at hour 0. B) Parasite clearance of each clone before and after luciferase 
transfection was compared. Synchronous ring-stage cultures were exposed to 700nM DHA for 6 
hours and parasitemia was measured. Clearance rate was unchanged; however, a lag phase was 
observed in luciferase expressing W2 compared to W2. 
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Figure 4.10A. Parasite Maturation Following 6-Hour Exposure to Low Levels of 
Endoperoxides (10X IC50). ARC08-22 (4G) and PL08-09 (5C) maintained intraerythrocytic 
development while W2 parasites were dormant by hour 36 after treatment with 30nM DHA. All 
parasite cultures maintained intraerythrocytic development when treated with the same 
concentration, 30nM, of OZ439. Synchrony in artemisinin-resistant parasite cell cycle 
progression was observed following low level exposure to endoperoxides.  
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Figure 4.10B. Parasite Maturation Following 6-Hour Exposure to Low Levels of 
Endoperoxides (100X IC50). All parasite cultures entered ring-stage dormancy by hour 24 
following 300nM DHA exposure and by hour 36 following 300nM OZ439 exposure. More late-
stage parasites were observed following endoperoxide treatment in artemisinin-resistant ARC08-
22 (4G) and PL08-09 (5C) compared to W2 before entering ring-stage dormancy. 
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Figure 4.11. Luciferase Expression Following 6-Hour Exposure to 30nM (10X IC50) and 
300nM (100X IC50) DHA. Increasing parasitemia was observed in ARC08-22 (4G) and PL08-
09 (5C) clones over time when treated with 30nM DHA (A). Artemisinin-resistant clones 
recrudesced before W2, reaching starting parasitemia following 300nM DHA exposure more 
than 2 days before W2 (B). Luciferase expression remained higher in artemisinin-resistant 
ARC08-22 (4G) and PL08-09 (5C) clones compared to W2 when treated with 30nM DHA (C) 
and 300nM DHA (D). 
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Table 4.2. IC50 (ng/ml) of OZ Endoperoxide Antimalarials and Methylene Blue Determined 
by To [
3
H]hypoxanthine Drug Susceptibility Assay. Both artemisinin-resistant clones from 
Cambodia maintain a 2-fold increase in IC50 of endoperoxide compounds compared to W2. 
ARC08-22 (4G) maintained a 2-fold increase in IC50 of methylene blue compared to W2.      
(n=1) 
 DHA OZ277 OZ439 Methylene blue 
W2 3.7 0.94 0.44 3.48 
ARC08-22 (4G) 7.34 2.70 1.99 6.79 
PL08-09 (5C) 8.04 N/A 1.80 N/A 
 
Table 4.3. IC50 of Antimalarials Tested for Drug-Induced Dormancy. W2 laboratory strain 
values were used and 3D7 values were used when IC50 was not available for W2 
Antimalarial IC50 Reference 
Mefloquine 3.0 ng/ml Tucker, 2012 
Atovaquone 0.2 ng/ml Tucker, 2012 
Pyrimethamine 70 nM (13 ng/ml) Chapter 3 
Chloroquine 140 ng/ml Tucker, 2012 
Quinine 81.5 ng/ml Weisner, 2002 
Amodaquine 6 nM Eyase, 2013 
Lumefantrine 19.5 ng/ml Weisner, 2002 
Piperaquine 41 nM Davis, 2005; Schlitzer, 2007 
Primaquine 1,470 nM Vennerstrom, 1999 
Cycloguanil 37 nM Ang, 1996 
Doxycycline 3,400 ng/ml Weisner, 2002 
Dihydroartemisinin 70 nM Tucker, 2012 
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Figure 4.12. Area Under the Curve (AUC0-96) Determined Over Two Intraerythrocytic Life 
Cycles. AUC0-96 determined for W2_6G, ARC08-22 (4G)_5F and PL08-09 (5C)_11E following 
6-hour exposure of 10X and 100X IC50 . The percent of starting luminescence was determined at 
each time point AUC0-96 was calculated. Results were separated by antimalarial drug class: A) 
Amino alcohols, B) 4-aminoquinolones, C) Primaquine (8-aminoquinolone), and D) Others 
(Doxycycline and Dihydroartemisinin) 
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Figure 4.13. Luciferase Expression Over 2 Intraerythrocytic Cycles of Development 
Following 6-Hour Mefloquine Exposure. A) Increased luciferase expression is observed in 
ARC08-22 (4G) compared to W2 following 10X IC50 mefloquine exposure to synchronous ring-
stage cultures. A smaller shift was observed following 100X IC50 mefloquine exposure. Change 
in luciferase expression over time remained the same for ARC08-22 (4G) and PL08-09 (5C). 
This suggests artemisinin-resistant parasites with different cell cycles in the absence of drug 
pressure synchronize their progression in the presence of low levels of mefloquine. B) 
Morphology of treated parasite cultures at hour 24 and 48. ARC08-22 (4G) parasite culture was 
majority schizonts at hour 24 while W2 maintained majority ring-stages. At hour 48 there were 
majority ring-stage dormant parasites in both cultures. Artemisinin-resistant parasites enter 
dormancy at start of 2
nd
 cycle confirmed by morphology while W2 enters ring-stage dormancy in 
the first cycle following exposure to mefloquine. 
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Figure 4.14. Amino Alcohols. Luciferase Expression Over 2 Intraerythrocytic Cycles of 
Development Following 6-Hour Exposure. Increased luciferase expression is observed in 
ARC08-22 (4G) and PL08-09 (5C) compared to W2 following 10X IC50 and 100X IC50 exposure 
to synchronous ring-stage cultures. A smaller shift was observed following 100X IC50 exposure.   
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Figure 4.15. Aminoquinolones. Luciferase Expression Over 2 Intraerythrocytic Cycles of 
Development Following 6-Hour Exposure. Decreased luciferase expression over time was 
observed in artemisinin-resistant clones following chloroquine treatment while W2 maintained 
luciferase expression over time. Increased luciferase expression is observed in ARC08-22 (4G) 
and PL08-09 (5C) compared to W2 following 10X IC50 and 100X IC50 exposure to synchronous 
ring-stage cultures. Change in luciferase expression over time remains the same for ARC08-22 
(4G) and PL08-09 (5C) following exposure to all aminoquinoloes. A smaller shift was observed 
following 100X IC50 exposure.   
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Figure 4.16. Drugs with No Change in AUC0-96. Luciferase Expression Over 2 
Intraerythrocytic Cycles of Development Following 6-Hour Exposure. No change in AUC0-96 
when W2, ARC08-22 (4G) and PL08-09 (5C) synchronous ring-stage cultures were treated with 
atovaquone, doxycycline, and dihydroartemisinin. Change in luciferase expression over time 
remains the same for ARC08-22 (4G) and PL08-09 (5C) following exposure to all antimalarials 
tested.   
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Figure 4.17. Luciferase Expression Over 2 Intraerythrocytic Cycles of Development 
Following 6-Hour Primaquine Exposure. A) Increased luciferase expression is observed in 
ARC08-22 (4G) and PL08-09 (5C) compared to W2 following 10X IC50 and 100X IC50 exposure 
to synchronous ring-stage cultures. B) When exposed to 10X IC50 ARC08-22 (4G) parasites have 
progressed to schizont stage by hour 24 but when exposed to 100X IC50 majority dormant 
parasites are in culture at hour 24. W2 maintains schizonts in culture when exposed to 10X and 
100X IC50 primaquine. 
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Chapter 5 
Summary 
Artemisinin combination therapies (ACTs) are the recommended first line chemotherapy 
treatment for uncomplicated malaria and artesunate is recommended treatment for severe 
disease. Artemisinin alleviates symptoms associated with disease rapidly by acting on young, 
circulating ring-stage parasites [39]. Due to the short half-life of artemisinin derivatives, ACTs 
include a longer lasting partner drug usually acting on mature erythrocytic stages. Combination 
therapy was thought to help prevent the emergence of artemisinin resistance and preserve the 
best antimalarial treatment to date. Unfortunately, artemisinin resistance has emerged and has 
begun to spread in southeast Asia [47, 49]. Resistance has been identified in vivo as prolonged 
parasite clearance following treatment with an ACT leading to an increase in the number of 
positive parasitemia cases on day 3 following treatment. A molecular marker, single nucleotide 
polymorphisms (SNPs) in kelch propeller domain (K13), has been associated with artemisinin 
resistance in vivo [51]. Artemisinin mechanism of action remains elusive and the involvement of 
kelch in the generation of resistance to ACTs requires further studies. There has remained a dire 
need for a reliable in vitro phenotype that is associated with genetic mutations of artemisinin 
resistance and in vivo phenotypes observed in the field. to further. It is imperative to understand 
how artemisinin resistance is emerging in order to preserve our most effective antimalarial 
treatment today and prevent the spread of resistance outside of Southeast Asia. 
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 In this study we conducted a series of studies designed to elucidate the possible 
mechanism(s) of resistance, the fitness costs associated with artemisinin resistance, and we 
developed new tools to aid drug discovery and to further studies of abnormal cell cycle 
regulation in resistance to artemisinin and other antimalarial drugs. An important thread tying all 
these studies together is the critical role that drug-induced ring stage dormancy plays in 
artemisinin resistance and perhaps was a major factor in the eventual selection of resistance in 
vitro and in vivo. The purpose of this chapter is to summarize the most important results from 
these studies and to put these results in context with new data emerging from the study of 
artemisinin resistance in southeast Asia. 
Initially we laboratory adapted and cloned Plasmodium falciparum isolates from 
Thailand and Cambodia that were known to be resistant to artemisinin in vivo. Previous studies 
suggested in vitro phenotypes were nonexistent, yet by carefully evaluating the resistant parasites 
we discovered multiple artemisinin resistance phenotypes. The Kyle lab has developed a T0 drug 
susceptibility assay to confirm artemisinin resistance in vitro in which [
3
H]hypoxanthine is added 
to parasite culture when antimalarial drug is added [67].  We applied this technique and stable, 
reduced susceptibility to artemisinin derivatives was observed in P. falciparum clones.  
 A novel delayed clearance assay (DCA) was developed to determine parasite reduction 
ratio (PRR) at hour 12 or 24. Delayed parasite clearance was observed in vitro following 
dihydroartemisinin (DHA) treatment and this phenotype was significantly associated with 
parasite clearance in vivo and K13 mutations. This assay proved to be a quick, reliable way to 
assess artemisinin resistance in vitro. During the development of this assay parasite maturation 
and recrudescence was observed. There was an increase in the number of ring-stage parasites 
that mature following DHA treatment in artemisinin-resistant clones compared to W2 control. In 
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addition, artemisinin-resistant clones recrudesced before and after W2 control. Recrudescence 
remained consistent however recrudescence rates did not correlate to any other measure of 
artemisinin resistance.  
 Parasite growth phenotypes in the absence of drug pressure were observed in artemisinin-
resistant clones. Artemisinin resistant parasites have reduced the amount of time spent at 
trophozoite-stage, the most susceptible stage to artemisinin derivatives. A prolonged ring-stage 
phenotype was observed in many clones in which parasites spend up to 16 hours longer in ring-
stage compared to control W2. The life cycle time remains unchanged. Therefore, the additional 
time spent at ring-stage is compensated for by a shorter time spent at trophozoite-stage. In 
addition, one parasite had a 36-hour life cycle with equal amount of time spend at ring, 
trophozoite, and schizont stages. Parasite growth phenotypes in the absence of drug pressure 
reduce the area under the curve (AUC) for time spent at trophozoite to approximately the same 
value compared to control parasites (W2 and CB132). These data suggest parasites are being 
selected in vivo and there parasites are better able to tolerate artemisinin by altering cell cycle 
phenotypes. 
 The Kyle lab has previously identified a different cell cycle phenotype, intraerythrocytic 
ring-stage dormancy, to be associated with the generation of artemisinin resistance in vitro [67]. 
We have examined the relationship of dormancy with newly identified cell cycle phenotypes 
associated with artemisinin resistance. In other biological systems, such as E. coli and human 
cancer, multiple cell cycle phenotypes have been associated with the development of multidrug 
tolerance, especially in response to combination therapies. A variable phenotypic response of 
isogenic clones benefits the organismal community as a whole and provides a fitness advantage 
to survive drug pressure [88, 193]. The most fit parasite population will outcompete others and 
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be responsible for the evolution of the organism in the face of selective drug pressure; our data 
suggest dormancy is a fitness advantage that allowed for selection of additional mechanisms of 
resistance (e.g., abnormal cell cycle regulation) that led to artemisinin resistance in vivo. 
 Dormancy also is associated with tolerance of other antimalarials besides artemisinin. We 
have shown ring-stage dormancy leads to recrudescence in vitro following treatment with many 
known antimalarials. Pyrimethamine and mefloquine are two examples of antimalarials that 
induce ring-stage dormancy; however, unlike artemisinin dormancy is induced after completing 
one life cycle of intraerythrocytic development following antimalarial drug exposure. We 
hypothesize that dormancy in a general tolerance mechanism parasites have evolved to better 
resist antimalarial drug exposure. Generally there is a large fitness cost associated with genetic 
mutations causing drug resistance [97]. Overcoming fitness costs associated with drug resistance 
are vital to the survival and subsequent spread of drug-resistant parasites. 
 We have shown there is a fitness cost associated with artemisinin resistance in vitro. In 
the absence of drug pressure or following exposure to a different antimalarial, pyrimethamine, 
wild-type parasites outgrow resistant parasites. Following frequent exposure to DHA resistant 
parasites are selected for in a mixed population. Interestingly, two mutations thought to be 
associated with artemisinin resistance were lost in the artemisinin resistant parasite following 
exposure to DHA however the artemisinin-resistant phenotype remained. Most importantly, one 
of these mutations was in kelch and found not to be associated with artemisinin resistance at the 
end of the study. An increase in copy number of  Pf3D7_1030100 and one SNP on chromosome 
3 (Pf3D7_0307600) were the genetic mutations associated with artemisinin resistance at the end 
of the fitness study. These results suggest additional genetic factors besides K13 mutations are 
required to confer resistance to artemisinin. 
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 We have demonstrated artemisinin resistance leads to reduced susceptibility at ring-
stages and schizont-stages of intraerythrocytic development. Parasites are being selected for in 
the field that have altered their intraerythrocytic development in order to remain in less 
susceptible stages of development longer. This strategy could also increase the amount of 
parasites that are able to enter ring-stage dormancy due to an increase in time spent at this stage 
of intraerythrocytic development. Also, an increase in ring-stage parasites in vivo could lead to 
an increase in circulating parasites and ultimately delay parasite clearance compared to wild-
type. We have just begun to study the many ways altering intraerythrocytic development can 
benefit the parasite in response to antimalarial drug treatment. Additional fitness studies are 
needed to determine what developmental phenotypes are most beneficial to the survival and 
subsequent spread of resistant populations of parasites. We can use these studies to better 
understand how artemisinin resistance might spread and what strategies will be the most 
beneficial at preventing the spread of artemisinin-resistant parasites. 
 Green fluorescence (GFP) and luciferase have been transfected into highly characterized 
artemisinin-resistant clones. These parasites have been used to demonstrate an increase in 
survival of artemisininin-resistant parasites following exposure to ACT partner drugs. In 
addition, artemisinin-resistant parasites synchronize their progression through the 
intraerythrocytic life cycle following exposure to low amounts of all known antimalarials tested. 
In fact, artemisinin-resistant parasites appear to speed up life cycle following exposure to 
antimalarial drug pressure. Additional studies are needed to examine this response further. We 
hypothesize artemisinin-resistant P. falciparum clones isolated from southeast Asia are able to 
tolerate antimalarial drug pressure through a common mechanism that is being selected for by 
ACT treatment. Understanding drug tolerance mechanisms developed by P. falciparum in the 
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field will allow us to better develop new antimalarial treatment strategies and prevent the spread 
of artemisinin resistance outside of southeast Asia. Our data shows the necessity of new 
antimalarial drugs that act through novel pathways in order to prevent the further development of 
multidrug resistant P. falciparum if current treatment strategies remain the same. 
 In summary these studies have led to the first identification of altered cell cycle 
regulation and its role in artemisinin resistance, the identification of fitness costs and advantages 
artemisinin-resistant P. falciparum possess despite infrequent exposure to drug, and we show that 
GFP- and luciferase transfected parasites can be used to study the artemisinin resistance 
phenotypes and second cycle dormancy. These studies significantly expand our current 
knowledge of artemisinin resistance mechanisms and shed new light on how altered cell cycle 
regulation can confer fitness advantages and resistance phenotypes in P. falciparum. These new 
parasite reagents will be critical for future studies that can now be focused on how each of these 
new phenotypes contribute to drug resistance and furthermore to reveal insights into how the 
parasites controls its cell cycle. Artemisinin resistance already has emerged and is spreading, 
thus it is imperative that we use this new knowledge to perhaps control resistance or to discover 
new drugs that can target these resistance mechanisms. There is not greater challenge facing the 
international community that aim to eliminate malaria than artemisinin resistance; at least now 
we have these new data and tools to aid in the effort to control the disease and enhance global 
public health. 
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